Annual Report 2011-12



High Quality Patient Care - Medical Devices Development - Health Science Studies

Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum Thiruvananthapuram, Kerala, India - 695 011

SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM - 695011, KERALA



Annual Report 2011-2012

Annual Report 2011-2012

Sree Chitra Tirunal Institute for Medical Sciences and Technology Trivandrum - 695011

Design & Printing Akshara Offset, Trivandrum Ph: 0471-2471174

Photography & Graphics Medical Illustration SCTIMST

Contents -



History	05
Our Mission, Our Vision	07
Message from the President	09
From Director's Desk	11
Highlights of the Year	13
Hospital Wing	21
Biomedical Technology Wing	53
Achutha Menon Centre for Health Science Studies	91
Division of Academic Affairs	103
Research Activities	111
Scientific Publications	129
Honours, Awards and Visitors	139
Administration	143
Statements of Accounts	155



History

The origin of the Institute dates back to 1973 when the Royal Family of Travancore gifted a multistoried building for the people and Government of Kerala. Sri. P.N. Haskar, the then Deputy Chairman of the Planning Commission inaugurated the Sree Chitra Tirunal Medical Center in 1976, when patient services including inpatient treatment got underway. The Biomedical Technology Wing followed soon at the Satelmond Palace, Poojapura, again a gift by the Royal Family, 11 km away from the Hospital Wing.

The concept of amalgamating medical sciences and technology within a single institutional framework was regarded as sufficiently important by the Government of India to declare the center as an Institute of National Importance under the Department of Science and Technology by an act of Parliament in 1980, and named it as Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum.

Dr. Manmohan Singh, the then Honorable Finance Minister of Government of India, laid the foundation stone of the third dimension of the Institute, Achutha Menon Center for Health Science Studies (AMCHSS) on June 15, 1992. The AMCHSS was dedicated to the nation by Dr. Murali Manohar Joshi, the then Honorable Minister of Science and Technology and Human Resource Development, Government of India, on January 30, 2000.



Hospital Wing



BMT Wing



Public Health Wing (AMCHSS)

Our mission

- Promote research and development in biomedical engineering and technology
- Deliver high quality patient care in selected specialties and subspecialties
- Develop innovative postgraduate training programs in advanced medical specialties, and biomedical engineering and technology
- Participate in public health reforms through research, training and interventions



ANNUAL REPORT 2011-12-



- ANNUAL REPORT 2011-12

डॉ. आर. चिदम्बरम् भारत सरसार के प्रमुख वैज्ञानिक सलाहकार एवम् डी.ए.इ. - होमी भाभा प्रोफेसर

Dr. R. Chidambaram Principal Scientific Adviser to the Govt. of India & DAE - Homi Bhabha Professor



विज्ञान भवन एनेक्सी मौलाना आजाद मार्ग, नई दिल्सी - 110011

Vigyan Bhavan Annexe Maulana Azad Road, New Delhi - 11001* Tel: ++(91) (11) 23022112 Fax: +(91) (11) 23022113 E-mail: chairman@tfac.org.in rajachid@nic.in



MESSAGE

As the President of the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum, I have great pleasure in penning this message. The institute in its journey of over 36 years has scaled many heights and is now considered as one of the finest institutions in the country in the area of health care. The institute has always had the strong support of the Department of Science and Technology, in its efforts to develop itself into a premier medical institution of the country. The strength of the institute lies in its inter-disciplinary approach, combining uniquely patient care, academics, research and development with a very strong thrust on biomedical technology. Such an approach has led to unique contributions to the health care system in Kerala, with many patients also coming from other parts of the country. Recognising its' significant contributions, the Government of India has declared it through an Act of Parliament as an 'Institution of National Importance' with the status of a University.

The patient care activities include several subspecialty areas in the field of surgery for highly complex congenital cardiac anomalies, stroke and acute coronary problems, neuro-endoscopic surgery, movement disorders, epilepsy, sleep disorders and interventional radiology. The patient care wing of the institute has successfully conducted for the first time homograft valve transplant implantation in the State of Kerala and is the second public sector institute in the country to achieve this. The Neuroanesthesia Division has also initiated intraoperative evoked potential monitoring system. I am confident that this procedure will be beneficial to the patients who look up to this public institute for advanced and affordable health care.

The establishment of an information kiosk will improve the patient services in the outpatient departments and help patients. The launching of the health insurance scheme "Chis Plus Scheme" with M/s CHIAK is another milestone in the annals of the institute. The MoU signed with NIC for the implementation of National Knowledge Network (NKN) will further help the institute to network with the leading institutes in the country and also in dissemination of knowledge among doctors and researchers; it will also speed up the tele education and tele consultation.

The pioneering efforts of the Biomedical Technology Wing in the indigenous development of medical devices and implants have facilitated active collaboration and interaction between the institute and the medical device industry. This facility also provides the industry to address the problems of scale-up, production, market seeding of the product, as well as manpower training for setting up and running the commercial plant. The technology transfer to M/s. IFGL Refractories Ltd., Kolkata for injectable calcium phosphate cement for dental applications and bioactive composite ceramics for orthopaedic applications and hormone releasing intrauterine device to M/s. HLL Lifecare Ltd., Trivandrum are some of the notable achievements during this year. I am sure that the MoUs signed with various other institutes and companies will be mutually beneficial.

The Institute offers regular postdoctoral, doctoral and postgraduate courses in medical specialities, public health, nursing, basic sciences and health care technology. Apart from these, the institute also offers off-campus programmes such as Master in Epidemiology (MAE). The joint initiatives with IIT Madras and CMC, Vellore, offering M. Phil in Biomedical Technology, M. Tech programme in Clinical Engineering and Ph. D in Biomedical Devices are unique examples of inter-disciplinary initiatives.

The country's first Master's programme in Public Health (MPH) was started in 1997 by the School of Public Health, Achutha Menon Centre for Health Science Studies (AMCHSS) with the mission to train highly competent and socially committed health professionals, to advocate policies that promote equity in health, to undertake quality research on priority health issues and to offer consultancy services. The Centre conducts several diploma courses, short courses in subjects such as ethics in health research, biostatistics for Biomedical technology, Cardiac and Neuro Nursing, gender sensitization, maternal and child health etc. The Centre also runs the Asian Collaboration for Excellence in Non-Communicable Diseases (ASCEND), Kerala Diabetes Prevention Programs etc.

I am very happy to note that the mandate assigned to the institute by the Parliament is being successfully fulfilled by the hard work of doctors, scientists, engineers, nurses, paramedical staff, administrative staff and the students of the institute. I am sure that in the coming years the institute will scale greater heights and benchmark itself with the best in the world.

I convey my best wishes.

R. Chidambaran

R. Chidambaram



From Director's Desk

t is with immense sense of satisfaction that I am writing this message during the second year since I assumed the charge of the Director of the Institute. We are surging ahead fulfilling our mandate, namely biomedical research and development, high quality patient care and human resource development. The individual departments and divisions have narrated their achievements during 2011-12. I wish to highlight three of them:

First, after dedicated and untiring efforts, at last, we acquired 83 cents of land from the Medical College, Thiruvananthapuram. Let me place on record the services rendered by Dr. Douglas Lindsby, Officer on Special Duty, and Mr. Gopinathan, Estate Officer, who spent several days to overcome obstacles after obstacles in getting this area of land vacated and legally transferred to the Institute. A 750-bedded hospital facility in two blocks, a medical and surgical, will rise up here within an year or two. This will increase the bed strenth in the Hospital Wing to nearly 1000 predicting a quatum jumb in the area of advanced care of patients with cardiological and neurological diseases.

Second, the Board of Studies, through a series of deliberations, have come up with recommendation for the revisions of couse curriculam, postgraduate teaching methods and evaluations. This is a major undertaking in line with the changes that are happening in postgraduate education all over the world. I thankfully acknowledge the unitiring efforts of Dr. Asha Kishore, the Associate Dean of Curriculam and Examinations, in achieving this objective. In the coming years, with these innovations, there will be a sea of changes in the academic activities of the Institute. Third, with the formation of the Division of Research and Publication under the leadership of an Assiciate Dean, the research and publications have been given the emphasis required in an academic institutution of national and international standing. The quality of reseach and publications is expected to surge ahead because these are the attributes based on which faculty selection and promotion are decided.

Dear colleagues, let me thank each and every one of you from the bottom of my heart for your support and cooperation in advancing the Institute in its international standing.

Sincerely,

K. Radhakrishnan

HIGHLIGHTS OF THE YEAR



Smt. P. K. Sreemathi Teacher, Honourable Minister of Health & Family Welfare ,Government of Kerala is handing over the patta of the land transfer to Dr. K. Radhakrishnan, Director, SCTIMST on May 4, 2011



Dr. K. Radhakrishnan, Director, SCTIMST is discussing about the hospital facilities that are going to be esablished in the land transferred with Sri. Oomman Chandi, Honourable Chief Minister of Kerala.



A plan of the Medical Block that is going to be built in the acquired area. This eight storied building will have the most modern advanced care facilities in Cardiology, Genetics and Immunology, Imaging Sciences, Neurology and Physical Medicine and Rehabilitation. Nearly 500 beds, in both general and private wards, will be available.



Dr. K.N. Sharma, Emirates Professor of National Academy of Medical Sciences delivering the Golden Jubilee Lecture on May 7, 2011.



Dr. K. Shivakumar, Scientist G, Division of Cellular and Molecular Cardiology, receiving the ICMR Amrut Mody Unichem Prize from the Honourable Union Health Minister Shri. Gulam Nabi Azad on November 8, 2011.



Ms. Simi, the first recepient of the Homograft Valve along with the Homograft Valve Bank Team on December 20, 2011.



Dr. K. Radhakrishnan, Director, SCTIMST inaugurating the new Institute website on January 2 , 2012.



Dr. K. Radhakrishnan, Director, SCTIMST inaugurating the Indo-Swiss Symposium on Cohorts and Biobanks with special reference to Chronic Non- Communicable Diseases on January 27-28, 2012.



Dr. K. Radhakrishnan, Director, SCTIMST inaugurating the Sree Chithra Children's Park on February 16, 2012.



Exchanging of MOU signed between SCTIMST and SIDD Life Sciences for establishing a Hub for Cardiopulmonary Devices on March 6, 2012.



Signing of Technology Transfer Agreement on Hormone Relasing IUD between SCTIMST and HLL Life Care Ltd. on March 30, 2012.



Dr. K. Radhakrishnan receiving the Outstanding Achievement Epilepsy Award at the Asian Oceanian Epilepsy Congress, Manila, Philippines on March 22, 2012.



In the Asian Oceanian Epilepsy Congress, Manila, Philippines, Mrs. Yasoda Wakankar was honoured as the Outstanding Person with Epilepsy. Mrs Yasoda underwent epilepsy surgery at SCTIMST in July 2003. After becoming seizure-free, she dedicated her services to women with epilepsy at Pune, Maharashtra. The Institute wish to congratulate Mrs. Yasoda on her outstanding achievement and thank her giving an opportunity to make a difference in her life.



HOSPITAL WING

Mission

- Improve patient health outcomes
- Increase patient satisfaction
- Decrease medical errors, costs and waste
- Serve the underserved

Vision

 Be a global leader in high quality patient care and in postgraduate training programs in cardiovascular, thoracic and neurological diseases by 2020.







From the Desk of Medical Superintendent

The past year saw more of consolidation than of physical progress in hospital services. Our governmental austerity measures due to the difficult economic situation cast their shadow on us too. But, we could still march ahead though at a slower pace. Our staff rose to the occasion as one to embrace the slew of our Institute's efforts to contain expenditure and maximize utilization of men and material.

The newly introduced modified working hours in January, 2012 has been welcomed by all, without affecting our services. A few hitches noticed would be reviewed at year-end and addressed appropriately.

Our computerization efforts started bearing fruits in the fields of patient services - reducing the load on human resources, faster delivery of patient-care and support services, including laboratory reports and in-patient billing. Digitization of the medical records has reached half-way mark and hopefully would be completed by March 2013, paving the way for the digital case records by late 2013.

There has been a 23% increase in the outpatient attendance over the last five years, but till now we managed without spending more on infrastructure. To address this ever-increasing outpatient attendance, we would soon be launching modernization efforts to optimize out-patient facilities, which could not be significantly augmented over three decades. The newly acquired land will help in the addition of much-needed expansion and new facilities for our patients.

There has been a 13% increase in the number of Interventional procedures, with the optimal utilization of existing surgical and cath lab facilities. This has helped to reduce the wait-list of patients, but we still have "miles to go...."

As ever, we could get the whole-hearted support of all our dedicated and self ess staff, which is our best asset in the Institute's path to excellence.

R. Sankarkumar



Department of Hospital Administration

New Initiatives

- The Institute succeeded in acquiring 83 cents of land from Government of Kerala for building a modern hospital. Various other activities to improve infrastructure were initiated which included construction of a Neuro Interventional Center and Hospital Canteen Block. Proposals are already finalized for modification of out patient department and construction of a block for the Department of Hospital Administration, classrooms and faculty rooms.
- The Institute successfully conducted the first homograft valve transplant implantation in the State of Kerala. This is the second time in the country in public sector to undertake homograft valve surgery.
- A Memorandum of Understanding was signed with National Informatics Centre (NIC) for the implementation of National Knowledge Network (NKN) at SCTIMST on 12th September, 2011. NKN has been designed to ensure the highest level of availability, quality of service and robust and reliable connectivity for extending network-based services. Accordingly Network based connectivity has been successfully implemented at SCTIMST.
- The Division of Physiotherapy was renamed as Department of Physical Medicine and Rehabilitation with effect from 15th October 2011 with visiting professor of Physical Medicine as a faculty in order to augment the physiotherapy services.

- State level inauguration for the extension of benefits of Chis Plus Scheme was held on 12th November 2011. A memorandum of understanding (MoU) was also entered with M/s CHIAK for the implementation of Chis Plus Scheme at SCTIMST. The scheme shall provide coverage for meeting the expenses of hospitalization for medical and/or surgical procedures to the enrolled BPL families to a maximum limit up to Rs. 70,000/-(Rupees Seventy Thousand only) per family per year, in any of the network providers for the treatment of heart diseases and disease of nervous system. The benefit to the family will be on f oater basis, i.e., the total reimbursement of Rs. 70,000/- can be availed of individually or collectively by members of the family per year.
- A Patient safety programme was initiated. As an initial phase, study was conducted to evaluate the awareness of patient safety programmes and results were presented to the faculty and nursing staff of the Institute on December 26, 2011.
- A programme on hospital ergonomics was initiated for addressing the issue of work related musculoskeletal disorders among the staff. Accordingly, a one-day workshop was organized for doctors, nurses and supervisors. Experts in the field handled various sessions.
- In order to improve the patient services in the out

patient department an Information Kiosk was installed for the patients. This facility is utilized for providing information to patients about hospital services and for retrieval of investigation reports by patients.

 The hospital has taken initiatives to computerize the hospital records. The digitization of existing medical records was started and is progressing well. Steps are also taken to fully computerize the billing of hospital services and speed up patient discharges and account closure.

Clinical services

During the year 2011-12, for various services in Cardiology, Neurology, Cardiac Surgery, Neurosurgery and Imaging Sciences & Interventional Radiology 16,806 new patients were registered. A total of 10,487 patients were admitted for treatment including surgical and interventional procedures (Fig. 1).

Out-patient Department services attracted 1,24,559 patients for review in various Departments, including specialty clinics (Fig. 2).

About 10% of the patients were provided free treatment and 57% patients were offered subsidized treatment based on their socio-economic background (Fig.3). The facilities available were optimally utilized for the patient care services which is evident from the data related to bed turn over i.e., 43 (slight increase over the previous year) (Fig. 4). The average length of stay remained the same as that of last year ie, 7 days. The bed occupancy rate



Fig. 1. New Registrations and Admissions



Fig. 2. Follow Up







Fig. 5. Bed Occupancy Rate (%)

Tele-Consultation

- To provide expert advice available in the Medical Colleges, SCTIMST and Regional Cancer Centre (RCC) to the patients attending District Hospitals through communication networks.
- To provide a forum for scientific interaction between the doctors at District hospitals and the doctors of Medical Colleges, SCTIMST, RCC and other National and International Centres.
- Connectivity to Village Resource Centres.
- The State Planning Board has proposed to include SCTIMST in the Village Resource programme of Wayanad. As per the request, six Tele Talk sessions of health related issues would be handled by the experts of the Institute

International Tele Connectivity

International Tele Project discussions for the following projects were handled with dedicated Internet Connectivity.

- o Tobacco Quit Tobacco India
- o Community Intervention for Health (Oxford Health Scheme, London)

ANNUAL REPORT 2011-12



National Workshop on implementation of NABH standards in hospitals was held on April 9, 2011,The programme was inaugurated by Dr. Balraman Nair, Former Director of Medical Education, Government of Kerala



Dr. R. Sankarkumar, Medical Supdt. of SCTIMST is inaugurating International Nurses Day on May 12, 2011



Dr. K. Radhakrishnan, Director, SCTIMST inaugurated Medical Records scanning facilty on September 7, 2011



Workshop on making workplace safe-role of ergonomics was inaugurated by Dr. K. Radhakrishnan , Director, SCTIMST on February 4, 2012



Hand Hygiene Day was observed on May 5, 2011. Dr. R.Sankarkumar, Medical Superintendent, SCTIMST inaugurated the programme



Dr. K. Radhakrishnan, Director, SCTIMST inaugurated Patient information Kiosk on August 9, 2011



Dr. K. Radhakrishnan, Director, SCTIMST inaugurated online recruitment facility on October 21, 2011



Sri. Shibu Baby John, inaugurated Chiss plus Scheme on November 12, 2011



After the inauguration of inpatient service automation system on December 5, 2011, Dr K. Radhakrishnan, Director, SCTIMST watching the same



Nursing Education

The speciality nursing programmes continue to attract registered nurses as evidenced by the increase in the number of applicants for the two programmes – Diploma in Cardiovascular and Thoracic Nursing, and Diploma in Neuro nursing. 180 cardiac nurses and 127 neuro nurses trained in SCTIMST are presently working in many parts of the world, thereby promoting the reputation of the Institute.

Currently thirty-four students, Cardiovascular and Thoracic Nursing (19) and Neuro nursing (15) are enrolled for the 2-year Diploma programme in Speciality Nursing.

In addition, clinical rotation facility was offered for MSc. Nursing students from various other institutions (97 students from 20 Institutions).



ANNUAL REPORT 2011-12

Department of Anaesthesia

Division Of Cardiothoracic and Vascular Anaesthesia



The Division of Cardiothoracic and Vascular Anaesthesia provides peri-operative care during all the cardiothoracic and vascular surgeries as well as intensive care to all the patients in the cardiac intensive care units. The main mission of the division is to pioneer the development of new techniques for improving the perioperative and intensive care for all cardiac and vascular surgery patients and provide advanced training in this field.

New initiatives

- Pain Clinic: A multidisciplinary 'Pain Team' was formed to run a Pain Clinic on every Friday, where a comprehensive evaluation of the patient will be done clinically with appropriate investigations/imaging, and management will be based on broad consensus and standard protocols.
- 'Guidelines for Care of patients receiving ventilator therapy' was formulated to ensure that evidence based guidelines are followed while providing care for ventilated patients in the intensive care units (ICU) of our Institute.



Inauguration of Pain clinic on March 30, 2012

Division of Neuroanaesthesia



New initiatives

- Intraoperative Evoked potential monitoring is a highly specialized procedure which helps in monitoring the functions of the brain intraoperatively. Its use brings improved care, shortens ICU and hospital stay. Few centers in India only have facility for monitoring evoked potentials. We have started using intraoperative evoked potential monitoring recently. Patients who are at risk of neurological damage like aneurysms, CP angle tumors, posterior fossa tumors, and spine surgeries are increasingly managed with evoked potential monitoring at our institute.
- A new program of Day care for MRI procedures has been started since 6 months. All the patients are assessed for fitness in the special clinic as outpatients every day from 3-4 pm. These patients come to the MRI suite on the day of procedure, undergo MRI under sedation and are discharged home after recovery.
- The division is actively involved in the management of patients in stroke unit during the initial assessment and stabilization in the intensive care unit, while undergoing MRI and during intra-arterial thrombolysis. The division is also involved in the ventilatory care, hemodynamic management, and sedation of critically ill stroke patients.
- With the recognition of increasing incidence of chronic pain syndromes in the population, pain clinic has been inaugurated recently to address the plight of these patients. Pain clinic is managed by a team of experts from Neuroanesthesia, Neurology, Neurosurgery, Neuroradiology and physiotherapist.

Department of Biochemistry





Patient services

The central clinical laboratory (CCL) of this department is engaged in round the clock clinical diagnostic services employing sixteen technical assistants and two scientific officers. Three main sections of the CCL are: biochemisty, hematology and clinical pathology. Fully automated stateof-the-art equipments serving CCL include Dade-Behring RXL, OLYMPUS AU 400 Clinical Chemistry analyzers, Radiometer, GEM Premier 3000, NOVA blood gas analyzers, Beckman 5 part differential hematology analyzers, Roche U 411 urine analyzer and Amax (Germany) coagulation analyzer.

The Central Clinical Laboratory performed a total of 6, 91, 500 tests during this year in Biochemistry, Hematology and Clinical Pathology as detailed below

Biochemistry	2, 92,505
Hematology	1, 81,588
Coagulation parameters	44,948
Blood gas and electrolytes	31,809
Miscellaneous	1, 40,650

New Initiatives

 Studies on metabolic and biochemical changes occurring in cardiac tissues of type 2 diabetic patients have been started in collaboration with the CVTS department. Identification of monocyte/macrophage subtypes in subjects with atheroscelrosis and metabolic syndrome was also started.



Department of Cardiology

The Department of Cardiology is striving to be the leading center in the country for cardiac rhythm management especially, tachy arrhythmia management. The department has also initiated steps to start a Heart Failure Program and Registry with cardiac transplantation as the goal.

Patient care

7869 new patients attended the cardiology outpatient services and 47,400 patients attended the review outpatient services. 4065 patients were treated as inpatients during the year with an average bed occupancy rate of 83% and mortality rate of 1.5%.

The non invasive labs performed 27500 ECGs, 2500 Treadmill exercise tests, 1500 Holter tests and more than 950 special Echo Doppler investigations including trasesophageal echo studies.

The department performed 3657 invasive procedures including 670 coronary angioplasties, 300 electrophysiology (EP) procedures (including 225 radiofrequency ablations for tachyarrhythmias) and 200 permanent pacemaker implantations. More than 50 cases of complex cardiac arrhythmias were mapped and ablated with the assistance of EnSite, and Carto, the 3-D electroanatomical mapping systems.

Our institute continues to be the only centre in government sector in South India having this advanced technological tool in the electrophysiology lab.

The department continues to do maximum pediatric

interventions in India for the last two years with 209 ASD and 79 PDA percutaneous device closures.

The Department continued to peform state-of-the art coronary interventions aided by IVUS (Intra-vascular ultrasound) and also FFR fractional **f** ow reserve assessment of the intermediate coronary lesions.

Device



Heart defect well seen in real-time helps precise closure with devices

Invasive and Interventional Procedures

Diagnostic Studies	Number	
Coronary Angiography	1682	
Cardiac Catheterization	208	
EPS	70	
Total	1960	
Non-coronary Interventions		
ASD device closure	209	
VSD device closure	6	
PDA device closure	79	
Balloon mitral valvotomy	183	
Balloon pulmonary valvotomy	20	
PDA coil closure	27	
Balloon Atrial Septostomy	20	
MAPCA coiling, PDA stenting, Coronary AV fistulae closure	20	
<u>Coronary</u>		
Intervention		
PICA	674	
Electrophysiological procedures		
Electrophysiological study and RF ablation	225	
Permanent pacemaker implantation	202	
ICD	18	
CRT	9	
Total	434	
TOTAL PROCEDURES IN 2011-12	3657	



3D reconstruction of Atrial septal defect



CT Angiogram showing 3D reconstructed image of Crisscross origin of the right and left pulmonary arteries

Academic activities

- Organized a Live Transmission workshop on Pediatric Cardiac Interventions at SCTIMST, Trivandrum, during the Annual Pediatric Cardiac Society of India Annual Conference in October 2011.
- Organized South-East Asia region meeting of the PVRI on October 1st and 2nd, 2011.
- Organized the Coronary Intervention Update and Rotablator workshop in January 2012 and performed 2 rotablation cases and 3 complex coronary angioplasties.
- "Simulator based coronary intervention training program for Fellows" was organized at the Institute on December 18&19, 2011.
- Organized the Coronary Intervention Update and Rotablator workshop in January 2012 and performed 2 rotablation aided coronary interventions and 3 complex coronary angioplasties.
- As part of the ICMR Heart Failure study, the heart failure clinic was started in the surgical block from 1st January 2012.
- With commissioning of the new electro anatomic mapping system, the department undertook several complex atrial and ventricular arrhythmias for radio frequency ablation with success.



Department of Cardiovascular and Thoracic Surgery

The highlight of the year is the Homograft valve Bank project. In a landmark achievement, the first homograft implant was done succesfully in a girl with Tetralogy of Fallots with anomalous coronary crossing RVOT.The cryopreserved graft was used as an RV-PA conduit.This was the first surgery of its kind in the state. The program in running in a full swing. The harvesting, processing and storage procedures have been standadised and the implants are being used regularly.

Patient care: In the area of patient care, affordable, uniform, evidence based, high quality cardiac surgical care is given to the citizens of the country by well trained staff who are committed, knowledgeable and focused. The department is the biggest cardiac surgical service provider in the state and undertake all routine cardiac surgical cases like coronary bypass operation both on pump and off pump coronary artery bypass (OPCAB), valve replacement and repair, redo operations, aortic surgeries, pericardectomies and repair of congenital heart defects with excellent results. Specialized areas of focus are minimally invasive cardiac surgery, arrhythmia surgeries, heart failure operations and neonatal surgeries like Arterial Switch operation, BT Shunts, TAPVC corrections, neonatal ICRs. Vascular and Thoracic surgeries include thoracoabdominal aneurysm repairs, endovascular aneurysm repairs, carotid endarterectomies, carotid body tumors excisions, lobectomies and video thoracoscopic procedures.

In the year 2011-2012, 2065 Cardio Vascular and Thoracic operations were performed; of this 1523 were open-heart procedures. Of the surgeries on congenital heart defects 126 neonates weighed less than 5kg. The Division of Vascuar and Thoracic Surgery performed 332 operations.

Two typical surgerical procedures

Prosthetic graft Ascending Aorta to Bilateral Carotid arteries with an extension to left Subclavian artery followed by Thoracic EndoVascular Aneurysm Repair (TEVAR) i.e., HYBRID REPAIR in a case of distal aortic arch aneurysm (Right)



Ulcerated Carotid plaque



Procedures	No.
Adult Cardiac Operations	1311
Coronary artery bypass surgery	480
Valve replacement and valve repair surgery	369
Ascending aortic aneurysm repair and Bentall opeartion	23
Adult congenital heart disease, etc.,	88
Closed Heart	71
Surgeries for complex aortic aneurysms and aortoiliac occlusive diseases	43
Lung surgery including open and VATS – Lobectomy,Pneumonectomy ,LN Biopsy	58
Beating heart surgeries OPCAB	25
Coarctation repair- adult and paediatric	25
AV Fistula Creation	102
Carotid Endarterectomies	16
Thymectomies	8
Pericardectomy	1
BT shunt operation	2
Congenital Heart Surgeries	489
ASD Closure	112
VSD Closure	91
AV Canal defect Correction	12
TAPVC Repair	29
PDA and Coarctation Repair	19
Arterial Switch Operation	28
Tetralogy Of Fallot – Repair	144
BD Glenn and Fontan Operations	44

The Department Organised the following meetings and Workshops :

• Annual Meeting of Pediatric Cardiac Society of India was conducted at the Institute in September 2011 joinly by the Departments of Cardiology, CVTS and Anaesthesia.

Eminent cardiac surgeons and cardiologists from india and abroad participated. Workshop on pediatric valve repair was conducted by Dr.Pedro del Nido of Brigham and Womens hospital, Boston.

- The Department conducted a Mitral Valve Repair workshop by Dr.Carlo De Vincentis and Dr.Priyankar Sinha on repair of Rheumatic and non-Rheumatic valvular heat disease. Surgeons from all over the country attended the workshop.
- The Department conducted a workshop on Minimally Invasive Aortic Valve replacement and Mitral Valve Repair in March 2012 by Dr.Prem Sekher of Brigham and Womens'-Harward Medical school. A CME of Heart Failure was also conducted along with the worshop.
- "Vascular Day" was conducted in August 2011. A public awareness program was conducted in the forenoon followed by quiz program in Vascular Surgery for postgraduates from Medical college, Trivandrum. A CME program on Abdominal Aortic aneurysm, Endovascular procedures and Carotid revascularizations was conducted in the evening for medical professionals.



Inauguration of Workshop on Minimally Invasive Aortic Valve replacement and mitral, valve repair and CME on Heart Faillure Surger, March 2012



Division of Cellular and Molecular Cardiology

The aim of the Division is to carry out basic research in cardiology directed at understanding the molecular mechanisms involved in adverse cardiac remodeling. Experimental studies in animals and cell culture models focus on mechanisms in reverse remodeling. Convergence of basic research with clinical application and human resource development by training science graduates for a career in cardiovascular research are major objectives of the Division.

Research on cardiac responses to injurious and protective agents remain the focus of the Division. The major areas of research are cellular responses to hypoxia and hypertrophy-stimulating factors, modulation of energy metabolism for prevention of adverse cardiac remodeling, and stem cell response to hypoxia. The studies are supported by externally-funded research projects. Productive collaboration with the NIH, USA, was sustained during the year and the highlight of the year was a fresh collaborative project with the University of Connecticut Health Center, USA.





Computer Division

New Initiatives

The Division focused on expansion of system environments that included:

- Online application and processing for the recruitment of junior staff and senior staff for Personnel & Administration Division. This required new software development and implementation right from application registration to uploading of rank lists.
- Internet website renovation and its implementation.
- Integration of lab information system with lab equipments-software development and implementation to retract biochemistry test results of patients from Biochemistry Lab Equipments and display of results in Wards, ICUs and OTs
- Installation of Kiosks for hospital information and lab report printing.
- Medical record scanning & secured software for viewing in patient areas.
- Online leave application implementation in BMT Wing
- Integrated Nation Knowledge Network, Internet

connectivity with BSNL, Internet connectivity with load sharing

New Software Developments and Hardware Implementations:

- Salary, Pension, NPS, Arrears –6th pay implementation in continuation-modifications in GUI based program was made for revised pay fixation calculation of temporary and permanent staff
- Item code revision to 10 digits from 7 digits and updating of all programs related to that in Purchase, Stores, DCE and Accounts.
- Developed software for Doctors Order Form entries, patient billing entries for automatic inpatient billing and for inpatient service automation.
- Modifications of existing live softwares running in various departments as per user requirements.
- Installed two numbers of 40TB storage system.
- Installed robotic arm supported tape backup system.
- Network cabling for new units
- Integration of OMR Evaluation Software with Recruitement Software
Department of Imaging Sciences and Interventional Radiology



The department is providing Diagnostic Imaging and Interventional Radiology services in neurological and cardiovascular diseases.

Summary of Investigations done during the year

Diagnostic Procedures











Interventional Radiology Procedures



Patients attending Radiology OPD	1678
In patient admissions	279
Interventional Radiology Procedures in DSA lab (Both out patients and in patients)	714

Interventional Radiology Clinical Services:

New initiatives

- MoU signed between our Institute and the Indian Institute of Information Technology & Management, Kerala (an autonomous institute under the Govt. of Kerala) to collaborate in the field of medical imaging informatics.
- New procedures being done in CT :

Perfusion CT with optimised stroke protocol and Coronary CT were initiated

- New Procedures performed in Intervention
 - 1. Detachable tip microcatheter for AVM embolisation
 - 2. Detachable intracranial stent for aneurysm and stroke treatment



VRT reconstruction of post CABG coronary CT angiogram obtained from 256-slice CT scanner for stroke treatment



Patient presenting with acute left MCA occlusion within 6 hours successfully revascularised by mechanical clot removal using detachable completely retrievable Solitaire intracranial stent



Signing of MoU between the Indian Institute of Information Technology & Management, Kerala and SCTIMST



14th Annual Conference of Indian Society of Vascular and Interventional Radiology, October 13-16, 2011



Dr.C.Kesavadas receiving the Dr.M.L Aggarwal Memorial Oration Award at The Annual scientific meeting of Indian Radiological & Imaging Association at Hyderabad on January 29, 2012.

Department of Microbiology



The mission of the Department

- Provide accurate and quick reports on all specimens sent to the Laboratory.
- Give a consultant clinical microbiology service, one component of which is antibiotic stewardship.
- Develop molecular diagnostic services to include more infectious diseases.
- Maintain the viral culture facility.
- Train MD and MSc Microbiology students as observers and as Apprentice trainees respectively, which may in the future be upgraded to a course.

• Enhance research activities.

New initiatives

- Homograft valve bank was inspected by external experts and the license was extended for an additional period of 5 years. First Homograft valve was implanted successfully. This was followed by two more successful transplants.
- Patient safety initiative: A study on patient safety practices including Infection control measures was completed.



Department of Neurology

Department of Neurology continues to be a center of excellence in providing comprehensive patient care for all types of neurological disorders and in conducting basic and clinical research in neuroscience. The main focus of the department is to develop different neurological subspecialties and thus provide advanced patient care and conduct focused high quality research.

Clinical Services

Department of Neurology conducts five general neurology outpatient clinics every week and five different subspecialty clinics. Patients with all types of complex neurological disorders, who are referred from all over the country, are evaluated and expertly managed during these clinics. A total of 5529 new patients attended the Neurology clinics which represents an increase of 4.6% as compared to previous year.

Department has a total of 60 inpatient beds including Neurology and Stroke ICU beds. The number of admissions also increased from 2366 in the previous year to 2752 this year. The bed occupancy rate was 82% with an average hospital stay of 6 days and mortality of 1.44%

Research

Apart from the research being conducted in individual subspecialties, Department of Neurology is involved in international trials on multiple sclerosis and demyelinating diseases. The department is also conducting new clinical studies in Prion Diseases and subacute sclerosing panencephalitis.



The R. Madhavan Nayar Center for Comprehensive Epilepsy Care (RMNC) is the first center in India and South Asia catering to the diagnosis, treatment, awareness and overall welfare of people with epilepsy. Since its inception in 1998, headed by the current Director of the institute and Senior Professor in Neurology Kurupath Radhakrishnan, the center aims at facilitating and augmenting epilepsy care through a comprehensive care approach backed by sound academic and technological foundations. Presently it provides comprehensive evaluation and treatment for all kinds of adult and pediatric epilepsies with a special emphasis on surgical management of medically refractory epilepsy. It receives patients from all corners of the India as well as from neighboring countries and offers world-class yet affordable comprehensive epilepsy care, comparable to any other center in the world. The mission of the division is to provide:

• Medical, surgical, psychosocial and occupational management of individual patients with epilepsy.

- Educate the primary and secondary care physicians about the current trends in the management of epilepsy, and enhance the public awareness about epilepsy in order to dispel the prevailing misconceptions.
- Undertake clinical, applied and basic science research and evolve cost-effective investigative and treatment strategies.

RMNC Team: Comprehensive epilepsy care team at RMNC consists of four epileptologists, two epilepsy neurosurgeons, two neuroradiologists, three postdoctoral fellows in epilepsy, one neuropsychologist, one speech therapist, one occupational therapist, seven EEG technologists, three medical-social workers and six epilepsy nurses.

Clinical service

Patient care at tertiary level: RMNC conducts two epilepsy clinics every week where epileptologists evaluate patients with complex epilepsies, provide appropriate medical advice and treatment along with neuropsychological and occupational counseling. This year, an average of 492 patients/month were evaluated at these epilepsy clinics. The psychosocial issues related to epilepsy are dealt with by expert psychologist/medical social workers and occupational therapist. This year, neuropsychology evaluation for pre-surgical evaluation, development assessment and counseling were conducted in 1,112 patients. The Occupational Therapist evaluated and counseled 1,118 patients which included 238 post-operative cases to aid their emotional and social wellbeing.

Patients with drug resistant and difficult to diagnose epilepsies are admitted for Video-EEG monitoring. Epilepsy monitoring unit at RMNC has six VEEG units, largest in the country. This year, a total of 1096 video EEGs were conducted. Ninety-nine patients underwent surgery during this year which included four patients who underwent long-term video EEG monitoring following intracranial electrode placement.

A subsection of the comprehensive epilepsy care center, Kerala Registry of Epilepsy and Pregnancy (KREP) deals with epilepsy care for women in the reproductive age group. Appropriate epilepsy management and counseling related to issues like marriage, fertility and pregnancy for women with epilepsy is separately provided through KREP.

Patient care at community level: RMNS conducts

two outreach community-based epilepsy clinics per month in a rural set-up in central-north Kerala at PHC Changaramkulam and Ansar Hospital, Perimpilavu. On an average 75-80 patients were seen in both clinics. In addition to basic care, patients who require advanced care were referred to RMNC. Through these community-based epilepsy care programs, we also educate the public about epilepsy.

The section has established and supports a very active Epilepsy self-help group. It publishes a quarterly news letter, Pratheeksha, for the lay public. It provides counseling, financial assistance in procuring antiepileptic drugs and assistance in job placement for patients whose epilepsy is cured or controlled.

Academic activity and human resource development: Four post-doctoral fellows (PDF) and four technology students were recruited this year to undergo training in clinical, electrophysiological and technological aspects of epilepsy management in this academic year which commenced on January 1st 2012.

The fellows who have undergone training through RMNC have established epilepsy care programs in different regions, in India, and in SAARC countries like Sri Lanka and Bangladesh.



National Epilepsy Day on November 17, 2011



Comprehensive Movement Disorder Care Center

The Center provides high quality and comprehensive medical and surgical treatment to patients with Parkinson's disease (PD) and various other movement disorders. The centre conducts clinical, genetic, neurophysiological, neuropharmacological and basic science research and provides training to post-graduate trainees in Neurology, post-doctoral fellows in Movement Disorders and PhD scholars, with a vision to become a leading referral, training and research center for Movement Disorders in India.

Clinical service

- Movement Disorder Clinic: Movement disorder specialists conduct a weekly clinic dedicated to the treatment of all cases of Movement Disorders referred to this Institute and provides counseling, education and neuropsychological and psychiatric evaluation. A physiotherapist attached to the clinic provides guidance on exercise regimens, avoidance of falls, improvement of mobility, walking aids etc. Annually, approximately 1200 to 1500 patients attend the clinic.
- 2. Botulinum Toxin Clinic: This clinic is devoted to the treatment of focal and segmental dystonia, hemi-facial spasm, post-stroke spasticity etc. The faculty has vast experience with conducting more than 1,000 treatment sessions so far (1996-2012) and has an annual attendance of 150 patient vists a year.
- 3. Movement Disorder Surgical Program: The Center is the pioneer of Deep Brain Stimulation (DBS) surgery for Parkinson's disease (Figure 1) in India, with the first procedure of Globus Pallidus deep brain stimulation performed in India in August 1998 and one of the leading centers in this field in the country. The surgical procedures are done using state-of-theart techniques like Micro-Electrode Recording (MER) and image guidance (Surgical Planning System and Neuronavigation System). DBS treatment is also offered to patients with intractable tremor and dystonia. The Centre is also well experienced in lesioning surgeries like MR-guided radiofrequency lesioning of 'Globus Pallidus' for Parkinson's disease, and Stereotactic Thalamotomy for Essential Tremor. The Centre has performed around 270 functional neurosurgical procedures for medically refractory Movement Disorders and the faculty have presented the results at several international meetings and published their experience in reputed international journals.
- 4. Motor Physiology Lab: The motor physiology lab run by the Center is engaged in various research and treatment related projects using modern research tools like image guided Transcranial Magnetic Stimulation (TMS) (Figure 2). Findings from three of the completed research projects have been published in high impact journals in Neurology and Neurophysiology. The center

also performs activities like tremor analysis and back averaging studies for differentiating between different types of 'myoclonus'



Figure 1- A patient with advanced Parkinson's disease undergoing Deep Brain stimulation (DBS) surgery



Figue 2. A subject undergoing image-guided Transcranial Magnetic Stimulation (TMS) in the motor physiology lab

New initiatives during the year: The Neuronavigation system for image-guided TMS was acquired and TMS based research and therapeutic studies are now conducted with image guidance. This improves the accuracy and reliability of the results. The centre is represented by Dr. Asha Kishore as a member of the international consortium on Genetic Epidemiology of Parkinsons disease (GEOPD)

Summary of activities during the year:

Deep Brain Stimulation Surgery	12
DBS Neurostimulator replacement	11
Botulinum Toxin Injection	148
Movement disorder clinic attendance	1380
Post operative programming	52
Transcranial Magnetic Stimulation	458
Training to Post Doctoral Fellow	1

Important visitors/ trainees during the year

1. Prof. Mark Hallet, Chief of the Human Motor Control Section at the National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Health, USA visited the Comprehensive Care Center for Movement Disorders on 26th and 27th of September, 2011. He delivered a lecture on 'Myoclonus' on September27th, 2011 (Figure 3).

- Dr. Sabine Meunier, Professor of Neurology and Movement Disorders, Hospital Sal Petriere, Paris worked as Visiting Professor in Comprehensive Care Center for Movement Disorders from 08/07/2011 to 07/10/2011. She visited the Center again from 20/11/2011 to 04/12/2011, as part of the Indo-French collaborative project "Cerebellum and Cortical Plasticity – The Case of Dystonia". She also gave a lecture on the topic "Intracortical Inhibition" on 4th October 2011 at SCTIMST (Figure 4).
- 3. Dr.Traian Popa, Neurophysiologist and the French collaborator of the ongoing TMS projects visited the TMS lab in August 2011 and again in December 2011.



Figure 3- Prof. Mark Hallet, delivering his lecture on Myoclonus, during his visit to SCTIMST, September 27, 2011



Fig.4- Dr. Sabine Meunier, Visting Professor, Comprehensive Care Center for Movement Disorders



Comprehensive Stroke Care Center

The Comprehensive Stroke Care Center carries out evaluation and management of acute and subacute strokes and transient ischemic attacks (TIA). The center is equipped with a seven bed ICU and four ward beds with all facilities for giving acute care, including thrombolytic therapy. The center provides advanced and comprehensive stroke care including intravenous and intra-arterial thrombolysis, mechanical revascularization in hyperacute strokes, carotid revascularization, decompressive craniectomy for malignant middle cerebral artery strokes and surgical evacuation in intracerebral hematomas. The center has crossed the milestone of 100 carotid endarterectomies this year. The mission of the stroke center is to become leading center for hyperacute stroke care in the country, develop a state-of-the-art comprehensive stroke rehabilitation program, to help increasing stroke awareness in the society and carry out advanced research in stroke.

Clinical service

The team at the comprehensive stroke care center includes stroke neurologists, interventional radiologists, neuroanaesthesiologists, neurosurgeons, cardiologists

and vascular surgeon. In addition, stroke unit has a rehabilitation team comprising of a physiotherapist, occupational therapist, speech therapist, nutritionist and medical social worker who are actively involved in longterm care and rehabilitation of stroke patients. There is a 24-hour stroke helpline for receiving calls from other hospitals so that timely referral and early acute stroke care is possible. The centre conducts a weekly stroke clinic for follow-up and evaluation of stroke patients which caters to around 50 patients per week.

A summary of the clinical activities during the year

Stroke clinic attendance	2336
Stroke ICU admissions	393
Thrombolysis	17
Decompressive Hemicraniectomy	6
Hematoma evacuation	5
Carotid endarterectomy	17
Moya moya revascularization	5
Patent foramen ovale closure	1

New initiatives

 A 10-minute short documentary on acute stroke and emergency treatment was made for patient awareness in April 2011. It was displayed in patient waiting areas and was telecast in the local TV channels for creating awareness among the public regarding the urgency of acute stroke treatment.

- A collaboration with 108 emergency ambulance services was started to train the emergency medical personnel on identification of acute stroke and myocardial infarction and rapid transfer of patients to the Institute. This was done from May 2011 to October 2011 during which eight classes were conducted by the Cardiologists, Stroke Neurologists and Neuroanesthesiologists.
- An academic program was started for the nurses in the stroke ICU from April 2011, which consist of one class in a week. The classes are taken by Neurologists, Anaesthesiologists, nurses, physiotherapists, occupational therapists and speech therapists.

Important visitors/trainees

Dr Kasia Lipska, Endocrinologist from Yale University, US is currently conducting a research project "Diabetes, prediabetes and insulin resistance in patients with recent transient ischemic attack and ischemic stroke" in collaboration with Stroke Program from September 2011-May 2012.



Sri. Jagathy Sreekumar, Film Celebrity is inaugurating World stroke day 2011 on October 29, 2011

Cognition & Behavioural Neurology Center

The section provides clinical services to patients with cognitive problems and dementia. It also provides advice and technical support to the Alzheimer's & Related Disorders Society of India (ARDSI), a voluntary organization that helps dementia patients and care givers. The section carries out clinical and basic science research in the field of Dementia, Cognition and Behaviour. The staff members at the section include two Neurologist, Speech therapist, Neuropsychologist, Sociologist and Data manager.

Clinical service

The section conducts a weekly Cognitive Disorders Clinic where patients with complex cognitive problems are evaluated and counseled.

New initiatives

In addition to the ongoing research programs, a new

Comprehensive Care Center for Neuro-muscular Disorders

This subspecialty focuses on the management issues of patients with disorders of muscles, nerves, plexus and anterior horn cells of the spinal cord. Besides coordinating the investigations and treatment protocols of these patients, this subsection runs a specialty review clinic aimed at follow-up of their response to treatment.

Clinical activities

Neuromuscular Review Clinic: This clinic is conducted every Tuesday for four hours. Each clinic is conducted by one Neuromuscular Consultant, two Residents, one neuro nurse, one senior medical social worker, one occupational therapist and one physiotherapist to advice regarding further exercises and activities to promote functional recovery. Any additional monitoring, investigations and consultations from other specialties are advised from this clinic. The patients, depending on the disease status are reviewed at 3 months, 6 months or 1 yearly interval. This year, 1239 patients attended the clinic.

Group Sessions: Group therapy is conducted over one hour prior to each review clinic for patients with specific diseases like Myasthenia gravis. This is moderated by the Neuromuscular consultant along with a neuro nurse and a senior medical social worker during which patients discuss their disease states, clear their doubts, share their experience with other patients and get to know each other thus helping them to cope up better with their disease.

A summary of the clinical activities during the year

Speech evaluation	851
Speech therapy	361
Audio evaluation	274
Neuropsychological testing	1014
IQ assessments	103
Counseling sessions	177
Memory & Neurobehavioral clinic attendance	355
New patients with dementia	101

National Institute of Health (NIH) USA, funded multicentric Indo-US collaborative project, the Kerala-Einstein study, commenced from June 2011. This new project looks into assessment of life-time diet on the development of cognitive problems and dementia in old age.

Electromyography (EMG) and Nerve conduction laboratory: The section also runs an EMG laboratory for the evaluation and diagnosis of neuromuscular diseases. This is conducted on all week days and approximately 5-6 patients ae evaluated every day.

A summary of the clinical activities during the year

Nerve conduction studies (NCS)	1142
Needle Electromyography (EMG)	441
Repetitive Nerve Stimulation test (RNS)	110
Visual Evoked Potentials (VEP)	119
Brainstem Auditory Evoked Response (BAER)	46
Somatosensory Evoked Potentials (SSEP)	38
Muscle Biopsy	51
Nerve Biopsy	19
Specific immunologic tests	48
Genetic Tests	15
Large volume Plasma Exchange	14
Small volume Plasma Exchange	1
High dose Intravenous Immunoglobulins	8
Thymectomy for Myasthenia gravis	14
Mechanical ventilation (Neuromedical ICU)	61



Comprehensive Center for Sleep Disorders

Comprehensive Center for Sleep Disorders (CCSD) of the Department of Neurology was started at the Biomedical technology wing of Poojappura of SCTIMST in May 2009, with a mission of providing diagnostic support, patient care, research, training and education of the public about the sleep disorders. This is the first comprehensive care program of its kind in the country catering to people with all forms of sleep disorders through a disciplined approach. It thereby maintains a cohesive interface with the various other subspecialties in Neurology as well as other disciplines in medicine.

The Division aims to become India's premier center of sleep medicine and research. The division is committed towards providing comprehensive clinical care for sleep disorders and to conduct research on various aspects of sleep disorders.

Clinical service

CCSD has a three-bedded sleep lab with facilities for polysomnography (PSG), continuous positive airway pressure (CPAP) titration, multiple sleep latency test (MSLT), maintenance of wakefulness test (MWT) and suggested immobilization Test (SIT). Patients are seen in sleep clinic every Thursday between 2 and 5 pm. These patients in addition to medical consultation undergo neuropsychological evaluation, psychiatric counseling and dental sleep evaluation. All patients on CPAP are re-evaluated on Thursdays once every three months in CPAP review clinic. Group sessions moderated by social worker are conducted for patients for over thirty minutes prior to sleep clinic. Patients discuss their problems and experiences and get to know each other.

Academic activities

Apart from the clinical research, CCSD is actively involved in the basic science research pertaining to sleep disorders. Sleep Research Laboratory is an integral component of the CCSD and is aimed to explore the basic mechanisms and to conduct translational research in emerging aspects of sleep regulation for improving human health. The unique feature of this laboratory is that the knowledge gained from animal experiments would be applied to cure various sleep disorders in humans. The research laboratory works in close collaboration with the Sleep Clinic in identifying the unresolved puzzles of sleep disorders and seeks to find a solution to those human maladies. This most modern research laboratory is equipped with the latest instruments and technology to conduct basic sleep research in animal models and human subjects. A PhD program in Neuroscience is initiated to look into the various aspects of sleep loss on cognition (anxiety, learning & memory), developmental plasticity in neural networks, interrelationship of sleep and thermoregulation, and inf ammatory markers.

A summary of the chilical activities during the year			
	Total number of PSGs	308	
	Total number of CPAP trials	138	
	Total number of MSLT	23	
	Total OPD attendance	665	

A summary of the clinical activities during the year

New initiatives

- Initiative to design portable sleep detection devise based on EEG sensors with alarm system (in collaboration with instrumentation lab), DBT funding applied.
- Initiative to devise an apnea detection device for home-PSG in collaboration with CDAC.
- Initiative to design newer ambulatory polysomnography machines with EEG sensors (in collaboration with instrumentation lab).



The Honourable Speaker of the Kerala Legislative Assembly Shri. G. Karthikeyan inaugurating the National Sleep Day, 2011



Continuous Positive Airway Pressure machine in the sleep lab



Department of Neurosurgery

The Department of Neurosurgery continued to maintain high standards in patient care and academic pursuits as in previous years. The mission of the Department is to develop and pioneer new techniques in various neurosurgical subspecialties and provide excellent training to future neurosurgeons.

Clinical service

Routine clinical activities of the Department include outpatient clinics and the operation theatre, functioning five days a week. All the complex neurosurgical cases referred from within Kerala and from neighboring states, are evaluated and operated throughout the year. Major focus of the Department is subspecialty oriented development and the major areas of operative focus are micro vascular surgery, surgery of the skull base, endoscopic surgery, epilepsy surgery, movement disorder surgery, spinal instrumentation and minimally invasive procedures with the aid of neuronavigation equipment. This year, a total of 1431 cases were operated with an overall mortality of 1.2%. These results are comparable with the best centers of the world.

Academic activities

Regular academic activities are conducted on weekends wherein regular Neuroradiology meetings are held followed by grand rounds and case discussion or seminars. The faculty and the students maintained high standards in academic and research areas. The Institute was well represented at all major national and international conferences, symposia and seminars. Four candidates successfully completed their MCh training and four new residents joined the department.

A summary of the operative procedures during the year

Vascular: 203	
Intracranial aneurysms	178
AVMs	12
Cavernomas	07
Moya Moya	06
Skull base: 141	
Vestibular schwannomas	61
Skull base meningiomas	63
Others	17
Sellar suprasellar: 95	
Pituitary tumors	61
Craniopharyngiomas	26
Others	8
Spinal surgeries: 146	
Spinal tumours	66
Cervical degenerative disease	48
Lumbar degenerative disease	32
CV junction anomalies: 54	
AAD	09
Chiari	43
Others	02
Neuro-oncology:	327
Meningiomas	77
Gliomas	182
Pediatric posterior fossa	23
Colloid cyst	23
Others	22
Endoscopy:	65
Epilepsy surgery:	101
ATL-AH	59
Hemisphereotomy	3
Callosotomy	3
Lesionectomy	15
VNS	1
Intracranial Grid placement	19
Movement disorder	20
Others	396
Total	1483
10 (01)	1405

Department of Pathology

The focus of the Department is on the development of newer diagnostic parameters for neuromuscular and muscle diseases using nerve biopsies. The Department has developed an image analysis system for the neuronal cell counts in the surgical specimens from temporal lobe, amygdala and hippocampus of patients with temporal lobe epilepsy. The department has also developed simple immunodiagnostic system for tuberculosis.

Patient services

The Department performed histopathological analysis of 1900 surgical specimens in patients undergoing surgical treatment for neurological and cardiac diseases. Intra-operative tissue diagnosis (frozen section) was performed in 640 patients. Enzyme histochemical and immunohistochemical studies were performed in 65 muscle biopsies. Immunopathological investigations were performed in 3500 cases.

Academic activities

Apart from the service oriented diagnostic work, the Department also conducted weekly teaching programmes (case demonstration, CPC and seminars) for the postgraduate students in Neurology, Neuro-surgery and Neuroradiology. Specialised training was also extended to postgraduate students in Pathology from Medical Colleges of Trivandrum and Kottayam, Amritha Institute of Medical Sciences, Kochi and Madras Medical College, Chennai.





Department of Physical Medicine & Rehabilitation

The Division of Physiotherapy metamorphosed into the Department of Physical Medicine & Rehabilitation (PMR) with effect from 15 Oct 2011. Dr. U. Nandakumaran Nair joined the Department as Visiting Professor from 24 April 2011. The department currently offers services in these areas:

- a) Physiotherapy services for inpatients and outpatients.
- b) Rehabilitation consultations to patients in wards, outpatient departments and their follow-up

The department hopes to establish itself as an advanced centre for neuro & cardiac rehabilitation.

Rehabilitation services will focus on assessment of disability, improvement of QOL and opportunity for selfactualization in persons with neurologic and cardiac impairment.

Dr Pesi H. Khatrak, Senior Consultant in Rehabilitation, Dept of Rehabilitation Medicine, Prince of Wales Hospital, University of NSW, Australia visited the Department on 23/1/2012

Patient service

Name of service/ department	No: of sessions
Neurosurgery	2843
Neuromedicine	3887
Cardiac Surgery	7437
Paediatric Cardiology	4644
Out-patient Department	3483
Neuro-muscular Clinic	123
Total	22417



Department of Transfusion Medicine

The mission of the Department is to save human lives by carrying out medical services, imparting training and conducting scientific research that improves the safety and efficacy of blood transfusions. The Department aims to retain the leading position in the State, simultaneously striving to become a national leader in research, education and services in transfusion related healthcare.

A new initiative during the year, based on the decision of Hospital Transfusion Committee is the use of bigger size eye-catching labels on RBC packs as part of error prevention strategy.

Patient services

The blood requirements are met through regular, voluntary repeat donations. All efforts are made to maintain 100% voluntary blood donations through mobile camps and in house blood collections. Focus is on increasing the number of repeat voluntary blood donors to enhance blood safety. Blood component support is provided to other hospitals as well. Three levels of blood safety checks before donations ensures safe transfusions. Appropriate tests at each level of Blood Banking have made it possible to provide quality products with clinical efficacy. Improvement in quality is achieved with the introduction of Levy Jennings chart in Transfusion transmissible infections and Statistical process control charts for blood components. Blood support is provided round the clock for the patients. Blood component support is provided for other hospitals also.

Academic activity

Training is provided to doctors and observers on Modern Blood Banking Technology. The programme is sponsored by Kerala State AIDS Control society. World Health Day was celebrated with mega community based blood donation camp. Hospital Transfusion Committee meets regularly and discusses relevant matters and takes policy decisions.

Regular classes, practicals and seminars are held for students of Diploma in Blood Bank Technology along with short projects.

Community service in the form of awareness programme is provided to donors on health related issues and emphasis is laid on the need for voluntary donations.

Technical support and subject expertise is provided to Kerala State Aids Control Society as and when required.

Consultancy services for referred cases, resolving serological discrepancies, serological investigations for autoimmune hemolytic anemias and transfusion support for Thalasemia and Congenital dyserythropoiesis patients are extended for other hospitals.



On October 1, 2011, National Blood Donors' Day was inaugurated by Dr. R. Sankarkumar, Medical Superintendent

BIOMEDICAL TECHNOLOGY WING

Mission

To deliver high quality healthcare technology through innovation in science and education.

Vision 2020

- 1. 50% self sufficiency
 - a) 20% self sufficiency through externally funded R&D
 - b) 20% self sufficiency through testing services
 - c) 10% self sufficiency through technology transfer
- 2. 30 new technologies including 5 tissue engineered products
- 3. Two technology transfer to Multi National Companies
- 4. Fully functional incubator and 2 industry sponsored R&D Centres.
- 5. 50 papers in Biomaterials or equivalent in leading scientific journals.
- 6. Fully functional National Testing Centre with 2 franchisee/Public Private Partnership testing centres in the country







From the Desk of the Head of Biomedical Technology Wing

The year 2011-12 was another year of effective technology transfers, project collaborations, testing activities and academic programmes. The emphasis for technology transfer and industry linkages resulted in holding hands with industry through technology transfer of three products viz, Injectable Calcium Phosphate Cement for dental applications, Bioactive ceramic composites for orthopedic applications to M/s IFGL Refractories Ltd, Kolkota and Intrauterine Device to M/s HLL Lifecare Ltd, Trivandrum. An MoU was signed with M/S SIDD Life Sciences, Chennai to explore a hub for developing cardiopulmonary devices so that medical device development would cater to the market pull. Many other MoUs and non-disclosure agreements were signed with both industry and academic institutions for collaborative research of which those with M/s Lifecare Innovations Pvt Ltd, Indian Institute for Information Technology and Management-Kerala, Trivandrum (IIITM-K), Agharkar Research Institute, Pune etc are notable.

Testing services were offered to medical device industry on the evaluation of biomaterials and medical devices. The overwhelming increase in demand during the year, for these testing services clearly shows that the Institute has to continue to play a major role in this area for supporting the growth of the medical devices industry in the country. On the academic front, the second batch of M.Tech in Clinical Engineering and MPhil in Biomedical Technology students successfully passed out.

The various product development projects are steadily moving through the different stages of development. The research projects made excellent progress resulting in an increased number of publications in journals with good impact factor, while a record number of 19 patent applications were filed on new innovative developments.

Overall, it is clear that BMT Wing continues to grow from strength to strength in the development of biomedical technology and training of human resources for the advancement of the country, while maintaining strong industrial links through testing services and technology transfer.

G.S. Bhuvaneshwar

BIOMEDICAL TECHNOLOGY DEVELOPMENT

The period 2011-12 was yet another year of strengthened relationships with existing industrial partners. New collaborations with industries through support in technology transfer activities, testing services and joint product development were explored. The different projects made good progress towards the set objectives.

HIGHLIGHTS

Technology transfers: The year saw the technology transfer of three products to industry. The Injectable Calcium Phosphate Cement for dental applications and Bioactive ceramic composites for orthopedic applications were transferred to IFGL Refractories Ltd, Kolkata. The hormone releasing Intrauterine device, which was developed in collaboration with HLL Lifecare Ltd, Trivandrum was formally licensed to the company. Discussions are ongoing with prospective industrial partners for commercialisation of other products that are at various stages of development.

Collaborations: An MoU with SIDD Life Sciences, Chennai was signed for a establishing a hub for developing cardiopulmonary devices with a view to accelerate targeted development of devices based on market pull. The existing MoU with Agharkar Research Institute, Pune was extended and new MoU was signed with Lifecare Innovations Pvt Ltd, Gurgaon for technology partnerships. Nondisclosure agreements and material transfer agreements were signed with International Stem Cell Services Ltd, Bangalore and Vins Bioproducts Ltd, Hyderabad for exploring technology partnership for different products.

Quality: The quality management system continued to improve with the COFRAC Surveillance audit taking place during January 27th & 28th 2012 and the NABL audit held during 17th & 18th January, 2012.

Research & Development: The large number of research projects made good progress. While the product development projects moved towards clinical evaluation stage or towards technology transfer phase, the research projects contributed substantially to produce better outputs through patents and publications.

Patents

Year	Patents granted	New patents filed
2009-10	4	8
2010-11	NIL	15
2011-12	NIL	19

Patents held (sealed)	=	85 Nos.
Patents filed and pending	=	67 Nos.
Designs held (sealed)	=	13 Nos.

Publications – 74 publications in indexed journals were contributed during the year from BMT Wing with a impressive impact factor of 3. The table below shows a healthy growth during the last 3 years.

Year	Publications in indexed journals	Average Impact Factor
2009-10	55	3.01
2010-11	72	2.99
2011-12	74	3.00

Product Development, Technology Transfer & Industrial Linkages

Artificial Organs

(a) Device Testing Lab



Development of improved tilting disc heart valve

The project involves the development of an improved tilting disc heart valve with objectives of reducing thrombotic potential, enhancing MRI compatibility and improving hydrodynamic performance. The improved model incorporates an MRI compatible titanium alloy cage coated with titanium nitride ceramic coating to improve tissue and blood compatibility and reduce metal ion release while implanted.





Improved tilting disc heart valve prosthesis: Healing response of the improved valve model six months after implantation in the animal experiments

ANNUAL REPORT 2011-12-

The improved design has gone through all preclinical testing requirements as per the International standard ISO 5840 and is found to excel in terms of hydrodynamic performance. The accelerated durability studies showed no structural dysfunction during the evaluation of more than twenty five valves for a duration of 400 million cycles each. Preclinical animal evaluation showed excellent healing response, reduced tissue overgrowth and incorporation of the sewing ring.

A titanium nitride coating facility was set up to coat the valves for clinical trials. The Industrial partner is organizing a pilot production for conducting clinical trials of the device.

Development of Coronary Stent System

The project aims at the development of a coronary stent system for coronary artery stenting. The stent design with minimal gouging during deployment was achieved and validated though structural analysis studies. The metallic stent is coated with a non-porous ceramic coating (titanium nitride) in order to minimize the elution of metallic ions into the surrounding tissue.

Various test systems for qualifying the stent for safety and performance has been developed and validated. These include the ones for stent expansion characterization, fatigue life estimation, surface characterization etc. Most of the preclinical laboratory evaluations have been completed. Pilot production for carrying out the preclinical animal evaluation is in progress.



Finite element structural analysis showing that the lateral strain which produces gouging of the endo luminal surface during the deployment of the stent is brought down to less than 10 micron by optimization in the design

Development of PVDF coated and gel sealed vascular graft

The industry sponsored project (M/s TTK Healthcare Ltd) (executed in collaboration with Division of Polymer Processing) aims at imparting a thrombo-resistant **f** ouro polymer (PVDF) coating on the fabric along with closure of the graft pores using hydrogel. After the standardisation of the processes, a set of forty grafts was produced for conducting the preclinical animal trials. Animal trials have just begun in March 2012.



Finite element structural analysis showing that the lateral strain which produces gouging of the endo luminal surface during the deployment of the stent is brought down to less than 10 micron by optimization in the design

(b) Modelling & Prototyping Lab



Commercialisation of Centrifugal blood pump

Objective of the project is commercialisation of Centrifugal Blood pump for extra-corporeal cardiopulmonary bypass. In the completed project, the pump prototypes were fabricated in limited numbers for evaluation and in the current project, the aim was to develop a mould for mass production of pumps for pre-clinical and clinical evaluation and subsequently commercial production.

Process of finalisation of the mould is ongoing and a number of changes were made on the mould design to meet the requirements, with the help of in-vitro tests.

Activities during the year

- Additional process for improvement of surface finish was implemented during the year, which includes vapour polishing and annealing. The process of annealing and vapour polishing were standardised and validated.
- Number of prototypes were assembled for evaluations. In-vitro evaluations of few pump components were conducted for comparing the blood damage levels of the pumps.
- A new design with improved outlet geometry and better washout holes is prepared based on CFD analysis and the fabrication of prototype is ongoing.
- Completed Ex-vivo evaluation of 5 LVADs in porcine model for a duration up to 6 hours.



Ex-Vivo evaluation of SCTIMST-VSSC Left Ventricular Assist Device (LVAD)

Development of Left Ventricualar Assist Device

This is a collaborative project with VSSC, Trivandrum and the responsibility the lab is to evaluate the LVAD device in-vitro for hemolysis index, coordinate and conduct exvivo evaluation to assess the performance of the device on live animal models. Ex-vivo evaluation of the 5th device in the series was conducted during the year and the device performed successfully for the duration of evaluation. A report of evaluations were prepared and submitted to the sponsor. Waiting for further devices from VSSC (the sponsor) for the next phase of evaluation.

Biomaterial and Biological Products

Bioceramics lab



The following technologies developed in the lab were transferred to IFGL Refractories Ltd, Kolkata for the commercial production: (i) Injectable Calcium Phosphate Cement for dental applications (ii) Bioactive composite ceramics for orthopaedic applications. The agreement was signed on 10th May 2011

Production scale-up of Calcium phosphate cement (Chitra-CPC)

The project is aimed at the scaled-up production of the calcium phosphate cement developed in the Bioceramics Lab, named as "Chitra-CPC". This is an injectable bone substitute with cohesive consistency, and hence it is ideal for wide range of applications in orthopedics and dentistry. Pre-clinical studies were done as standard Endodontic Usage Test (ISO 7405), in a pig model. Two human clinical trials have been done in dental applications, with encouraging outcomes.

Dental products



Development of a drug releasing intrauterine device for contraceptive applications (Colloborative programme between SCTIMST and HLL Lifecare Ltd): The developmental part was completed during the year and the technology transfer documents were prepared and handed over to HLL Lifecare (industry partner). HLL has already set up a limited production facility at their factory in Aakkulam. They have also identified a CRO for carrying out the clinical trials for proving the safety and efficacy of the product. Approval from Drug controller has already been obtained for test manufacturing and marketing the product. The industry hopes to put the product into market at the earliest.



Signing of the TT agreement and handing over of TT documents to HLL Lifecare



H-Care IUD developed jointly by SCTIMST and HLL lifecare Ltd



Development of decellularised animal tissue for cardiovascular application

Through this project, a source of quality bovine tissue, which is safe for biomedical use, has been set up at Kerala Livestock Development Board unit, Kulathupuzha. A decellularised bovine pericardium safe for human implantation was developed in this project.

'Expression of interest' from the industry for this technology was invited through our website and discussions were initiated with the companies which showed interest for technology transfer.



Decellularised bovine pericardium developed in this project.

In vivo Models & Testing

Laboratory Animal Sciences

Development of a paper pulp product was completed with the co-operation of an industrial partner MASPAK, Alleppey. Discussions are underway to launch the product.

Thrombosis Research Unit

Discussions were held with a biological products manufacturer who showed interest in commercialising the know-how of anti-snake venom raised in chicken and purified from egg yolk by a process developed at the Institute.

Diagnostics and Instrumentation



Instrumentation lab

The laboratory has been involved in development of indigenous technology for Disposable ECG Electrodes. The preclinical evaluation of raw materials and prototype electrodes has been completed. This technology is ready for clinical evaluation and transfer of technology to an industry. The laboratory, in collaboration with Centre for Development of Advanced Computing (CDAC), Trivandrum, have completed indigenous technology development for Portable Medical Electrical Safety Analyser. The prototypes have been evaluated and this technology is expected to be transferred soon.

Laboratory for Polymer Analysis



Non-enzymatic Blood glucose measurement system

The goal of the programme, currently undertaken in collaboration with Vinvish Technologies, Trivandrum is to design simple, cost effective non-enzymatic methods in an easy to read out format for the detection of glucose in f uids such as blood, urine and tear. The immediate objective is the demonstration of glucose measurement in f uids like blood using non-enzymatic method based on molecularly imprinted f uorescent polymeric hydrogel and functionalized gold nanoparticles. One of the chemical approaches depending upon the suitability for the application will be integrated with appropriate optics and electronic components to generate a prototype non-enzymatic glucose-measuring device.

Microbiology

RAPID Antibiotic sensitivity kit for urinary tract infection (UTI)

At present by classical clinical microbiology methods it takes 48 to 75 hours for UTI identification and antibiogram

which requres a microbiologist and an established microbiology laboratory.

The objective of the project is to develop a rapid diagnostic kit for UTI with antibiogram where the results will be available by 6 hours without sophisticated equipments and expert manpower. The kit is to be cheap and without the need for infrastructure and technical skills demanded of classical microbiological diagnosis for UTI. A prototype of the kit for rapid diagnosis for UTI has already been developed and 20 kits have been tested at Department of Microbiology, Hospital wing, SCTIMST.

Toxicology

In vitro pyrogen test kit for the evaluation of pyrogenicity using human whole blood' assay is developed. This new development will be an ELISA method for pyrogen test and will be suitable for evaluating wide spectrum of applications to measure the undetected non endotoxin pyrogens, such as pyrogens of any chemical or biological nature. Validation part has been initiated.

Technology Transfer & Project Coordination

Technology Business Division



Technology Business Division facilitates active collaboration and interaction between the Institute and medical device industry in research, technology development and transfer. The division fosters the industry and intrainstitutional linkages by facilitating instruments such as research agreements, non-disclosure and confidentiality agreements, material transfer agreements, MoU, technology transfer license agreements etc. The customer service cell coordinates all external and internal testing requirements for the accredited testing services offered by the BMT wing of the Institute.

Technology transfer agreements

The division co-ordinated the following technology transfers during the year:

- 1. Technology Transfer agreement was executed on 10th May 2011 with M/s IFGL Refractories Ltd, Kolkota for
 - a. Injectable calcium phosphate cement for dental applications
 - b. Bioactive composite ceramics for orthopedic applications
- Technology transfer agreement was signed on 30th March 2012 with M/s HLL Lifecare Ltd, Trivandrum for hormone releasing intrauterine device. The technology transfer documents were also handed over to M/s HLL Lifecare Ltd.

Memorandum of Understanding (MoU)

During the year, the following Memorandum of Understanding (MOU) were signed:

- 1. MOU with M/s Lifecare Innovations Pvt Ltd on 11th Nov 2011 for collaboration in oral heparin.
- 2. MOU with Indian Institute for Information Technology and Management, Kerala, Trivandrum (IIITM-K) on 12th Dec 2011 for cooperation in the area of medical informatics.
- 3. Extension of MOU was signed in January 2012 with Agharkar Research Institute, Pune for evaluation of Actinokinase molecule.
- 4. MOU with M/s SIDD Life Sciences Pvt Ltd, Chennai on 6th March 2012 to set up a hub for development of cardiopulmonary devices.

Non disclosure / Confidentiality agreements / Material Transfer Agreements

Different instruments such as NDAs, MTAs etc were entered into with the following organizations for various projects:

- NTU, Singapore
- International Stem Cell Services Ltd, Bangalore
- Vins Bioproducts Ltd, Hyderabad

Industry interactions

Several industrial interactions for different projects at different levels were coordinated by the division, some of which includes interactions with the following industries:

- Reliance Lifesciences, Mumbai
- Kerala Livestock Development Board (KLDB), Trivandrum
- ISCSL, Bangalore
- Trivitron, Chennai
- CDAC, Trivandrum
- Vins Biotech, Hyderabad
- Manali Petrochemical Ltd, Chennai

Project co-ordination

As part of the monitoring of technology development and technology transfer activities, the following statutory committee meetings were convened and conducted during the year:

- i) The technology development committee (TDC) meeting was held on 6th and 7th April 2011.
- ii) The Standing Internal Technology Transfer Committee met on 15th July 2011.

The 12th Internal Research Conclave, RESCON was conducted during 12th, 14th and 16th March 2012 to review all the research activities and projects by faculty of BMT wing.

The system for internal funding from the Technology Development Fund was coordinated with new projects being sanctioned during the year and 2 projects given extension.

The division co-ordinated the preparation of statutory reports to DST and other reports to DSIR etc.

Training programmes

A customised training program on medical devices was conducted for the Engineers from L&T IES Ltd, Mysore from 2nd May to 4th May 2011, which included a hospital wing orientation, as part of the Industry Institute Partnership Cell.

Personnel targets & self assessment system

The division was involved in evolving and developing a system for personnel targets and self-assessment for the academic staff of BMT Wing using a wiki based Conf uence software.

Meeting of the Minds-Brainstorming meetings with Industry Captains and Academia

As part of a DST sponsored project to develop recommendations for setting up a mission mode programme for medical instrumentation and devices development through Science and Technology, the Institute organised three brainstorming meetings with captains of medical device industry in India at Chennai, New Delhi and Mumbai during Aug to Sept 2011. A fourth meeting with innovators from industry and experts from academia and clinicians was held at Thiruvananthapuram on 29th Oct 2011 under the chairmanship of Dr M. S. Valiathan. A report titled "From Neglect to Nurturing" was submitted to the Department of Science and Technology.

Biomaterials and Biological Research & Development

Bioceramics Laboratory Pulsed laser coating of bioactive ceramic composite on Titanium bone implants

The present project aims at the development of stateof-the-art bioactive composite (calcium phosphosilicate) material coatings on titanium/Ti-alloy bone implants. The work plan includes the development of the coating through Pulsed Laser Deposition (PLD), optimization and characterization of the coatings and their functionality testing (biological as well as mechanical) in animals.

Synthesis of oxide based magnetic nanoparticles for biocompatibility studies, magnetic hyperthermia and MRI applications

In this project, the focus is on the synthesis of oxide based magnetic nanoparticles for biocompatibility studies, magnetic hyperthermia and MRI applications. In our study, size controlled formation of iron oxide (Fe₂O₄) has been synthesized by chemical methods. The stable iron oxide formation and appropriate temperature required for coating of this iron oxide with hydroxyapatite have optimized. Also a new series of iron oxide embedded hydroxyapatite particles by an in-situ precipitation method was developed. Superparamagnetic hydroxyapatite composites with varying concentrations of iron oxide formation has been studied for biomedical application. The various percentage of iron oxide did not cause any phase changes in the formation of iron oxide embedded hydroxyapatite composite; hence it is an advantage for biomedical applications.

Biophotonics and Imaging Laboratory

Development of iron oxide nanoparticle probes for organ specific molecular MR imaging, under Dr.Jayasree R. S., has



been funded by Board of Research in Nuclear Sciences, DAE, Govt. of India.

Biosurface Technology

Metallic bhasma preparartions are highly efficient in Ayurvedic treatments. Uptake of these particles can occur not only



via micro-fold (M)–cells, the highly specialized epithelial cells in the Peyer's patches and isolated follicles of the gut associated lymphoid tissue (GALT), but also across the

apical membrane of enterocytes. Therefore, compatibility of these preparations with blood is an extremely important factor when these particles are absorbed into the blood stream. The in vitro biological evaluation of bhasma preparations are needed along with their physicochemical characterization and clinical evaluation to meet the criteria that supports their use worldwide. Therefore, attempt has been made to standardize the methods of physicochemical characterizations and blood compatibility/biological evaluation of bhasma preparations. Two batches each of gold, zinc and mercury bhasma preparations namely Swarna bhasma, Naga parpam and Rasa chenduram were studied.

Bovine serum albumin capped f uorescent gold clusters were demonstrated as nanosensors for Cu2 + ions. Results on the quenching of the fluorescence by addition of Cu2 + ions and recovering the f uorescence by addition of glycine were reported. The f uorescent probe was found to be useful to sense the free copper ions in live cells up to a concentration of 50 μ M. The f uorescent probe can be used for cancer cell imaging and targeted drug delivery applications.

A nanoceramic matrix from a combination of calcium phosphate, zinc phosphate and magnesium phosphate was developed. The matrix was prepared along with chitin nanofibres which help in the nucleation of the mineral phase. The matrix developed was having pores in the range of 100 to 200 microns. Cell proliferation studies (osteoblast like cells, MG63 and HepG2 cells) were studied along with growth factor loaded matrix. An increased collagen production as well as alkaline phosphatase activity was demonstrated with the growth factor (BMP 2) loaded nanomatrix. Compressive strength was also similar for all matrices, which were comparable to various ones reported in literature for bone tissue engineering. SEM micrograph has shown irregular pores in the range of 100 to 200 microns. 1:1:1 matrix and the physiological ratio of 1:0.1:0.5 matrix exhibited elevated alkaline phosphatase activity, which is a strong indication of mineralization. 1:1:1 matrix showed good MG63 cell proliferation. Studies on the degradation of the matrices and pore volume Vs cell proliferation are progressing.

Development of nanodevices for DNA delivery and cell transfection using Elastin Like Polymers coupled to cell interaction motifs

The objective of this programme is to synthesize appropriate elastin like polymers for gene delivery applications by means of genetic engineering using bacteria. Elastin like polymers thus synthesized will be developed as nanodevices for DNA delivery and cell transfection using cell interaction motifs. Four ELP polymers synthesized by Spanish group were received and its hemocompatibility and efficacy of these recombinant polymers for intracellular gene delivery were studied in various cell lines using reporter genes. Though the polymers exhibited good hemocompatibility and DNA complexation, the transfection efficiency was not high enough. On discussion between the two groups new ELP's are designed and the development of new ELP is progressing.

Facility for nano/microparticles for Advanced Drug Delivery systems

The fundamental requirement in in vitro- in vivo correlation of drug delivery systems is the understanding of gastrointestinal permeability of the drug. The correlation of insulin permeability and its efficacy on diabetic rats were established. Similarly, heparin nanoparticles have been developed and standardized for its oral delivery. PLGA nanoparticles based growth factor (VEGF) delivery system at the site of rabbit ear demonstrated gualitative changes in angiogenesis compared to the controls. The significant effect of bFGF on cell proliferation and collagen synthesis was demonstrated on chitosan sponges in vitro. On rabbit experiments the extent of re epithelialisation was similar for chitosan sponge with cells and without cells. Although the epithelialisation was similar, studies related to cell cultured chitosan sponge are relevant since the final application is for burn cases. Keratinocyte cell culturing has been shown to reduce collagen production. Therefore an attempt has been made for co culture of keratinocyte cells with fibroblast cells.

Dental Products lab

Toxicological evaluation of a new dental restorative composite containing `Diphenyl [2,4,6-trimethyl benzoyl] phosphine oxide [TPO] as photoinitiator

TPO is preferred over camphorquinone (CQ) as photoinitiator in dental composite curing due to its colourless nature, lower cost and good efficiency; only drawback being that it needs a light source between 390-410 nm to generate free radicals. We had already completed the evaluation of physicochemical properties and cytotoxicity studies of the TPO based dental composites last year. This year the toxicological evaluation was taken up in a TDF project. Samples for acute systemic toxicity test, intracutaneous irritation test, subcutaneous implantation test and sensitization test were prepared as per ISO 10993 standards and toxicological studies are in progress. The composite has already cleared the intracutaneous irritation test. The pulp and dentine test has been planned to be carried out during the next 6 months in large animals.

Development of smart dental composites consisting of calcium containing resins and fillers

Our objective is to develop visible light cure smart restorative composites based on calcium containing inorganic-organic hybrid resins with high refractive index and fillers like, calcium hydroxide, zirconium oxide, calcium carbonate, tricalcium silicate/calcium chloride, hydroxyapatite and /or silica along with conventional fillers such as silanated quartz/ radiopaque glass which can enhance dental remineralization by releasing calcium and phosphate ions depending on the pH of the surroundings which controls dental decay.

Tissue engineered small diameter vascular graft (TEVG) fabrication & evaluation



Electrospinning of double layered small diameter vascular graft and micro CT pictures of the same showing different porous nature of the layers

97 polymer scaffolds (21 electrospun, 33 solvent cast and 43 double layered) were fabricated and supplied to TRU for biological modification during the last year.

In vivo studies are in progress with novel double layered biologically modified scaffold material. Already 10 animals have been implanted during 2011-12 with the graft. More studies are in progress.

Development of bioactive bone cements based on organically modified ceramic resin

Objective is to develop potentially bioactive cement capable of strengthening the mechanical retention of the implant by allowing direct bone apposition. Novel calcium, barium and zirconium containing inorganicorganic resins were synthesised which were used as precursors for bone cement. Various parameters were optimised. Synthesis conditions for copolymers of poly methyl methacrylate (PMMA-co-PS) and hydroxyl apatite (HAP) were standardised.

Development of hemostatic scaffold using biodegradable polymer and biomimetic extracellular matrix components for healing of chronic dermal wounds

Synthesis and characterization of 6 batches of PLGC (polylactide-co-glycolide-co-caprolactone) terpolymer was completed. Formulation is undergoing optimization, while fabrication conditions of scaffold using Electrospinning were optimized. Evaluation of electrospun scaffold and in-vitro hydrolytic degradation studies are ongoing. Cytotoxicity evaluation was completed and found non-cytotoxic. Cytocompatibility study using fibroblast cells for 7 & 30 days was completed.



Electrospun sheet of PLGC terpolymer and its SEM image showing the fibres

Quantum dots for cardio-vascular applications

CdSe/ZnS core/shell synthesis and their physicochemical characterization- at different concentrations- optical, structural, chemical and surface characterization (TEM, XRD, UV, PL, IR, Raman, EDAX, DLS) were carried out during the year. Effect of purification (dialysis), surface modification (biological) and aging on the properties of the core/shell- Luminescence and DLS technique were studied. Cytotoxicity Evaluation using different cell lines (L-929 and HUVEC) - MTT assay, both morphological and Flow Cytometry studies showed that the Core shell had better cytocompatible compared to bare quantum dots. Drug (Urokinase) binding to core/shell using a crosslinker was carried out. Drug/core-shell characterization using absorption and luminescence were performed and drug estimation was done using Lowry's method and UV spectrometry.

Bioengineered hybrid skin substitutes for burn wounds

Synthesized five batches of poly(l-lactide-co-glycolide-cocaprolactone)-PLGC Physico-analytical characterization of PLGC so synthesized were carried out using spectroscopic and thermogravimetric methods. NMR data provided information about the monomer ratios present in the polymer. Electrospinning of the polymer so obtained provided very fine sheets which are being subjected to biological modifications. Degradation study of electrospun scaffold was conducted for the periods 7,21 and 45 days. Studied on morphological and mechanical characterization of scaffold before and after degradation.

Discussions were held with the experts from Burns Unit in Jubilee Mission hospital in Trichur and Amrita Institute, Kochi.



Electrospun terpolymer sheets for hybrid skin substitutes prepared at DPL

Development of organically modified ceramic based dental composites

Pulp and Dentine test was carried out on 3 dog models. 8 indigenously developed composite samples (test) samples and 4 negative control (glass ionomer cement) samples were used to restore teeth on each dog. The restorations will be subjected to histopathological studies after 7 days, 28 days and 70 days.



Hydrogel scaffold developed at DPL



Small diameter vascular graft with optimum porosity developed in DPL

Studies on polyurethane based dental composites

Novel urethane dimethacrylate based dental composites were prepared in the lab and properties evaluated. Characterization of UDMA using FTIR, FT Raman and UV Spectrophotometer was carried out. Determination of mechanical properties like depth of cure, diametral tensile strength, compressive strength and f exural strength of the prepared dental composite completed after varying diluent concentration from 20 parts to 60 parts; optimum concentration finalized. Studies on the effect of varying concentrations of combination of resin matrices Bis-GMA and UDMA in dental composites was also carried out.

Histopathology Laboratory



Medical device retrieval programme

The objective of the study is to examine failed medical devices, which are removed from the patient at revision surgery. The examination will include investigations of the surface and bulk physical properties of the retrieved components of the device with advanced techniques and carry out detailed study of the adjoining tissue using microscopy, immuno histochemistry and techniques in molecular biology. Cells, cytokines, signaling molecules and modulatory niche involved in determining the end fate of the implant within the host will be studied. The data obtained will help in creating a source of information, both biological and material, on behaviour of materials in the physiological environment of the human body and how tissues respond over a period of time. This information will help the industry in the development and manufacture of improved medical devices and will help clinicians to devise strategies to prevent adverse tissue responses leading to clinical failure.

Colour atlas of tissue response to biomaterials

Biomaterials for medical devices are evaluated by structured programmes following International standards. Material scientists and medical device companies get their materials evaluated by agencies specific for the purpose. The field of biomaterial science being interdisciplinary, young researchers, entering this field need to know the response of tissue to materials placed in vivo. The histological evaluation of cells and tissue around implanted biomaterials is important. Researchers and students need help in identifying the various changes occurring in the tissues. A self-help atlas of photomicrographs with detailed explanations would be very useful and provide important information. The Histopathology laboratory in Sree Chitra Tirunal Institute of Medical Sciences and Technology is dedicated to the study of tissue response to materials for purpose of evaluation of biocompatibility and pre-clinical evaluation of medical devices. The laboratory has valuable material for the preparation of an Atlas, the first of its kind in the world.

Transmission Electron Microscopy laboratory

Bioconjugation of nanomaterials and their applications in cancer therapy

Major challenge in cancer diagnosis is to determine the cancer biomarkers to detect tumour at an early stage without affecting the normal surrounding cells. Metal particles like gold nanoparticles for skin cancers & photo thermal therapy; gold nanorods for deep-seated cancers, semiconductor nanomaterials (Quantum dots) conjugated with specific antibodies for the early detection of cancer and imaging are few such applications addressed in the project.

The principal aim of the study was to develop

nanobioconjugates for cancer cell diagnosis and therapeutics using in vitro and in vivo models.

Salient features

- Efficient for cellular imaging applications
- Internalization efficiency of CdSe-Silica 640 QDs are very high
- In vivo cancer targeted imaging results showed the tumor targeting efficiency of CdSe-Silica 640 QD probes in solid tumor developed mice
- In vivo early cancer diagnosis results showed the high targeting efficiency CdSe-Silica 640 QD probes in skin cancer developed initial stage mice.

Tissue Culture

Development and feasibility study of polymeric scaffolds for tissue culture under microgravity

Microgravity or weightlessness is a state attained when the acceleration due to gravity has negligible effect. This issue can be studied with the concept of tissue culture under microgravity as an in vitro model using bioreactors capable of simulating microgravity. This project aims at

Polymer Division

developing a suitable hydrogel scaffold, which can be used in tissue culture under normal conditions as well as under microgravity.



Photograph of A-solid tumor bearing mice, B-whole body imaging of mice after 4 h of injection, C-inset showing tumor area, D-Ex vivo imaging of mice organs: 1)Liver, 2) Heart, 3) Kidney, 4) Solid tumor, 5) Spleen, 6) Lungs and 7) Brain, CLSM micrograph of the cryosection of (E) the solid tumor site and (F) the liver.

The weak f uorescence signal from the liver (marked with white arrows) is due to the distribution of QDs, whereas no evidence for the localization of QDs in tumor site. Nuclei were counterstained (blue f uorescence) with DAPI.



Dispensable and biodegradable polymeric bone cement for minimally invasive treatment of bone diseases – product validation

In the present project, the newly developed candidate bone

cement will be evaluated and validated as per standard protocols for safety and efficacy for the treatment of spinal lesions, vertebral haemangioma and spinal compression fractures. The biomechanical stability and biomechanically

ANNUAL REPORT 2011-12-
induced degradation will be evaluated to assess the efficacy and functional performance of the bone cementloaded vertebral disc. Safety tests will be carried out with the newly developed candidate bone cement. The blood compatibility will be evaluated. The most promising bone cement formulation will be identified for clinical trials and limited clinical trials will be carried out. The technology package will be developed for technology transfer.

Polymer Processing



Development of a Dura Substitute by Electrospinning of $\epsilon\text{-}\mathsf{Caprolactone}\text{-}\mathsf{Co-}$ Lactide

The main objective is to develop innovative porous polymer scaffold materials with tailored properties and to explore the interaction mechanisms at nanoscale between the cells and porous membranes/scaffolds. It is also envisaged to design nano-fibrous structures that could slowly degrade over a period of time. Thus the current project could lead to the development of an ideal dural substitute for neurosurgery applications. The major works carried out in the project during the current year are:

- The electrospun mats of polycaprolactone blended with caprolactone-co-lactide polymers were prepared and evaluated for the various mechanical properties.
- Cytotoxicity evaluation of the fibrous mats was carried out and found that they were non-cytotoxic.

Pre-clinical evaluation of fluoropassivated and hydrogel sealed vascular graft

The objective of the project is to evaluate a f uoropolymer coated hydrogel sealed vascular graft by analytical,

mechanical and biological techniques so that its suitability can be assessed for clinical applications. Polyvinylidine f uoride was deposited onto the polyester vascular graft by dip coating. A hydrogel forming material, prepared from alginate dialdehyde and gelatin, was spray coated onto the external surface of the graft. SEM image of the coated graft is shown below. Coated grafts were subjected to various performances tests as per the international standard, ISO 7198. Performance tests such as water permeability, burst strength, longitudinal tensile strength, circumferential tensile strength, etc. were conducted for grafts of different sizes. Water permeability of the coated graft was optimized to a level \leq 5ml/min/cm². Various mandatory in vitro and in vivo biological tests were completed successfully and the graft is made ready for preclinical evaluation in pigs.

Development of Mandibular Advancement Device for the Treatment of Obstructive Sleep Apnea

This project is aimed to design, fabricate and evaluate prototype models of oral mandibular advancement device for the treatment of obstructive sleep apnea. A detailed literature survey of various national and international patents on sleep apnea devices was carried out. A procedure to construct a 3D model of a real time object was developed. It is planned to develop devices with silicone rubber as this material is expected to provide better patient comfort than devices made of other plastic materials. So a number of silicone rubber formulations were developed and tested to get appropriate hardness levels for the device.

Toxicology

Laboratory for Polymer Analysis

Visible light induced insitu gelling multifunctional hydrogels as potential wound dressings

The aim of the project is to develop new wound dressing formulations having multiple abilities like **f** uid absorption, antibacterial effect, biocompatibility are easily removable from the wound site without causing any trauma to the patients.



Molecular and immunotoxicological effects of Dextran coated Ferrite and Hydroxylapitite nanomaterials

The objective of this project is to evaluate the molecular and immuno-toxicological effects of Dextran coated Ferrite and Hydroxyapatite nanomaterials. This will lead to the development of safe nanomaterials which can be used in targeted drug delivery for minimizing adverse reactions; e.g., the use of hyperthermia of cancer cells and magnetic properties of ferrite for targeted delivery of drugs in cancer therapy. The following activities were completed during the year.

In Vitro studies (two materials)

- In vitro cell culture cytotoxicity test
- DNA Analysis (Genomic and mtDNA)
- Analysis of 80HdG
- Lipid peroxidation
- Estimation of antioxidant enzymes

In vivo studies

- 28 days repeated dose dermal toxicity (1 material)
- Delayed hypersensitivity by guinea pig maximization test

In Vitro alternative test system development for Ocular Irritation (ICMR)

The objective of this project is, to develop an in vitro test system for acute and sub-acute ocular irritation, which will be suitable for evaluating biomaterials, medical devices, pharmaceuticals, cosmetics and chemicals. The outcome of the proposal will be a more comprehensive assay for acute and sub acute ocular irritation tests, which will be cost effective and readily available to the various segments of health care industry and a total replacement of animal experimentation. The following activities were completed during the year:-

- Development of organo typic culture
- Standardization of corneal cell culture for in vitro test

Development of National GLP Guidelines & Identification and selection of National Regulatory Guidelines for Testing and Evaluation of Medical Devices (National GLP Compliance Monitoring Authority, Dept. of Science and Technology, New Delhi)

The objective of the project proposal is to develop an appropriate National Guideline for GLP compliance and regulatory guidelines for testing and evaluation of medical devices in India, which conform to current global practices. The following activities were completed during the year.

- 12 documents prepared and is in final draft stage.
- One vertical and I horizontal standards prepared
- First National Steering Committee held at SCTIMST and evaluated the draft documents on 2nd March, 2012.

Evaluation of Interleukin 1 β levels from human lymphocytes in response to pyrogens (MPhil research work)

The objective of the present study is to detect the Interleukin-1 β levels from single and pooled human lymphocytes in response to gram negative and gram positive pyrogens. The study was carried out to evaluate the role of pyrogens in inducing inf ammatory response, from human lymphocytes (O Positive, A Positive, B Positive and AB Positive donors). Lymphocytes isolated from blood of healthy individuals were challenged with 5EU of gram negative (LPS) and 1 μ g /ml of gram positive pyrogens (LTA) in vitro and the inf ammatory cytokine, Interleukin 1β (IL-1 β) release was measured by Sandwich ELISA method. The results suggests that the IL-1 β release is concentration dependent; i.e., when the cell numbers are greater, there is more release of Interleukin 1β . Furthermore, the release of IL-1 β increases immediately after the initiation of incubation and reaches a maximum at 4 to 6th hour and then stabilizes for both the pyrogens. Based on the results obtained, it can be concluded that the isolated lymphocyte system can be used as an alternative test system to the in vivo rabbit pyrogen assay.

Evaluation of molecular toxicity of newly developed materials intended for biomedical applications'. Indian Council of Medical Research (ICMR), New Delhi

The objective of the project is to evaluate the molecular level toxicity of the six newly developed materials and their chemical leachants on mtDNA, antioxidant enzymes, lipid peroxidation and cytogenetic effects. The results of the study shows, that the physical presence of the material or chemical leachants of the material did not induce any toxic effects at the molecular level and established that all the material used were safe. Hence it can be concluded that the evaluation of toxicity at the molecular level is a cardinal change in approach to biocompatibility evaluations leading to a paradigm shift in bringing in newer regulations for development of safer medical devices, implants and tissue engineered organs for life time application.

Thrombosis Lab

In vitro and preclinical evaluation of curcumin released from biodegradable drug carriers

Objective: Develop proteinous carrier for curcumin for cancer therapy

Progress during last year: Loading of curcumin with fibrin was standardized. Loading efficiency of curcumin with fibrin was determined and release profile from fibrin sheet was evaluated. Curcumin-loaded fibrin sheet induced significant death of cells; A549 lung carcinoma cell lines within 24h of contact which is equivalent to ~ 10 uM curcumin in the medium.

To study the role of platelet proteins on the endothelial cells and smooth muscle cells proliferation

Objective: To identify the differently expressed platelet protein in diabetic/hypertensive (high risk) groups and to study effect of few of these proteins on EC and SMC proliferation.

Results of this study have shown remarkable difference between the protein profile of high risk group when compared to control. Protein profile of these two groups (diabetes and hypertensive) also showed difference in the expression. Cell culture studies are initiated to identify if these differently expressed proteins infuence cell proliferation.

Quantum Dots (QDs) as Drug Carriers for Cardiovascular Disease

Objective: To test the cytocompatbility of quantum dots (QDs) and their efficacy in clot lysis after conjugation with a fibrinolytic drug.

Different batches of QDs were tested for cyto- compatability on ECs; based on the results the synthesis parameters were optimized to obtain non cytotoxic QDs. It was found that PEG coated QDs are best for the cells and were used for further studies. The best cytocompatible one is chosen for conjugating urokinase for the clot-lyse assay. Preliminary data suggested that the urokinase conjugated to QD induced clot lysis.

Coronary artery diseases in the young

Objective: To estimate the non-conventional risk factors – thrombotic risk factors, and activated platelets in young CAD patients

Platelet activation and clottable fibrinogen was studied

Tissue Engineering & Biological Research

Device Testing Lab

Bioreactor Development

Three programs for development of suitable bioreactors (in collaboration with the divisions of Thrombosis Research, Tissue culture and Tissue Engineering & Regenerative Technologies) for cartilage tissue, liver cells and vascular tissue engineering applications have been taken up. The systems have been developed and the validation studies on these bioreactors have been completed.

Microbiology



Epithelial-mesenchymal interactions in tissue engineered hybrid artificial lung: role of angiogenic factors

Current limitations of monolayer cell-culture hinder progress in understanding the features and dynamics of heterotypic cell communication pathways critical for the development of more sophisticated or efficient tissue engineered devices. This is important as cell-cell communication and biochemical cross-talk have been shown to be essential for the maintenance of differentiated cell functions in tissues and organs, and in FP this cross talk has turned aberrant promoting chronic fibrosis. Alveolar epithelium is composed of two specialized cells – the Type I pneumocyte, which is squamous epithelial cell and the Type II pneumocyte, which are the surfactant producing cuboidal cells and also progenitor cells for Type I. But Type II cells lose their specific properties by 5 -10 days of culture. So to have a functional in vitro system, this tendency should be controlled and a system, which will maintain specific characters for prolonged periods of culture. For this, porous Gelatin-vinyl-acetate (GeVac scaffold) was chosen and interactions of alveolar Type II cells and fibroblast are being studied with their inf uence on surfactant synthesis. At the same time, Bleomyicin, a

in 30 test and 10 control subjects in TRU. Very high level of fibrinogen was observed in the patients when compared to control. Percentage of activated platelets was also very high in CAD patients as compared to healthy subjects. Study is ongoing to estimate the level of other prothrombotic factors. known agent causing lung fibrosis in vivo is being used to study its effect using the electrical cell impedance ECIS system. A clear understanding of the epithelial/ mesenchymal interactions will help in understanding alveolar fibrosis and IPF and help in devising better treatment modalities so that such patients have a better chance of survival.



ECIS multi-well for seeding cells and culture to study effect of drugs etc using the ECIS system

The ECIS system was used to study the effect of Bleomycin on co-culture of alveolar epithelial and fibroblast cells



With cells attached and spread upon this region, the current must now f ow in the spaces under and between the cells, as cell membranes are essentially insulators



Role of Transformation growth factor-alpha in neuronal growth and regeneration

Regenerating damaged neurons is a challenging area mainly because of the post mitotic nature of the cell as well as the complex signaling pathways required for developing functional connection between neurons. Various approaches have been tried like growth factors and scaffolds as guiding molecules for the damaged neurons to recover. However, the success of these approaches has been limited. We have developed a recombinant transformation growth factor (TGF) alpha protein, which

Molecular medicine

was found to induce cellular growth, including neurons. There are recent reports that TGF-alpha induces growth of inhibitory neurons, especially the dopaminergic neurons. However it is not clear whether the neurons, which are growing under these stimulatory conditions, have the same cellular architecture for growth cone formation and axonal growth as in normal cells. This study will be analysing the actively growing neurons on transport of synaptic vesicles to the axonal terminal and the microtubule dynamics: phosphorylation dephosphorylation cycles of actin and tubulin. It is essential to understand the variations in cellular architecture to predict the success of functionally active neuroregeneration. This study aims to answer these fundamental questions.

Evaluation of functional efficacy of recombinant TFG alpha and VEGF proteins

Objectives:

- MALDI-TOFF for sequence confirmation of TGF alpha and VEGF.
- Assay the efficacy of recombinant TGF alpha and VEGF with that of commercially available ones.
- Measure the activity units of the enzymes for functional comparison.
- Develop HUVAC cell culture assay for VEGF.



Differentiation of foetal progenitor cells and fabrication

of a prototype of bioreactor for bioartificial liver

Liver disease is a serious health problem affecting millions of patients all over the world. Due to the shortage of donor organs for liver transplantation, alternate methods using stem cells are looked into. The project intends to fabricate and evaluate the indigenously developed prototype bioreactor for bioartificial liver (BAL). Primary hepatocytes are the best cell source identified for cell based therapy in liver regeneration. Mature hepatocytes have the limitation of low proliferation and reduced differentiated function in vitro. Hence alternate primary stem cell sources (both embryonic and adult) were considered to overcome these challenges. The initial screening of fiber assembly components for BAL were evaluated for cytotoxicity and cell adhesion. Cell lines were used to evaluate the efficacy of the prototype. Many batches of prototypes were fabricated and evaluated for the performance by in vitro culture methods. Both cell lines and primary isolated hepatocytes were considered for the evaluation. Primary cells were cultured to verify the performance of the bioreactor. It was observed that the bioreactor inoculated with hepatocytes effectively maintains liver specific functions such as protein synthesis, detoxification etc. Since the ethical clearance for collecting discarded nonviable human fetus liver is ongoing, alternate stem cell source were also identified and studied. Rat bone marrow mesenchymal stem cells were selected as progenitor source. The procedure for standardization

ANNUAL REPORT 2011-12-

Tissue Culture Laboratory

of differentiation conditions of MSC to hepatocytes is ongoing. More stem cell sources are being screened for the present study.

Tissue engineering of a carrier free corneal endothelial construct towards transplantation for endothelial keratoplasty

The common mode of treatment of corneal endothelial failure has been via corneal transplantation wherein the whole donor cornea is used to replace the damaged corneal endothelial layer. A new paradigm shift in the field is the evolvement of the technique of endothelial keratoplasty, which involves the surgical replacement of only the diseased endothelial corneal layer. However both modes of treatment require a donor cornea. To make up for the inadequate supply of donor corneas, the use of in vitro cultured corneal endothelial cells, as an alternate therapeutic option is being studied. The use of amniotic membrane, collagen and gelatin membranes as carriers for transplantation pose the risk of contamination and affecting corneal transparency, hence the present project proposes to generate carrier free corneal endothelial cell sheets via the use of an in-house developed thermoresponsive polymer. The project has been initiated using animal corneal endothelial cells. To this end, initial standardization of cell isolation techniques, in vitro culture conditions and characterization of cells is being conducted. Culture and retrieval of the corneal endothelial cells is being standardized.

Cell Sheet Engineering on Electrospun Scaffolds for Efficient Cell Supply in Skin Tissue Engineering

Skin tissue engineering represents one of the most successful clinical applications of regenerative medicine. Certain technical and functional restrictions like fragility, contraction, handling and in vitro manipulation time still remain as limitations to this approach. Efficient cell supply to a three-dimensional matrix known as scaffold and from scaffold to host tissue after implantation are critical parameters. The proposed project aims to develop a biosynthetic product using polymeric matrix and skin cells. Skin cells cultured on thermoresponsive surface enable harvest as monolayer and transfer to polymer scaffold is expected in improved cell supply.

Transmission Electron Microscopy

Bone tissue engineering using adipose stromal cells on 3D porous bioactive ceramic scaffolds

Repair of critical sized segmental bone defects caused by severe trauma; resection of tumours, and congenital deformity remains a big challenge to orthopaedic surgeons. Autologous bone grafts are usually limited by considerable donor site mobility and less availability. Strontium calcium phosphate (SrCaPO4) is applicable in cases of trauma & tumours in Orthopaedic Surgery because of its relevance in radio-opacity in view of easy clinical and radiographical evaluation. Besides, strontium has also been reported to play a special role in bone remodelling and formation of de novo bone. Again, using differentiated adipose derived stem cells (AdMSCs) in conjunction with SrCaPO4 takes a step forward in the bone healing process.



1, 3 & 6 months post- implanted samples depicted new bone formation in par with material degradation. Immature woven bone and slow degradation of material was found in one month post implantation studies. Mature lamellar bone establishing osteointegration was observed in 3 months post implantation studies. Six months post- implanted samples depicted mature mineralized lamellar bone establishing osteointegration and ensuring stability of the implant.



Cell based tissue engineered fabrication of osteochondral constructs

Thrombosis Research Unit

Articular cartilage may be damaged by trauma or disease processes. For both full-thickness and partial-thickness defects, repair tissue fails to recreate a fully functional articular surface. The avascular and low cellularity of articular cartilage may stand in the way of effective repair. In particular, cells with chondrogenic potential may fail to be recruited to the site of injury in sufficient numbers. For these reasons, there is considerable interest in developing cell therapies to treat damaged cartilage.



Tissue Engineered Small Diameter Vascular Graft (TEVG): Fabrication & Evaluation

Objective: Standardization of Vascular Tissue Engineering Technology

Silver nanoparticles (SNP) were found to inhibit platelet activation, secretion, aggregation and adhesion. SNPincorporated polycaprolactone (PCL) scaffold was demonstrated to be nonthrombogenic. Platelet adhesion to virgin PCL and SNP-PCL are demonstrated by scanning electron microscopy of both after exposure to platelet rich plasma (PRP) (Fig.23 A &B).



Fig.23. Micrographs demonstrating reduced platelet adhesion to SNP-PCL scaffold from PRP; A, platelets on virgin PCL; B, platelets on SNP PCL.

The in vitro construction of TEVG with endothelial cells (EC) and smooth muscle cells (SMC) on 4 mm diameter PCL conduit was standardized. Objective was to seed the EC in the lumen and SMC in the albumen of the conduit and to culture cells under dynamic medium f ow using a bioreactor, to produce a functional vessel with stabilized cell. Between 4 to 7 days of culture was found to be sufficient to align the EC towards the direction of medium f ow; which indicates generation of contractile phenotype of the SMC after dynamic culture.



Fig 24 Micrographs showing alignment of cells in TEVG due to shear stress; A, EC in the lumen aligned to the direction of flow; B, SMC aligned perpendicular to the direction of flow.

The EC released NO into the medium indicate non thrombogenic phenotype of EC. Communication from EC to SMC was confirmed by the generation of NO-induced cGMP during dynamic in vitro culture of the construct. Thus functional tissue engineered vascular graft (TEVG) construction is standardized using EC and SMC obtained by differentiating circulating adult progenitor cells.

Development of hemostatic scaffold using biodegradable polymer and bio mimetic extra cellular matrix for healing of chronic dermal wounds

Objective: Skin tissue engineering for diabetic wounds.

Progress during last year: The biodegradable electrospun scaffold, developed by Co-PI at DPL was modified by hybridizing with fibrin. The hybrid scaffold was seeded with dermal fibroblast and showed that the cells proliferate and connect electrospun fibers of scaffold (Fig 25 A&B).



 Fig. 25. Micrographs showing cell sheet formation on hybrid scaffold seeded with fibroblasts; A, Cell-grown bare PGLC electrospun scaffold; B, Cell-grown PGLC-fibrin hybrid scaffold.
Fibroblasts grown on hybrid scaffold deposited both

collagen (Fig 26 A&B) and elastin indicating the skin tissue generation on the modified scaffold. Engineered tissue constructs are ready for testing in diabetic rabbit models.



Fig. 26.Immunof uorescent micrographs showing collagen deposition on cell grown & decellularized scaffolds; A, bare PLGC scaffold; B, decellularized PLGC-fibrin scaffold Bioengineered hybrid skin substitute for burn wounds

Objective: Skin tissue engineering for burn wounds using biodegradable scaffold and ADMSC.

Progress during the last year: With the development of a biodegradable scaffold, we attempted to differentiate adipose derived mesenchymal stem cells (ADMSC) into dermal fibroblast using biomimetic matrix directed strategy using cells grown on tissue culture polystyrene as control. The differentiation of ADMSC into fibroblast is proven by the expression studies using RT-PCR for differentiation markers; fibrillin (Fig27A) fibroblast specific protein (FSP) (Fig 27B) and qPCR for collagen and elastin expression in the differentiated fibroblasts (Fig. 27C).





Deposition of collagen (fig 28A) and elastin (fig 28B) by fibroblasts differentiated from human ADMSC was demonstrated by immunochemical staining of the decellularized culture surface. Use of biomimetic matrix as in vitro niche is found to be a good strategy for generating dermal tissue using adult autologous ADMSC.



Fig. 28 Immunof uorescent micrographs showing deposition of collagen and elastin after ADMSC culture on biomimetic niche. A, collagen,; B, elastin.

Development of neurons from adult stem cells for the application of regenerative medicine

Objective: Differentiation of circulating neural progenitor cells (NPC) to neuron for regenerative application

Progress made during last year: For differentiation of circulating NPC to neurons and for their long term survival, specific niche with different compositions were experimented. Presence of various important growth factors such as fibroblast growth factor-2 (FGF-2), brainderived neural factor (BDNF) and vascular endothelial growth factor (VEGF) were verified using Western blot analysis of bovine hypothalamus extract (HE) and human platelet releasate (PR) which are used as components of biomimetic matrix. Dose response of BHE and PR on NPC was tested and identified optimum concentration of both for getting differentiated neurons that expressed specific differentiation markers. It was found that the designed niche directed NPC differentiation to neuron-like cells (Fig 29A); but when all-trans retinoic acid (RA) was also added to the medium, glial cells were seen more frequently (Fig 29B).



Fig. 29. Neurons derived from NPC by culture of peripheral blood mononuclear cell on a specifically designed biomimetic niche; A, cells on matrix+RA; B, cells on matrix without RA.



Tissue Engineering & Regeneration Technologies

Program support for a Lead program on Centre of excellence in Tissue engineering (COE) program of the Department of Biotechnology (DBT), Govt of India

This program apart from the Lead program initially comprised the support to 4 projects for the initial 3 year period. Project completion report for first phase (3 years) of DBT COE program support for Tissue Engineering was defended at TAC meeting of DBT at New Delhi and extension of sanction for 2 more years for 3 of the 4 projects was obtained.

Approved programs are as follows:

1. Tissue engineering of cartilage using biomimetic scaffolds under dynamic conditions – Dr. Prabha D Nair (PI)

- Differentiation of foetal progenitor cells and fabrication of a prototype of bioartificial liver – Dr. T. V. Kumari (PI)
- 3. Cell-based tissue-engineered fabrication of Osteochondral Constructs (Dr. Annie John PI)-

Under the acitivities of the core program,

*Bioreactors for TE of liver and cartilage tissue engineering are developed and validation studies are underway.

*An electrospinning facility is set up for the fabrication of polymer nano fibres and other morphologies for various TE applications.

*Atomic force microscope and isothermal titration

calorimeter have been installed and studies are in progress.

*New biomaterials-various polymers, honeycomb structured polymer membranes, bioceramics and composites have been prepared

*Animal models for disease and standard implantation methods are being developed as part of core activity and in individual projects.

* 8 PhD students are being trained in specific parts of the program.

Tissue engineering of cartilage using biomimetic scaffolds under dynamic conditions

Significant research contributions are towards development of biomimetic and mechanically strong novel scaffolds for larger cartilage defects whilst maintaining their chondrogenic phenotype. Other novel fast gelling and injectable gels and electrospun membranes have been developed for cartilage cell encapsulation and delivery in smaller defects.

Other contributions are towards delineating the biochemical and biomechanical stimuli that can dictate adult and fetal stem cell differentiation toward a chondrogenic lineage in tissue engineered constructs. The program is currently engaged in carrying out the preclinical trials in animal models and limited clinical trials with the help of CMC Vellore.

Chondrocytes were isolated from goat articular cartilage and their chondrogenesis on 3D- PVA-PCL scaffold were evaluated for their ability to maintain their phenotype and induce ECM deposition. The in vitro chondrogenic induction was studied by culturing rabbit adipose MSCs, human umbilical cord MSC and goat MSC on the PVA-PCL scaffold. The chondrogenesis was evaluated by biochemical analysis of aggrecan, GAGS, DNA and protein content, and gene expression studies by real time PCR (Biorad, India) as well as histology of tissue-engineered constructs.

Effect of compressive forces (cyclic unconfined compression) on chondrogenesis of goat chondrocyte seeded scaffolds were studied in Cartigen bioreactor from Tissue Growth Technologies (Minnetonka, MN) and compared with mechanical stimulation through compression, hydrostatic pressurization and shear stress on goat chondrocyte on scaffolds in an in-house built bioreactor.

Dynamic stimulation of the goat chondrocyte seeded

scaffolds on compression alone had resulted in higher deposition of GAG.The GAG accumulation was found to be higher in the constructs cultured under mechanical stimulation with perfusion. Chondrogenesis was also confirmed by the expression of Col2a and aggrecan gene expression. With the combination of perfusion and compression, the relative expression of Col 2 and aggreegan were higher than the results with compression alone



PVA-PCL electrospun membranes



Viable chondrocytes on the PVA-PCL electrospun membrane



CHHDA gel



Chondrocyte viability within CHHDA gel

Quality Management Systems, Testing & Technical Services

Quality Management System

Calibration Cell (CAC)

During 2011-12 period, CAC carried out 396 calibrations/ validations, of which 78 were for external customers, which predominantly were healthcare industries and clinical laboratories. The external calibration activities showed a marked increase from 29 operations during the previous year to 78 operations during the current year.

Two batches of in house reference materials (for hemolysis and implantation studies) to meet the requirements of testing services were prepared. Three inter laboratory comparisons (ILC) with reference laboratories were conducted as part of routine quality assurance programs in calibration.

Quality Cell

Following were the major activities of the quality cell during the period from April 2011 to March 2012

- a. COFRAC surveillance assessment was carried out on January 27th & 28th 2012. There were no nonconformances reported.
- b. NABL Assessment was conducted on 17th & 18th January, 2012 at Calibration Cell. Relative Humidity and mass calibration was included in the scope. NABL renewed the accreditation for another two years up to 13-01-2014.

- c. Training: Seven internal training programmes viz. "Introductory training for newcomers" were organised.
- d. Management review
 - A Management Review Committee meeting was held on 06th July 2011.
 - Two Technical Management Committee meetings were held on 31st May 2011 and 15th December 2011.
- e. Internal Audits
 - 09th -19th May 2011. Total of 30 Non-conformities reported.
 - 14th–22nd November 2011. Total of 31 Nonconformities reported.
- f. Document initiated/revised

System Procedures: SPBMT306 was revised during the period. Also a new guideline GLBMT007 was also introduced to the system.

The following were revised / issued during the period

- (i) 12 system procedures of various laboratories.
- (ii) Work Procedures: 202 Nos
- (iii) Lab notebooks 94 Nos
- (iv) Registers & Logbooks 107 Nos
- (v) Quality related forms: 4 Nos of forms were revised
- (vi) Corrective/ preventive actions/ Accident reports.
- A total of 31 CAR's were generated in this period by different laboratories
- Two preventive actions were raised this year.
- Three accidents were reported during the period. Necessary corrective actions are in progress in two of them and one has been closed.

LIST OF COFRAC ACCREDITED TESTS - 2012

No	Name of Test	Reference		
1	Animal skin irritation test	ISO 10993-10: 6.3		
2	Intracutaneous reactivity test	ISO 10993-10 B-2/ USP 28(88)		
3	Test for local effects after implantation: -implantation in subcutaneous tissue -implantation in muscles and in bone(s)	ISO 10993-6: 4, 5, 6		
4	Acute systemic toxicity: acute intravenous application	ISO 10993-11: 6.5.4/ USP 28(88)		
5	Acute systemic toxicity: acute intraperitoneal application	ISO 10993-11: 6.5.5/ USP 28(88)		
6	Standard practice for assessment of haemolytic properties of material	ISO 10993-4 / ASTM 756		
7	Maximisation test for delayed hypersensitivity	ISO 10993-10: 7.4		
8	Closed patch test for delayed hypersensitivity	ISO 10993-10: 7.5		
9	Penile irritation test	ISO 10993-10 B-5		
10	Vaginal irritation test	ISO 10993-10: B-7		
11	Systematic toxicity – Selection of test for Pyrogenicity-testing for pyrogenic substances of either endotoxin or non-endotoxin origin(pyrogen test)	ISO 10993-11: 7.1 / USP 28(88)		
12	Medical-surgical material. Medical devices and materials biocompatibility. Extraction methods	ISO 10993-12		
13	Standardised method for extraction of medical plastics	ASTM F 619-03		
14	Invivo test for genotoxicity Micronuclei test	ISO 10993-3: 4.4.2/ OECD nº 474		
15	Invivo test for genotoxicity -Metaphase analysis in rodent bone marrow	ISO 10993-3: 4.4.2/ OECD nº 475		
16	Invitro test for genotoxicity- carcinogenicity and reproductive toxicity	ISO 10993-3: 4.4 / OECD nº 471		
17	Sterility test to check particularly the date of "end of use" of the product - Medical device	USP 28(71)		
18	Partial thromboplastin time (PTT)	ISO 10993-4 B 3.1		
19	Fibrinogen Assay	ISO 10993-4 B 3.5		
20	Prothrombin Time (PT)	ISO 10993-4 B 3.2		
21	Quantification of platelet aggregates	ISO 10993-4 B 2.7		
22	Complement Activation test	ISO 10993-4 B.6		
23	Haematology- Leucocyte Count & Haemoglobin	ISO 10993-4 C.6.1.2.1		
24	Leucocyte adhesion on materials- Light microscopy	ISO 10993-4 B 2.7		
25	Tests for in vitro cytotoxicity	ISO 10993-5		
26	Estimation of ATP in Red Cell & Platelets	ISO 10993-4 C.6.2		
27	Estimation of Plasma Glucose	ISO 10993-4 C.6.2		
28	Estimation of Plasma Lactate	ISO 10993-4 C.6.2		
29	Estimation of Plasma Potassium	ISO 10993-4 C.6.2		
30	Estimation of Plasma Sodium	ISO 10993-4 C.6.2		

Customer Service Cell: Testing & Evaluation Activity

The Customer Service Cell coordinates the testing requests from both external and internal clients for testing requirements. The external customers mainly

The summary of the testing services is as follows:

Description	External	External			Internal		
	2009-10	2010-11	2011-12	2009-10	2010-11	2011-12	
Work orders	512	718	672	413	304	335	
No. of test materials handled	2060	3278	2097	1523	1144	997	
Income (Rs)	32,95,378	44,32,572	34,40861	19,96,495	21,36,875	22,80,480	

The biofunctional evaluation of drug eluting stents for M/s Sun Pharma, carried out as a study project was completed during the year and report submitted to the sponsor. New study requests from various sponsors are being reviewed and planned for this year.

SUMMARY OF TESTING SERVICES OFFERED BY VARIOUS LABORATORIES

Microbiology Lab

SI No	NAME OF TEST	Number of requests [number of samples]
1	Sterility test	67
2	Air monitoring	98
3	Water analysis	63
4	Spore viability test	10
5	Anti microbial activity testing	11
6	Culture/ staining	22
7	Ames test	1
8	Growth promotion study in media validation	8
9	Screening for pathogens in small experimental animals	

Toxicology

Toxicity tests done during 1st April 2011 to 31st March 2012

	No. of Tests			
1	1 Closed patch test (sensitization)			
2	Maximization test (sensitization)	10		
3	Intracutaneous test	13		
4	Acute systemic toxicity test	39		
5	Implantation in muscle	24		
6	Implantation in subcutaneous tissue	6		
7	Pyrogen test	1		
8	Haemolysis test	2		
9	Animal skin irritation test	2		

10	Vaginal irritation test	1
11	Penile irritation test	1
12	Chromosomal aberration study	9
13	Micronuclei study	9
14	Bone implantation	28

consist of medical device industry, research institutions and academia. The scope of testing services includes

accredited tests under ISO 10993 standard for the

biological evaluation of medical devices as well as physico-

chemical characterisation of materials.

Non accredited Test

15	Water analysis	36
16	Dermal toxicity	1

GLP Studies					
No	Title	Sponsor			
1	90 day sub-chronic toxicity by intraperitoneal implantation of degradable Polycaprolactone (PCL) based scaffold in wistar rats.	Dr. V. Kalliyana Krishnan, DPL, BMT			
2	Evaluation of long term biocompatibity of degradable Polycaprolactone (PCL) based scaffold in albino rabbits (ongoing)	Wing, SCTIMST Completed			
3	Evaluation of Chronic toxicity (12 months) by intraperitoneal implantation of degradable Polycaprolactone (PCL) based scaffold in wistar rats.	Dr. V. Kalliyana Krishnan, DPL, BMT Wing, SCTIMST Ongoing			
4	Chromosomal aberration study of P.Saline extract of ECSIL				
5	Chromosomal aberration study of ethanol-saline extract of ECSIL	Aortech Biomaterials Pty			
6	Micronucleus study of P.Saline extract of ECSIL	Ltd, Australia completed			
7	Micronucleus study of P.Saline extract of ECSIL				
8	Mammalian erythrocyte micronucleus test of UHMWPE	Dr. Vinay Agarwal, Gujarat			
9	Mammalian bone marrow chromosome aberration UHMWPE	Ongoing			

COLLABORATIVE WORK					
Wound healing (BST) 9 rabbits					
LAL test (DIMT)	1 LAL				
Brain Implantation (ICMR 8018)	13 rats				
Dermal Toxicity (DST 8043)	50 rats				
Genotoxicity (ICMR 8018, DST 8043)	176 mice				

ANNUAL REPORT 2011-12-

Laboratory Animal Science



The Division facilitates research and testing using small laboratory animals by imparting care, welfare and management of small laboratory rodents and rabbits. The animal care and welfare is as per ISO 10993 Part-II for testing facility of which the quality system is based on ISO/IEC 17025; 2005, under the surveillance of COFRAC. The primary mandate of DLAS is to breed, stock and supply good quality small laboratory animals for testing and research. The Division is CPCSEA registered and has to its credit many work procedures maintained as per International guidelines applicable to the field. DLAS has set up a state-of-the-art experimental animal facility with Individually Ventilated Cages (IVC) System and changing stations. The HVAC system was also revamped for maintaining the macro environment for the experimental animals. The Division also has to its credit several animal models which are used for biomedical research by various investigators. Apart from these objectives, the division also carries out a bi-annual training session for budding researchers in ethics and technicalities of small laboratory animal handling and this course is attended by MSc and PhD scholars from all over the country.



Newly added IVC facility with Environmentally Controlled Rooms for small Laboratory Animals (mice, rats and guinea pigs).

Precision Fabrication facility





Completed the machining of Dampan er system for Bioreactor project of DTERT lab





Completed the machining of Bioreactor components and connectors to Tissue culture lab



Completed the designing and machining of ceramic slurry extruder setup for Bioceramic Lab





Completed the machining of blood pump pivots, bottom bearing and top bearing for the Blood pump project to MPL

5



Completed the machining of compression test fixture to device testing lab

- 6. Completed the designing and fabrication of intramedullary rod mould to Polymer Division.
- 7. Completed the designing and machining of various types of Tef on moulds to Dental Products Lab.
- 8. Completed the machining of intra cranial pressure sensor mould to DTL.
- Completed the machining of potting fixture, vascular graft sample holding fixture, compression mould for bio reactor component, compaction dye for hemolysis test & muscular implantation test sample preparation to DTL.

- 10. Completed the designing and machining of 3 sets of Titanium prototype dental implants.
- 11. Completed the designing and machining of sample holder fixture to ceramic coating facility lab.
- 12. Completed the machining of for tensile testing of the graft in Instron.
- 13. Completed the machining of 6 sets of f ow chamber to test the sample 1cm x 1cm to TRU.
- 14. Completed the machining of 100 nos. of Titanium coins and 30 nos. of Haynes alloy coins in wire cut machine to ceramic coating facility.
- 15. Provided support in machining the required fixtures for the Bio reactor project.
- 16. Completed the designing and machining of 3 nos. of conical valve sizer to Homograft valve project to hospital wing.
- 17. Completed the machining of multi start threaded Bioreactor cartigen chamber to DTL.
- 18. Completed the machining of digital f ow control apparatus to Modeling and prototype lab.
- 19. Designed and fabricated 10 nos. of canister for LN2 f ask for Cryopreservation purpose to Tissue culture lab.

LIST OF NEW PATENT APPLICATIONS (2011-12)

Details of the design registration filed during this year is as follows

Serial No	Application No	Date of Filing	Title	Inventors
1	2675/CHE/2011	04/08/2011	"A PROCESS FOR THE PRODUCTION OF BIOACTIVE CHITOSAN WOUND DRESSING SPONGES FOR BURN WOUNDS".	Willi Paul, Chandraprakash Sharma
2	71/CHE/2012	06/01/2012	NOVEL PROTEIN MIMETIC POLYMER NANAOPARTICLE BASED THERMO-RESPONSIVE COATING FOR TISSUE ENGINEERING	Kaladhar Kamalasanan Chandraprakash Sharma
3	Awaiting application Number		A METHOD FOR EVALUATING PYROGENICITY BY IN VITRO USING HUMAN WHOLE BLOOD	P.V.Mohanan Siddarth Banerjee Muraleedharan Chirathody Vayalappil Lissy Kalliyana Krishnan Gobichettipalayam Subbratnam Bhuvaneshwar
4	Awaiting application Number		A SIMPLIFIED PROCEDURE FOR ISOLATION OF TISSUE ENGINEERING- SCAFFOLDS FROM CHOLECYST	Thapasimuthu Vijayamma Anilkumar
5	Awaiting application Number		A SIMPLIFIED PROCEDURE FOR ISOLATING TISSUE ENGINEERING SCAFFOLDS FROM SMALL INTESTINAL SUBMUCOSA OF WARM BLOODED ANIMALS	Thapasimuthu Vijayamma Anilkumar
6	Awaiting application Number		A SIMPLIFIED PROCEDURE INVOLVING PRE- ISOLATION IN SITU CROSS LINKING OF BIOMOLECULES FOR ISOLATING TISSUE ENGINEERING SCAFFOLDS FROM URINARY BLADDER OF WARM BLOODED ANIMALS	Thapasimuthu Vijayamma Anilkumar
7	Awaiting application Number		METALIC STENT FOR USE AS SUPPORT IN BLOOD VESSEL	Sujesh Sreedharan Muraleedharan Chirathody Vayalappil
8	114/CHE/2012	11.1.2012.	AN IMPROVED SYSTEM FOR VAPOUR POLISHING OF PLASTIC COMPONENTS IN A METALLIC VESSEL	Nagesh Divakara Panickar Sulochana Vinod Kumar Viswanathan Pillai
9	4470/CHE/2011	20/12/2011	POLY URETHINE ELASTOMER WITH ADAPTABLE SURFACE PROPERTIES	Muthu Jayabalan, S.Dawlee
10	149/CHE/2012	13/01/2012	INHERENTLY RADIOPAQUE AND NON-TOXIC POLYURETHANE COMPOSITION	Roy Joseph, Kiran Sukumaran
11	115/CHE/2012	11/01/2012	RAPID ANTIBIOTIC SENSITIVITY TEST KIT FOR URINARY TRACT INFECTION(UTI)	Mayanandkumar Pradeepkumar Soman Pillai Sarojini Amma
12	80/CHE/2012	09/01/2012	PREPARATION OF IRON OXIDE NANOPARTICLES WITH HIGH TRANSVERSE RELAXIVITY AND SATURATION MAGNETIZATION FOR IMAGING APPLICATIONS	Jayasree Ramapurath Sarojini Amma Harikrishna Varma Parimanathu Kovilakom Rama Varma,
13	Awaiting application Number		RESERVOIR FOR IN-VITRO EVALUATION OF CARDIOPULMONARY DEVICES	Nagesh Divakara Panickar Sulochana Vinod Kumar Viswanathan Pillai Arun Babu
14	Awaiting application Number		NON TOXIC POLYURETHANE COMPOSITIONS WITH INHERENT RADIATION SHIELDING CAPABILITY AND OPTICAL TRANSPARENCY	Roy Joseph, Kiran Sukumaran
15	Awaiting application Number		STRONTIUM CONTAINING CALCIUM SULPHATE BONE FILLER CEMENT	Manoj Komath Parimanathu Kovilakom Rama Varma Hari Krishna Varma,
16	Awaiting application Number		AN IMPROVED BLOOD PUMP FOR CARDIOPULMONARY BYPASS	Nagesh Divakara Panickar Sulochana Vinod Kumar Viswanathan Pillai

Serial No	Application No	Date of Filing	Title	Inventors
17	Awaiting application Number		WATER ACTIVATABLE POLYURETHANE SYSTEM CONTAINING MICRO-ENCAPSULATED CATALYST FOR ORTHOPEDIC CASTING TAPE	Muthu Jayabalan
18	Awaiting application Number		VASCULAR GRAFT SEALED WITH BIODEGRADABLE HYDROGEL	Roy Joseph, Chirathodi Vylappil Muraleedharan, Adathala Rajeev.
19	Awaiting application Number		VASCULAR GRAFT SEALED WITH BIODEGRADABLE HYDROGEL AND PASSIVATED BY FLUROPOLYMER COATING	Roy Joseph, Chirathodi Vylappil Muraleedharan

Serial No	Reference No	Design No	Date Of Filing	Title	Inventors
1	IPDTL010.Y12	241378	09/12/2011	A STENT FOR USE IN BLOOD VESSELS	Sujesh Sreedharan, Chirathodil Vylappil Muraleedharan

ACHUTHA MENON CENTRE FOR HEALTH SCIENCE STUDIES

Mission

- To train highly competent and socially committed public health professionals.
- To advocate for policies that promote equity in health
- To undertake quality research on priority health issues of the country
- To offer consultancy services to national and international agencies

Vision

Be a Global Leader in Health Sciences Studies by 2020







From the Head of AMCHSS

As a part of faculty development in Achutha Menon Centre for Health Sciences Studies (AMCHSS), two of our junior faculty members, Dr. Biju Soman and Dr Manju R Nair completed their advanced training at the London school of Hygiene and Tropical Medicine, under the European Commission project on "Partnership for better health" and rejoined on September 22, 2011. This one year Masters' training in infectious diseases and environmental health will strengthen these core areas of public health.

Two major research projects were started in this year. The first one was the Asian Collaboration for Excellence in Non-Communicable Diseases (ASCEND). The project supported by a grant from the NIH, US through the Monash University Australia aims to build sustainable research capabilities in relation to the prevention of chronic non-communicable diseases for a network of research trainees and research institutions in three middle income countries in Asia: India, Malaysia, and Sri Lanka. The second one is a grant from the Australian Health and Medical Research Council for the Kerala Diabetes Prevention Program (K-DPP), a cluster randomized controlled trial that aims to find out the effectiveness of a culturally tailored and group-based lifestyle intervention program on the incidence of type -2 diabetes mellitus.

Dr. A.S. Pradeepkumar who was awarded the PhD degree in chronic disease epidemiology is currently working as the Additional Director of Public Health in the Government of Kerala and is in charge of the national program for the prevention and control of non-communicable diseases (NCD) along with other public health activities of the State. The State is likely to benefit immensely from his PhD training particularly in the area of NCDs.

Under our collaboration program with the Bielefeld University, Germany, three MPH Students from our Institute completed their two months mandatory field placement in that University during November-December 2011 fully supported by the German University.

The 10 core faculty members of AMCHSS published 21 peer reviewed indexed journal articles with an average of 2.1 articles per faculty with a mean impact factor of 2.25. In addition, two papers were published by the MPH students and one by a project staff. The faculty also published one chapter of a book and a report for the WHO.

Dr. Josephine Kershaw, Director of Health Care Management in the College of Business in the University of Findley in Findley Ohio, USA joined as a Full Bright lecturer at AMCHSS on 2nd January 2012 for a period of six months. She along with a few other Full Bright fellows from Kerala offered an AMC seminar on the various aspects of the Full bright fellowship.

An important activity this year was the formation of the Public Health Students Forum in September 2011. The Forum organized two major events between October 2011 and March 2012. The first one was a seven day program from 1-7 October 2011 around the World Elder's day and the second one was a workshop on water, food security and public health.

Anhanen

K.R. Thankappan

Achutha Menon Centre for Health Science Studies



Academic Activities

One PhD student was awarded the degree in chronic disease Epidemiology, one submitted her dissertation and another one was awarded the ASCEND (Asian Collaboration for Excellence in Non-Communicable Diseases) fellowship. One PhD student of the National Institute of Epidemiology (NIE), Chennai, affiliated to SCTIMST, defended his thesis.

Fourteen MPH students successfully completed their program. Fourteen MPH students graduated from the NIE Chennai and five from Christian Medical College (CMC) Vellore. From the NIE 15 Master of Applied Epidemiology students also completed their course. As part of our collaboration with Bielefeld University, Germany, three MPH Students completed their two months internship and to of them participated the summer school program in Germany.

Ten Diploma in Public Health (DPH) students completed their course and four joined in 2012. Short courses on Biostatistics, Research Methodology and Ethics in Health Research were conducted. Major research projects of the centre are tobacco cessation, community interventions for health addressing three risk factors of non communicable diseases (tobacco, unhealthy diet and physical activity), diabetes prevention programs, workload of public health workers, capacity building for safe motherhood program and mental and social health outcomes of Tsunami affected people.

New Intiatives During The Year

Two of our faculty members, Dr. Biju Soman and Dr Manju R. Nair completed their advanced training in infectious diseases and environment health at the London school of Hygiene and Tropical Medicine, UK under the European Commission project on "Partnership for better health".

Asian Collaboration for Excellence in Non-Communicable Diseases (ASCEND)

The project aims to build sustainable research capabilities in relation to the prevention of chronic non-communicable diseases for a network of research trainees and research institutions in three middle income countries in Asia: India, Malaysia, and Sri Lanka. In view of current trends observed in each of these countries, the long-term objective of the project is to curb and ultimately prevent the growing epidemic of chronic non-communicable diseases. At least ten mid-career professionals, policy makers and/or researchers will be recruited from each of the three countries annually over four years and each individual will participate in a 12 month training program. The program will consist of a mentored research project in participants' home countries, international mentorship, and participation in a three week short course in Malaysia/ Sri Lanka/India focused on non-communicable chronic disease prevention. The first cohort of trainees was selected and they were given the initial three weeks training at Monash University, Malaysia.

Kerala Diabetes Prevention Program

The Kerala Diabetes Prevention Program (K-DPP) is a cluster randomized controlled trial of a culturally tailored and group-based lifestyle intervention program. The K-DPP targets individuals at high risk of developing type 2 diabetes mellitus (T2DM) in 60 neighborhoods from a rural area of Thiruvananthapuram district in Kerala State. The aims of the study are to implement and evaluate the K-DPP and its impact on T2DM incidence at 36 months compared with a standard care control group. (ii) To identify individual-, household-, and neighborhood-level factors likely to affect the wider system-wide uptake of K-DPP in India and other developing countries in the future. (iii) To estimate the population health impact and cost-effectiveness of screening and intervention in reducing the incidence of T2DM in a developing country with a very high prevalence of T2DM.

Training on Health Informatics

A joint proposal to conduct a week long training on Health informatics was submitted to the Indian Council of Medial Research by Dr. C. Kesavadas, Dr. Biju Soman, Dr. S.K. Jawahar and Dr. K. Srinivasan

The Public Health Students Forum

Students of the MPH program of the Centre formed the Public Health Students Forum in September 2011. The Forum organized two major events between October 2011 and March 2012.

A seven day program to mark the World Elders Day was organized from 1-7 October 2011 in collaboration with the Kerala Social Security Mission (KSSM). The program included medical camps, seminars and inter-generational sports events. The highlight was a one day conference organized in collaboration with KSSM and National Rural Health Mission (NRHM) on the theme "Ageing Kerala – A challenge", at the auditorium of Achutha Menon Centre for Health Science Studies. More than 250 delegates attended this Conference.

A workshop on Water, Food Security and Public Health was organized in association with the Communication and Capacity Development Unit (CCDU), Department of Water Resources, Government of Kerala, on 22 March 2012. The workshop was co-sponsored by Kerala State Pollution Control Board and co-ordinated by the Food and Agricultural Organization of the United Nations. More than 80 participants attended the workshop including students and faculty from five engineering colleges and faculty and students of AMCHSS. An exhibition with more than 50 posters and working models of rain water harvesting, Terafil filter etc. accompanied the workshop.

Research

Completed Projects

Capacity Building for Safe Motherhood Program

This was a collaborative initiative between Society for Education, Welfare and Action – Rural (SEWA Rural), Jhagadia; Centre for Study of Ethics and Rights, Mumbai (CSER, Mumbai) and Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum (AMCHSS, SCTIMST; Trivandrum)' The study is completed and the following papers are in various stages of communication:

Impact of the 2004 Indian Ocean Tsunami on People in affected Regions of India and Sri Lanka: A Longitudinal Study of Mental and Social Health Outcomes and Recovery of Individuals, Families, and Communities

This parent project has been completed in 2009. A nocost extension of the project, using savings from budget allocation, was taken up to study the major concern of the womenfolk in the community, alcoholism. Alcohol usage pattern in the community was studied in 750 randomly selected households (using GIS sampling techniques) in the Panchayat. Data collection was done by 15 trained women volunteers from the community and the male members were interviewed with the support of their female spouses.

Study on workload of public health nurses and other women health workers

The study on workload of "Public Health Nurses and other women health workers" completed in the year 2011-12. The study gathered information on work load among women public health workers and factors associated with this in Thiruvananthapuram, Alappuzha, Ernakulam, Malappuram and Wayanad districts of Kerala. An increasing number of nurses were reported to have workload and suffering from related problems. Primary data collection was done from 1238 respondents that included, Junior Public Health Nurses, Junior Health Inspector, Staff nurses, Lady Health Inspectors and Lady Health Supervisors. In addition, time and work study in selected work places and Qualitative enquiries also been done. The prevalence of three components of workload namely role overload, role stagnation and self role distance were documented. The findings suggest workload higher among women. The study has given an insight in to the problem and given an opportunity to understand the nuances of workload among the public health nurses.

Ongoing Projects

Athiyannur Sree Chitra Action (ASA)

This is the ongoing initiative of SCTIMST in collaboration with the Athiyannur Block Panchayat. The two action research projects are being carried out in the area under the Women Component Plan. Recently Public Health Foundation of India has identified ASA as one among the 17 field based interventions that would be documented in detail under their India Research Site Landscape Analysis Initiative. ASA specialty clinics are being offered as a service to the community. The specialty clinics are being conducted on every alternate second Saturdays (Neurology) and all fourth Saturdays (Cardiology) since 2010 November. Now it has been changed to alternate first Saturdays (Neurology), and all third Saturdays (Cardiology) from 2011 February onwards. The functioning of clinic is going smoothly. Last year 27 referred patients were treated in the Neurology Clinic and 151 patients in the Cardiology clinic. Four patients from Neurology clinic and 16 patients from Cardiology clinic were referred to SCTIMST for further expert evaluation.

Building Capacity for Tobacco Cessation in India and Indonesia

This is a collaborative project between Achutha Menon Center for Health Science Studies of SCTIMST, Gadjah Mada University of Indonesia, and the University of Arizona USA. The overall objective of this project is to strengthen capacity for tobacco cessation training and research in India and Indonesia. The specific objectives of the project are to incorporate tobacco education into undergraduate medical education in selected medical colleges in Kerala and Karnataka. Memorandum of understanding was signed between the SCTIMST and the above five medical colleges. Twelve modules were finalized after pilot testing and are being implemented in the five partner medical colleges. A randomized control trial of tobacco intervention among diabetes patients has been progressing in two specialty hospitals, Indian Institute of Diabetes (IID), Trivandrum and Medical Trust Hospital, Pandalam. Three oral presentations and eight poster presentations were made in the recent 15th World Conference on Tobacco or Health in Singapore during March 20-24th 2012. A community was also selected by each of the above medical colleges for tobacco control activities. Tobacco smoke free household initiative is one of the activities under the community project.

Community Interventions for Health

This pilot project was awarded by the Oxford Health Alliance, UK initially for four sites in the world. Three other sites that got this award are Mexico, China, and the United Kingdom. The objective of the project is to find out the feasibility of community based intervention to reduce the three major risk factors of chronic noncommunicable diseases namely tobacco use, unhealthy diet and physical inactivity. Two community development blocks are selected, in Trivandrum district: one block is the intervention site and the other control site. A delayed intervention will be provided in the control community in the fourth year of the project. School, work site, hospital and community are the four settings where tailor made interventions will be provided. Interventions to reduce all the above risk factors were implemented in all the settings. A repeat survey was completed in both the intervention and the control sites.

Capacity building of women health workers

This project aims at capacity building of Junior Public Health Nurses in the study area in the monitoring of cardiovascular diseases with optimal adaptation of public health technologies. Baseline data collection has started in the selected wards using cluster spatial sampling method using GIS software. Algorithm for decision support system of the software is being developed in consultation with cardiologists, general physicians and grass root level workers.

Impact of type 2 Diabetes on women's lives and wellbeing

Objectives: The study proposed to describe the burden of diabetes on men and women's lives and the consequences of this condition on the life style of other members of the patient's family. Methodology and outcomes: Phase 1.a: This phase is an exploration of available secondary data to examine the associations between diabetes household level factors and also gender mediated factors. The 60th round of the National Sample Survey Organization's health survey was analyzed and a paper on 'The prevalence of diabetes mellitus and its correlates among the elderly in India: an exploration of the NSSO 60th round' is being drafted. A second paper Gender differentials is envisaged.

Phase 1.b: A set of 10 men and 10 women identified as diabetic patients for more than five years were interviewed for the development of case studies. The data collection for this phase has been completed and the materials transcribed. Report writing is in process.

Phase 2: This phase consists of a survey to examine the gender mediated factors determining the burden of households with diabetes and the patients' ability to manage diabetes. Patients coming to the Medical Trust Hospital for treatment will be prospectively recruited for the study, 150 men and 150 women. The inclusion criteria is diagnosis of diabetes for at least 5 years and not experiencing any acute ailments. The ethics clearance for this phase is being awaited.

Public health impact of use of yechnology by women

This project aims to create a set of user manuals for rural women on optimal and healthy use of household technologies through participatory action research. Preliminary trainings for the selected women volunteers are completed. Baseline data on use and pattern of household technologies from the selected 380 households in the area has been completed. Volunteers have been providing education sessions for womenfolk in the selected households through neighborhood meetings in the study area (Athiyannur and Chirayinkeezhu).

Partnership for better health

The objective of this project is to strengthen public health capacity of two Asian public health institutions namely the Achutha Menon Centre for Health Science Studies (AMCHSS) of SCTIMST in India and the Bangladesh Rural Advancement Committee (BRAC) School of public Health in Bangladesh. Three institutions in Europe are partnering with this initiative: the London School of Hygiene and Tropical Medicine (LSHTM) UK, The Karolinska Institute of Sweden and the University of Amsterdam, The Netherlands. Two faculty members from the BRAC School of public health were sent for PhD training and two faculty members from AMCHSS were sent of Masters training at the London School of Hygiene and Tropical Medicine, The MPH student manual was updated and distributed to the MPH students under this project.

Prevalence of Type II diabetes in a rural community in Central Travancore: identification of the contributing economic and socio-cultural factors

Objectives: The study objectives were to examine the economic and socio-cultural determinants of life style modifications in a selected rural community in central Travancore.

Methodology and Outcomes: The study will be a qualitative study to facilitate the identification of the community perceptions of life style changes that have happened over the last 15 years. It consisted of 32 indepth interviews among adults living in Ward A and B of Venmony Panchayat, including migrant and local households and persons of different socio-economic and diabetic status. In addition 8 focus group discussions were conducted among this community to identify the community perceptions of diabetes mellitus.

Workshops, Training Programs Organized

Short Courses

Basic Biostatistics Course

Instructors - Dr. V. Raman Kutty and P. Sankara Sarma

This course was designed for senior residents of SCTIMST and were mandatory for residents from the departments of Anesthesiology, Cardiology, Cardiovascular and Thoracic surgery, Neurosurgery, Neurology, IS & IR. All doctors doing PDCC and PDF programs were encouraged to attend this course but not mandatory. Interested faculty members could also attend this course.

The objective of this course was to familiarize common statistical terminologies and design issues in biomedical and clinical research. The course was scheduled as eight lectures of two-hour duration each, adding to a total of 16 hours.

During the year 2011-12, this course was conducted twice; one during June 2011 where about 20 residents were deputed and another during October where about 30 were deputed.

Biostatistics classes in the Research Methodology course for MPhil (Biomedical Technology)

Instructor - P. Sankara Sarma

This course was designed for the MPhil program in Biomedical Technology that is conducted at BMT wing. In addition to the MPhil students, this course was attended by the PhD Scholars from the BMT wing and Hospital also.

Outline of the course: An introduction to the principles of statistics as it applies to the understanding and interpretation of the biomedical literature. The emphasis of this course is on the application of statistical tests commonly employed in biomedical research and the interpretation of their results. Topics which will be covered include: probability, principles of inference, hypothesis testing, parametric and non-parametric tests, principles of epidemiology, statistical vs. clinical significance, and quasi-statistical methods (e.g., meta-analysis, decision analysis).

There were eight lectures of two-hour duration each adding to a total of 16 hours and a written in-class exam (two credits for the program).

For the biostatistics classes that were taken during September, 2011, there were 23 participants.

Ethics in Health Research

A short course on Ethics in Health Research was organized by the AMCHSS and the IEC-SCTIMST from August 9-13, 2011 and was co-ordinated by Dr. Mala Ramanathan, Additional Professor, AMCHSS. The module aimed at enabling the participants to recognise and apply ethical analysis for decision making in research ethics. In all, 10 participants including AMCHSS research staff, researchers from BMT and faculty from SCTIMST completed the course. Dr. Rama Menon, Member, IEC-SCTIMST was an observer. Faculty for this course were drawn from the AMCHSS, Hospital wing and BMT wing. Certificates of participation were given to all those who completed the course.

Basic Statistics for Diploma in CVT/ Neuro Nursing program

It was a one-week course (12th Dec to 17th Dec 2011)

including five lectures (10 hrs) and an exam. The topics covered were organization and presentation of data, measures of central tendency and dispersion, correlation and regression, fundamentals of hypotheses testing and interpretation of statistical tests, critical evaluation of research studies /articles, statistical reporting and general rules for designing tables and graphs. Fifteen students attended the course. All passed in the examination.

Workshops/Conferences

An Indo-Swiss symposium on "Cohorts and Biobanks" was organized at the AMC auditorium January 27-28, 2012. There were 15 participants from Switzerland including the Swiss ambassador at Swiss Embassy at New Delhi and his wife, and a member of the Swiss parliament. Overall, there were around 100 participants from various institutions in India. Participants of the symposium were given five continuing medical education credits by the Travancore Medical Council, Trivandrum.

An international seminar on the role of tobacco control in the prevention and control of NCDs was inaugurated by the Honourable Minister for Health and Family Welfare, Government of Kerala, Sri Adoor Prakash on May 31, 2011. A tobacco information Kit was released on the occasion which was received by the Health Secretary Government of Kerala. More than 250 delegates from all the Medical Colleges in Kerala and selected Medical Colleges in Karnataka participated in the seminar. Twelve tobacco education modules implemented in the five partner Medical Colleges were presented by the faculty members from the partner Medical Colleges.

The Government of Gujarat organized a one day seminar on health systems development in Gujarat and all the MPH and DPH graduates along with two senior faculty members from AMCHSS were invited for the seminar. The former director of NIE Prof. MD Gupte also participated in this seminar.

A one day research methodology workshop was conducted for the cardiologists of Kerala which was organized by the Cardiology Society of India, Kerala Chapter in Trivandrum on June 12, 2011.

Collaboration with the Centre for Studies in Ethics and Rights, Mumbai and the University of Washington, Seattle (Drs. Neha Madhiwala and Beth E Rivin) to submit a proposal to the Wellcome Trust, UK on 'Fairness in drug trials, perspectives of medical professionals in two states of India' was established.

The second board of studies meeting of the Health Science Studies was held on July 28, 2011 at AMCHSS.

Dr. K. R. Thankappan, Professor and Head and Dr. P. S. Sarma, Professor offered expert consultation in Epidemiology and Statistics for investigators of the Cardiology Society of Kerala for their ongoing study on the prevalence and risk factors of CAD in three districts of Kerala on August 20, 2011 at AMC

Aspecial session of the "Quit Tobacco India project" was held at the Indian Public Health Association Annual Conference at Kochi during February 10-12, 2012. Professor Mark Nichter, Mimi Nichter, Prof KR Thankappan, Dr Yamini Thankachi, Dr GK Mini and Ms Sreedevi Padmajam participated in this session and presented papers.

AMC public health students' forum conducted World Elderly Day on October 1, 2011. The function was inaugurated by Sri.K.Muraleedharan, MLA.

AMC Public Health student's forum conducted World Water Day on March 22, 2012

AMC Seminar Series

The following seminars were conducted during the past year:

"The Ethical Challenges relating to the Global Reproductive Tourism Industry" by Dr. Raywat Deonandan, Assistant Professor in the Faculty of Health Sciences, University of Ottawa, Canada 2nd June 2011.

"Identifying potential high risk behavior for post partum morbidity and neonatal mortality among women in Jhagadia- a Pilot research" by Dr Mala Ramanathan, Additional Professor-(AMCHSS) 4th July, 2011

"Through the Historical Looking Glass: The Medicalization of Childbirth in Travancore, 1880-1950". by Dr. Aparna Nair, Associate Professor, Centre for Development Studies on 25th November 2011.

"Shifting the locus of NCD Prevention: Insights from a qualitative study of adult onset diabetes in Kerala, South India." by Dr. Caroline Wilson, MRC-ESRC Post-Doctoral Fellow, School of Social and Community Medicine, University of Bristol, 4th February 2012.

Important Visitors /Trainees

Dr. Josephine Kershaw, Full Bright Fellow from the United States joined as a Full Bright lecturer at AMCHSS on 2nd January, 2012. She is the Director of Health Care Management in the College of Business in the University of Findley in Findley Ohio, USA.

As part of the student exchange programme between Bielefeld University Germany and AMCHSS of SCTIMST,

six students (Anna Hansen, Elzbieta Krupa, Josephine Goldner, Myriam Tobollik,Heiko Zimmermann, Lena Werdecker) from the Bielefent University visited AMCHSS and participated in the academic programmes.

A planning meeting of the Kerala Diabetes Prevention program (K-DPP) was organized in AMCHSS during May 27-30, 2011. Four people from Monash University Australia including Prof Brian Oldenburg and Prof Pilvikki Asbetz from Finland participated.

Professor Mitchell Weiss, the Swiss coordinator for the Indo-Swiss symposium on Cohorts and bio-banks for chronic diseases visited our Institute and held discussions with the Director, SCTIMST and Director, NIE Chennai from during June 13-14, 2011 to plan for the above symposium scheduled for January 2012.

Dr Aparna Nair, Assistant Professor from Centre for Development Studies, Thiruvananthapuram spoke on "Through the Historical Looking Glass: The Medicalization of Childbirth in Travancore, 1880-1950 on 25th November at AMC Seminar Hall. Kerala's current high rates of institutionalized childbirths were analyzed from a historical and sociological perspective in this paper; which employed both archival research and oral history.

Prof. Sara Varghese, who is heading the State Prevention of Epidemics and Infectious Diseases (PEID) Cell took class for MPH students as part of the Infectious Disease Epidemiology module on 17th Apr 2011.

One video conferencing session was conducted at the telemedicine room for MPH students on 19th April 2012 with experts from New Delhi (Dr John Lewis, HISP India) as part of their Public Health Technologies module.

Prof. Sandeep Sahay and Dr John Braa, faculty members from Department of Informatics, University of Oslo, Norway took classes on Public Health Informatics for MPH students as part of their Public Health Technologies module on 19th and 20th of April 2012.

Prof. Jacob John, former Emeritus Professor of Virology, Christian Medical College, Vellore took classes for MPH students as part of their Infectious Disease Epidemiology module from 21st to 27th of April 2012.

The 10 core faculty members of AMCHSS published 21 peer reviewed indexed journal articles with an average of 2.1 articles per faculty with a mean impact factor of 2.25. In addition, two papers were published by the MPH students and one by a project staff. The faculty also published one chapter of a book and a report for the WHO.



Sri Adoor Prakash, Hon. Minister for Health and Family Welfare, Government of Kerala is inaugurating World No Tobacco day on May 31, 2011



World Elders Day 2011 inaugurated by Sri. K. Muraleedharan, MLA on December 1, 2011





Dissemination Workshop on Clinical Trials Registry on August 28, 2011



Biostatistics for Neurology Workshop, September 2-3, 2011



Participants of the Indo-Swiss workshop January 27-28 2012



Quit Tobacco International team members presented three oral and eight poster presentations at the World Conference on Tobacco or Health in Singapore 20-24th March 2012





Academic Division







From the Dean's Desk

The Annual Report of the Institute for the Year 2011-2012 documents the Institute's activities in keeping with the mandate conferred on it by the Indian Parliament and thereby the people of India and hence it ref ects the continuing relevance of the institute to the national health priorities. It showcases the Institute's achievements during the past year in the three important fields of clinical medicine, public health and biomedical technology.

The Academic Division of the Institute has taken several steps to fine tune the academic curriculum and evaluation process of the various Post Doctoral programs leading to award of DM and MCh degrees in cardiac sciences, neurosciences, anesthesiology and radiology. This process is expected to make these programs at par with similar programs all over the world. The Academic Division is in the process of upgrading the curriculum and continuous evaluation process for all the diploma programs related to various clinical fields and this will be completed within a year. The Institute takes care to evaluate various academic programs conducted by other premier institutes and affiliated to our institute for quality and relevance to national needs and its health priorities. The Institute for Biotechnology and Toxicology (IIBAT), Chennai and the Indian Institute for Information Technology and Management-Kerala(IIITM-K) to explore areas for academic collaboration which can be mutually beneficial.

Research and Publication Cell was established in the Academic Division in August 2011. One of the objectives of the cell is to facilitate the smooth functioning of extramural and Institute funded research projects. The other objective is to establish norms and standards for publication of scientific and popular articles, annual reports, bulletins, and facilitate research initiatives by the academic community. As a first step, "Guidelines for writing research papers" was posted on the Institute's website.

The Annual Convocation for the 27th batch of graduates was held on the 7th of May 2011. Dr. R. Chidambaram, Principal Scientific Advisor to Government. of India and President of the Institute presided over the solemn function and Dr. K. Kasturirangan, Honorable Member, Planning Commission, Government of India was the Chief Guest and delivered the convocation address. Dr. K.N.Sharma, Emeritus Professor, National Academy of Medical Sciences, the Guest of Honor, addressed the graduates. The faculty and students wholeheartedly participated in the program and now the Annual Convocation takes a prominent place in the Institute's academic calendar.

The demand of the student community for various academic programs of the Institute continues to be encouraging, going by the large number of applicants nationally and the Institute is striving hard to elevate these programs to high standards to attract talented students from all over the country.

The Annual Report will remain as important reference document with which one can measure the institute's performance in the years to come.

Jagan Mohan Tharakan

Division of Academic Affairs

The Institute currently offers 25 academic (diploma, postgraduate, doctoral and post doctoral) courses in medical sciences, biomedical engineering and technology, basic sciences and public health. All academic programmes continue to attract students in significant numbers from all over India and for the MPH couse, from other countries.

Admission of students and evaluation of students registered for various programmes are the primary responsibilities entrusted to the division. The division co-ordinates the work of standing Academic Committee of the Institute which has been constituted to make recommendations to the Governing Body on general supervision over the academic policies of the Institute and method of instruction, teaching, training, evaluation of research and improvement in academic standards.

Programmes offered in 2011-12

Post-doctoral

DM Cardiology

DM Neurology

DM Neuroimaging and Interventional Neuroradiology

DM Cardio Thoracic & Vascular Anaesthesia

DM NeuroAnaesthesia

MCh Cardiovascular & Thoracic Surgery

MCh Vascular surgery

MCh Neuro Surgery (after M.S)

MCh Neuro Surgery (after MBBS and 1 year Residency in General Surgery)

Certificate course in Cardiovascular & Neuro Surgical Anaesthesia

Certificate course in Cardiovascular & Neuro Radiology Certificate course in Vascular Surgery

certificate course in vascular surger

Post DM/MCh Fellowship

Doctoral and Master's

PhD

Master of Public Health(MPH)

M.Phil

MTech Clinical Engineering

Diploma

Cardio Vascular & Thoracic Nursing Neuro Nursing Blood Banking Technology

Cardiac Laboratory Technology

ANNUAL REPORT 2011-12

Neuro Technology

Operation Theatre Technology

Advanced Medical Imaging Technology

Clinical Perfusion

Medical Records Science

Sponsored Courses

Diploma in Public Health(DPH)

Students Enrolment

The student strength for DM/MCh degree, Post-doctoral certificate courses and Post DM/ MCh Fellowships during the year was 87. The Master of Public Health degree programme has 24 scholars. The Institute has, as of now, 82 students for the PhD programme, 66 scholars for the various Nursing and Technology related Diploma Programmes. The affiliated programmes of SCTIMST at the National Institute of Epidemiology have an enrolment of 39 students for the Master of Applied Epidemiology programme and 32 students for the Master of Public Health.

Joint programmes with other Institutions

Two affiliated prgrammes of two-year duration are offered at the National Institute of Applied Epidemiology, Chennai (NIE) an institution under the Indian Council of Medical Research (ICMR)

- 1. Master of Applied Epidemiology
- 2. Master of Public Health (Health Services, Development and Research)

Joint Programme by IIT Madras / CMC Vellore / SCTIMST - Trivandrum

The three institutions–IIT Madras, CMC Vellore and SCTIMST Trivandrum, each having a set of unique strengths and facilities, have joined together in starting two Programmes – 'M.Tech in Clinical Engineering' and 'Ph.D in bio-medical devices and technology' to address the issue of capacity building for reducing India's dependence on imports of medical devices. A unique feature of these courses is the clinical attachment with a maximum exposure to the clinical environment. This ensures that, at the end of the course the students will be able to interact effectively with the clinicians and other medical and paramedical staff in the hospital resulting in the identification of unmet 'clinical needs'. This is also expected to trigger further research leading to development of innovative indigenous healthcare technology.
MS / Ph.D Bio-engineering courses at CMC Vellore

This affiliated campus programme of the Institute, postgraduate Bioengineering programme, emphasizes the R&D needs of health care in India to be developed. There are two students admitted for the programme.

Short-term training/observership upto period of three months

Candidates sponsored by the Government /Autonomous institutions/ Health sector organizations, approved Medical/Dental/Nursing colleges, paramedical Institutions and Government / Defence services are provided short term training.

This training / observership is arranged in consultation with the respective department / discipline and the time and period of training is decided by the Academic Division in consultation with the Head of the Department/Division.

Around 215 observers from 60 institutions all over the country spent varying periods from two weeks to three months in different department of the Institute.

Programmes Organised by the Division

National Science Day

In connection with the National Science Day, various activities were organized for the Higher Secondary School / College Students. About 150 students visited the Institute on 24th February 2012. The Institute held an open day in all three wings in the Hospital Complex, Achutha Menon Centre and in the Biomedical Technology wing for the visitors. The exposure to the service and research programmes and facilities of the Institute was greatly appreciated by the young visitors and the faculty.

Progressive use of Hindi

The Institute complied with the provisions relating to the Official Languages Act, Rules and instructions and Directives of Government of India.

During the year, various competitions were held for the employees in Hindi. Hindi fortnight / Hindi day was observed. Hindi workshops were conducted for the benefit of staff members to increase the knowledge of functional Hindi. Letters received in Hindi were also reported in Hindi.

The Institute participated in the various Town Official Language Implementation committee meetings.

Library

The Hospital Wing library has a collection of 14538 books and 14651 back volumes of journals. During the current year, 333 books and 22 back volumes were added and 103 journals were subscribed. Electronic access to most of the journals has been activated and is available throughout both the campuses.

Being part of National Knowledge Resource Consortium, our library has access to full text of journals in addition to those we subscribe. The consortium resources includes journals of major publishers like Elsevier, Springer, Wiley, ACS, Sage, OUP, IEEE, ASME, Taylor & Francis, Nature, Science etc., and databases of ASTM Standards, ISI Web of Knowledge, and Derwent Patents Index.

The information management system and library automation are based on Microsoft SQL Server 2005. The library information is available to both the wings through intranet.

Medical Illustration

The Medical Illustration Division offers support to the Academic activities of the Institute by assisting the faculty and students in the preparation of slides and movies, photography and digital imaging graphic arts for national and international conferences.

The photographs seen in this Annual Report are contributed by the Division.



The Annual Convocation of the 27th batch of graduates was held on May 7, 2011. Dr. R. Chidambaram, President of SCTIMST presided, Dr Kasturirangan was the Chief Guest of the function and Dr. K.N. Sarma was the Guest of Honour



Dr. K.M. Chandrasekhar, Vice Chairman, Kerala State Planning Board presiding the valedictory function of Joint Hindi Fortnight of TOLIC held at SCTIMST on January 24, 2012



Dr. V.C.Joy, Principal Secretary, Finance, Government of Kerala inaugurating National Science Day, February 24, 2012



Research Activities



Clinical Research

Hospital Administration

An internally funded Research Project titled, "Clinical Application of Cryopreserved Homograft Valves in Cardiovascular Surgery" with Dr. K. Jayakumar as Prinicipal Investigator and Ms. Molly Antony, Dr.S.K. Jawahar as co-investigators is under progress.

The primary objective of the project is to establish a homograft programme, by harvesting 120 homograft valves, processing, sterilizing and cryo-preserving them followed by clinical implantation and follow-up to ensure feasibility of the programme and safety and efficacy of the homografts.

The project is supported by Technology Development Fund of the Institute for a period of 2 years at a cost of Rs 5 lakhs

Biochemistry

Lactose-binding serum immunoglobulin (LIg) binds to Lp(a): Lactose-binding IgG from normal serum, prepared using lactose-Sepharose recognizes Lp(a) in its desialylated form, while LDL is inert. This may be a major source of Lp(a)-IC, especially in diabetes and infections that cause a surge in desialylation.

Desialylated Lp(a)-serum antibody immune complexes (IC) retain antibody binding sites that enable their binding to cell surfaces: De novo IC formed between Lp(a) and normal serum antibodies are found to consist of lactose binding immunoglobulin (Llg) and anti-T antibodies. Moreover, they retain part of the antibody binding sites, enabling the IC to anchor to other desialylated host cells. This may represent a major route for Lp(a) uptake by macrophages or smooth muscle cells.

Anti- α -galactoside antibody (anti-Gal) of normal serum binds Lp(a): All samples of anti-Gal antibodies prepared by affinity chromatography contained Lp(a) as co-purified molecule. Reconstitution experiments confirmed that anti-Gal, but not any other serum antibody complexes with Lp(a). Serine- and threonine-rich peptide sequences in Lp(a), akin to that in MUC-1 type peptides, may account for anti-Gal binding to it since Lp(a), but not LDL inhibited another α -galactoside and MUC-1 peptide-specific plant lectin, GS14. Notably, anti-Gal and Lp(a) arose contemporarily in mammalian evolution. Adduct with Lp(a) may help tissue uptake of LDL: Using purified Lp(a) and LDL de novo adduct formation between the two was demonstrated. LDL from pre-existing adducts and free LDL were equally efficient in adduct formation. Further, Lp(a)-LDL adduct, but not free LDL could bind to immobilized human galectin-1, suggesting that adduct may be a vehicle for LDL transport across cell membranes.

Functional characterization of high-density lipoprotein [HDL]: This study is focused on the prevalence of dysfunctional HDL if any, in subjects and its compositional and functional characterization. HDL from majority of healthy subjects [~30] showed remarkable antioxidant property. However, HDL from a very few healthy subjects and all subjects with inflammatory disease [coronary heart disease] were found to lack antioxidant capacity and were thus considered dysfunctional. Further, dysfunctionality in HDL does not show any association with HDL-cholesterol concentration. Functional assay of HDL offers the potential for early identification subjects at risk of developing chronic inf ammatory diseases since dysfunctional HDL is a significant risk factor.

Oxidised high-density lipoprotein [HDL] and atherogenesis: Oxidized-HDL was found to enhance the production of reactive oxygen species, pro-inf ammatory cytokine-TNF, Matrix metalloproteinases in monocytes/ macrophages by the activation of NADH-NADPH oxidase pathway and induce lipid accumulation mediated by expression of CD36- scavenger receptor for oxidized lipids, while native HDL and mildly oxidized HDL had no such effects. These findings demonstrate that HDL can lose its cardioprotective function depending on the extent of oxidative modification and mediates deleterious effects such as enhanced oxidative stress and pro-inf ammatory response in monocytes/macrophages. The generation of oxidized HDL in vivo might therefore augment atherogenesis.

Coronary artery disease in the young [collaborative research with the Dept. of Cardiology]: This study is aimed at developing a database: starting from anthropometric to angiography of young CAD patients in Kerala to evaluate the prevalence of both the conventional and non-conventional risk factors and for developing appropriate preventive strategies for our population. As part of the study, lipid profile, several thrombotic factors such as fibrinogen, homocysteine and lipoprotein (a), platelet activation and small dense LDL were quantitated in~30 young CAD patients [<55 years] and age and sexmatched healthy controls. Preliminary finding of this ongoing study indicate that the prevalence of these non -conventional risk factors is much higher in CAD patients.

Gliomasphere forming ability of cells isolated from human glioma tissue: The size and number of gliomaspheres developed from the cells isolated from different grades of human glioma tissues were found to have a positive correlation with the grade of tumor. Gliomaspheres were further characterized and their stemness was confirmed by analyzing the expression of stem cell marker protein nestin. Some cells within gliomaspheres also expressed glial and neural lineage markers such as GFAP and β -III tubulin respectively.

Phenethyl caffeate benzo[kl]xanthene lignan (PCBL) with DNA intercalating properties induces DNA damage and apoptosis in colon cancer cells: We have found that PCBL, a synthetic lignan with DNA intercalating properties was inducing autophagy along with apoptosis in colon cancer cells from results of comet analysis and the phosphorylation status of various DNA damage response proteins such as H2AX, ATR, Chk1 and BRCA1. Effector molecules of apoptosis such as caspase 3, 7 and 9 were activated along with the PARP cleavage in PCBL treated cells suggesting that apoptosis was the main mode of cell death induced by PCBL.

Molecular evidence for anticancer activity of aloe emodin in colon cancer cells: Aloe emodin (AE), a natural anthraquinone, inhibited cell proliferation by arresting cell cycle at G2/M phase and inhibition of cyclin



Figure showing staining in normal tissues and different grades of tumor

B1. AE appreciably induced cell death through induction of apoptosis, activating caspases 9 and 6. Relatively nontoxic concentration of AE suppressed the phorbol-12myristyl-13-acetate (PMA) induced migration and invasion of tumor cells. Further investigations revealed that AE downregulated expression of MMP-2/9, and RhoB. It was also a strong inhibitor of Vascular Endothelial Growth Factor (VEGF) expression, promoter activity and endothelial cell migration/invasion and in vitro angiogenesis. AE suppressed the nuclear translocation and DNA binding of NF-κB.

Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways: Nitric oxide (NO), an uncharged free radical increases the proliferation of cancer cells and simultaneously prevents apoptosis. Expression of MMP-2/9, RhoB and Rac-1 was enhanced by NO in a time-dependent manner. Further, NO increased phosphorylation of ERK1/2 and induced nuclear translocation of Fra-1 and Fra-2. Electrophoretic mobility shift analysis and use of deletion mutant promoter constructs for the proteins MMP-2/9. iNOS, MMP-2/9, Fra-1 and Fra-2 in normal and colon adenocarcinoma tissues revealed increased expression of these proteins in cancer when compared to normal providing support to our in vitro findings. Normal epithelium showed mild staining for iNOS, MMP-2 and MMP-9. Cells in the inf ammatory region showed moderate staining for iNOS, MMP-2 and MMP-9. Almost all cells in the tumor region showed intense and moderate staining for iNOS, MMP-2 and MMP-9. Metastatic lymphnode showed moderate staining for iNOS, MMP-2 and MMP-9. The study showed that the NO-cGMP-PKG promotes MMP-2/9 expression by activating ERK-1/2 and AP-1.

Cardiology

Faculty members are working on validation of a clinical protocol creation of a hospital registry for cardiac ion channelopathy.

Correlation between fetal echocardiographic findings and neonatal trans thoracic echocardiographic findings at segmental level is carried out as a Faculty Project by Dr.Bijulal S and Dr.Sivasankaran.

D-Dimer as a tool to diagnose left atrial thrombus in rheumatic mitral stenosis is a student project supported by SCTIMST.

Other projects carried out with extra mural support are:

Atrial Fibrillation Registry

Coronary artery disease and its risk factors prevalence

Feasibility study for establishing nationwide network of registries on Management of Acute Coronary Event (MACE REGISTRY)

Use of a Multidrug Pill in Reducing cardiovascular Events(UMPIRE)

Coronary artery disease in the young

Does non-regression of Pulmonary Hypertension following balloon mitral valvotomy correlate with Bmpr2 Mutations?

Comprehensive Heart Failure Intervention Program

Cardiovascular and Thoracic surgery

The Department has taken up a study on "Steroids in Cardiac Surgery" as part of international trial with Mc Master University, Canada. The study entails ascertaining the efficacy of low dose steroids in periopeartive period in high risk patients undergoing cardiac surgery. Dr.Jayakumar is the Principal Investigator and the study co-ordinator is Dr.Vivek V. Pillai.

A number of animal trials were carried out in collaboration with the BMT Wing. This includes the LVAD program.. Dr.M.Unnikrishnan commenced animal experiments on tissue engineered small diameter graft and hydrogel coated large diameter grafts. Animal trails on decellularised bovine pericardium is in progress. The treated bovine epricardial tissue was implanted as an atrial defect closure patch in sheep and autopsy was done after 6 months to study the nature of the implanted patch invivo conditions. The experiments were conducted by Dr.Jayakumar and Dr.Umashanker.

Comprehensive Heart Failure Program in collaboration with the Dept of Cardiology aims at identifyng and treating patients with heart failure and efforts are underway to start the heart transplantation program.



Mitochondrial metabolism in Type 2 Diabetic Heart- The meatbolic effects of Diabetes Mellitus on the human heart is studied from cells obtained from the right atrial appendage and tissues from the papillary muscles. The study is conducted along with the Department of Biochemistry by Dr.Jayakumar, Dr. Vivek Pillai and Dr. Srinivas. G.







Cryopreserved Homograft prior to implantation

Cellular and Molecular Cardiology

Cardiac fibroblasts in myocardial remodeling: molecular mechanisms

The Division continued to focus on mechanisms in heart failure. Cardiac fibroblasts, the most abundant cell type in the heart, play a critical role in myocardial remodeling following injury. Replicative capacity, retained throughout adult life, and relative resistance to apoptosis are two major attributes of these cells that are central to their role in wound healing and myocardial remodeling post injury. Understanding the mechanisms regulating the cardiac fibroblast cell cycle and relative resistance to apoptosis could potentially lead to therapeutic strategies to regulate these processes and is therefore a clinically desirable goal.

Mechanisms regulating G1-S transition in cardiac fibroblasts

Investigations over the past year showed that p44/42 MAPK is a positive regulator of the cardiac fibroblast cell cycle. Mitogenic stimulation of cardiac fibroblasts leads to activation of p44/42 MAPK. In mitogenically-stimulated MAPK-inhibited cells, accumulation of cells



Fig. 1 p44/42 MAPK inhibition in mitogen-stimulated cardiac fibroblasts impaired G1-S transition

in the G0/G1 phase with a corresponding reduction in the number of cells in the S phase indicated that p44/42 MAPK is required for G1-S transition in cardiac fibroblasts. (Fig. 1) A significant reduction in cyclin D1 and cyclin A levels and hypophosphorylation of Rb were observed in serum-stimulated, p44/42 MAPK-inhibited cells MAPKinhibited cells, consistent with impaired G1-S progression. Induction of p21 and p27, observed upon p44/42 MAPK inhibition, could explain the G1-S block in these cells.

The expression of Skp2, an F-box protein involved in the post-transcriptional regulation of p21 and p27, was markedly reduced upon MAPK inhibition, which suggests a post-translational mechanism of regulation of p21 and p27 by Skp2.

Mechanisms underlying apoptosis resistance in cardiac fibroblasts

Since cardiac myocytes are susceptible to oxidative injury and cardiac fibroblasts are not, and oxidative stress is known to be a major component of much cardiac pathology, this laboratory examined the apoptosis-resistance mechanisms recruited in cardiac fibroblasts exposed to oxidative stress. Oxidative stress was found to enhance the mRNA and protein expression of cIAP-2, an important anti-apoptotic protein. siRNA-mediated silencing of cIAP2 rendered the cells susceptible to oxidative injury, confirming its protective role. Further, cIAP2 was found to be regulated by NF- κ B whose inhibition reduced cIAP-2 expression and promoted cell death under conditions of oxidative stress. Electrophoretic Mobility Shift Assay showed that oxidative stress activates NF- κ B in cardiac fibroblasts.

Modulation of energy metabolism in the prevention of cardiac remodeling

Cardiac hypertrophy in chronic pressure overload is a risk factor for cardiac failure and sudden death. Cardiac hypertrophy is associated with a shift in energy metabolism from predominantly fatty acid to glucose, leading to energy depletion. The decrease in fatty acid oxidation is mediated by down regulation of the gene peroxisome proliferator activated receptor – alpha (PPAR α). Based on the contention that reactivation of PPAR α can prevent cardiac remodeling by restoring the energy status of the heart, studies were carried out in spontaneously hypertensive rat. Reactivation of PPAR α using the synthetic ligand fenofibrate showed that stimulation of fatty acid metabolism in the early stages of hypertrophy reduced oxidative stress and prevented cardiac remodeling, whereas treatment with fenofibrate in older rats with established hypertrophy showed enhanced oxidative stress

and aggravation of hypertrophy. Downregulation of the fatty acid transporter CD36 led us to infer that substrate insufficiency may be the major cause for the adverse remodeling in older animals. Experiments are in progress to examine the cardiac response on supplementing medium chain triglycerides to Spontaneously hypertensive rat.

Autocrine and paracrine mechanisms in human resident cardiac stem cell signaling following hypoxic injury

Stem cells are the mediators of tissue repair in the event of myocardial injury. The presence of scar tissue subsequent to ischemic injury is the consequence of inadequate repair mechanisms. A more profound knowledge of the biology of stem cells and their fate following pathologic insults is essential for promoting the resident cardiac stem cells for in situ repair of the injured myocardium. A study has therefore been designed for delineation of the behavior of cardiac stem cells in the event of hypoxic injury.

Atrial biopsies obtained at the time of insertion of catheter for coronary artery bypass graft in patients with coronary artery disease



Fig. 2 a. Cardiospheres



Fig. 2 b. Cardiospheres

The explants were set in culture and cardiospheres were derived from cultured explants (Fig.2a). Cardiospheres were expanded on fibronectin coated dishes. (Fig.2b) Cardiosphere derived cells stained positive for the stem cell markers-c-kit, MDR-1, GATA-4 and MEF-2c and negative for myosin heavy chain and cardiac troponin I. On supplementation with 5 azacytidine, invitro differentiation was apparent, including cellular arrangement and elongation. Immunostaining confirmed the presence of cardiomyocyte specific markers – troponin I and myosin

Culture of mesenchymal stem cells obtained at sternotomy

An invitro angiogenesis assay in matrigel was carried out in both mesechymal and cardiosphere derived cells. Endothelial tube formation was apparent within 5h in hCDCs and by 12h, these cells involuted to form a central cell cluster from which secondary vascular structures started to migrate out. (Fig. 3a) Tube formation was considerably delayed in mesenchymal stem cells. (Fig. 3b)





Fig.3- Invitro angiogenesis assay following 12h in culture on matrigel. A. Cardiosphere derived cells, B. Mesenchymal stem cells.

Imaging Sciences and Interventional Radiology

The main areas of research in the department include

- 1. Advanced functional neuroimaging techniques of functional MRI, DTI, perfusion imaging, susceptibility weighted imaging & spectroscopy
- 2. Advanced functional and morphologic cardiac MRI
- 3. Brain computer interface
- 4. Cerebral vasoreactivity studies
- 5. Medical image processing: Collaborations have been established with University of Tubingen, Germany, Indian Institute of Information Technology, Kerala, and University of Allahabad. Industrial collaborations exist with Seimens healthcare (MRI research) and Philips healthcare.
- 6. Multimodality carotid plaque imaging: pomparison of USG, CT & MRI
- 7. Prospective study on the Hypertrophic Cardiomyopathy (HCM): Prospective observational study correlating the MRI patterns with the arrhythmia load and symptoms in patients with HCM

Projects completed

- 1. Dr.Bejoy Thomas along with Dr. P. Gayatri, Additional Professor, Department of Anaesthesia carried out project on 'Development and evaluation of a nonrebreathing sequential gas delivery circuit to maintain constant end tidal Carbon dioxide (ETCO2), to be used for Cerebro Vascular Reactivity (CVR) assessment using fMRI and allied techniques'. This was funded by the Institutional Internal fund.
- 2. Dr Narendra Bodhey was co-guide for the research project of Mr Avinash Dhontula, on Design and simulation of Vortex Flow Ventricular Assist Device for the MTech degree awarded jointly by IIT Madras, SCTIMST Trivandrum and CMC Vellore. He is also a core group member for the project titled " Development of the indigenous stent graft for Thoracoabdominal Aneurysm repair" along with the scientists at BMT wing.

Neurology

R.Madhavan Nayar Center for Comprehensive Epilepsy Care (RMNC)

Ongoing research projects include

a) Study the long-term outcomes of epilepsy surgery

including seizure outcome, psychological outcomes and quality of life outcomes

- b) To study the antiepileptic drug profile of patients following epilepsy surgery
- c) Standardization of neuropsychology test scores through a case-control study in patients with refractory temporal lobe epilepsy
- d) Multimodality imaging in pre surgical evaluation of temporal lobe and extra temporal epilepsy
- e) Positron emission tomography-magnetic resonance imaging (PET-MRI) co-registration
- f) Electroencephalography-functional MRI coregistration (EEG-fMRI)
- g) Role of diffusion tensor imaging tractography (DTIT) in tracking of eloquent areas and aiding in pre-surgical evaluation of drug resistant partial epilepsies
- h) Clinical, electrophysiological and pathological differences within temporal lobe epilepsy
- i) To study the knowledge, attitude and practice of epilepsy in different community groups
- j) To develop cost-effective models of presurgical evaluation suitable to the developing world
- k) Pharmacogenomic research on drug resistance in various epilepsies
- I) Indigenous development of intracranial electrodes

Comprehensive Care Center for Movement Disorders

- Elucidation of molecular interactions between autophagic pathways and alpha-synuclein accumulation in a cell model with endogenous expression: relevance to sporadic PD.
- Study of factors promoting aggregation of alpha synuclein and their infuence on the clearance mechanisms in an endogenous cell model with relevance to pathogenesis in Parkinson's disease.
- Non Invasive Cerebellar inhibition by Transcranial Magnetic Stimulation for the treatment of Levodopainduced dyskinesias in Parkinson's Disease.
- Plasticity of Motor cortex in motor fluctuations and dyskinesias of Parkinson's disease.
- Pattern of impulse control disorders in PD: impact of socio-economic and cultural factors in Indian patients.
- Prevalence and pattern of Non-motor fluctuations and their impact on Quality of life in PD.

- Ten year -outcome of bilateral subthalamic nucleus deep brain stimulation in PD.
- Comparison of sleep disorders in Sporadic vs. Familial Parkinson's Disease.
- A comparative study of transcranial sonography in Parkinson's disease, atypical Parkinsonism and normal controls.

Comprehensive Stroke Care Center

- Prevalence of microbleeds and its correlation with stroke subtypes
- Socioeconomic and caregiver burden of stroke patients
- Quality of life in stroke survivors
- CT angiogram as a predictor of outcome in symptomatic ICA occlusion

Comprehensive Care center for Neuro-muscular Disorders

The section is involved in following broad areas of research:

- 1. Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis", (protocol number 205MS301). The study has recruited 4 patients of Multiple sclerosis, after obtaining IEC clearance
- 2. Standardisation of temperature measurements in the EMG lab
- 3. Standardisation of F wave parameters in nerve conduction studies
- 4. Family and genetic studies in myotonic dystrophy patients
- 5. Review on mortality in the Neuromedical ICU
- 6. Trigeminal nerve stimulation in diagnosis of Myasthenia gravis
- 7. Cognitive aspects in multiple sclerosis. MUNE in motor neurone disease
- 8. The prevalence of Campylobacter jejuni infection associated with Guillain Barre Syndrome: This is a Collaborative project with Department of Neurology at KS Hegde Medical Academy, Mangalore
- Collaborative nodal center for National Polio Surveillance program for acute f accid paralysis (AFP) under the aegis of WHO acute f accid paralysis: Neurology Department of our Institute has been identified as a state nodal centre to periodically report AFP cases so

that accelerated strategies can be adopted to ensure the interruption of wild Poliomyelitis transmission

Comprehensive Centre for Sleep Disorders (CCSD)

Sleep Research Laboratory unit of the CCSD looks into the unresolved questions related to sleep and its functions. The mechanisms for sleep regulation are studied in rat models. Telemetric system is used for recording sleep, body temperature and blood pressure in rats. Different types of transmitters for recording sleep, temperature, blood pressure are chronically implanted into animal's body for recording these parameters in unrestricted natural state. EEG electrodes are implanted using stereotaxic instrument. Along with visual scoring, SleepSign software is employed for analyzing various components of sleep. Simulation studies are carried out in an environmental chamber which provides meticulously controlled experimental conditions essential for study involving interaction of sleep and thermoregulation. The main ongoing projects include:

The effects of maternal sleep deprivation (restriction) on cognition in the offspring in an animal model: Insufficient sleep in pregnant women is a common feature, with growing number of women working not only in offices but also at home. This study aims to evaluate the effects of maternal sleep loss/deprivation on cognition and the mechanisms involved in it. Sleep deprivation is carried out in different groups of pregnant rats using an automated telemetric sleep monitoring system, during the three trimesters. Apart from studying the cognitive parameters in the adult offspring, the anxiety in neonatal pups will be assessed through the ultrasonic vocalizations. The study will also look at the possible alteration theta activity coherence from hippocampus, amygdala and prefrontal cortex.

To investigate the role of rapid eye movement (REM) sleep during development in regulation of sexual arousal and erectile events in adult rats: Sleep and sexual behavior are essential physiological entities. Though it is known that disturbances in REM sleep during early development have a bearing on sexual behavior, it is not known whether it affects erectile dysfunctions in adults. We have standardized the recording of erectile events in free moving animals, and conducting a longitudinal study to study the effect of disturbances in REM sleep during early life on sexual activity during adulthood.

In addition, the center also concentrates on, scientific evaluation of the sleep-wake altering property of a-asarone, an active principle of Acorus Calamus and investigation on the effects of acute sleep restriction on sleep and body temperature interactions in different age groups of healthy subjects.



Research is also conducted on the following:

- 1) Prevalence of sleep disorders in the general population.
- 2) Epworth sleepiness score standardization in Indian population
- 3) Formulation of new sleep apnea clinical score and its correlation with OSA severity
- 4) Contribution of SDB in the manifestations of ADHD in children
- 5) Neuropsychiatric manifestations of patients with OSA and its improvement after CPAP treatment
- 6) Contribution of sleep apnea in the progression of CHF, systemic hypertension, isolated pulmonary hypertension, COPD and Type 2 DM
- 7) Prevalence of Sleep Disordered Breathing (SDB) in patients with drug resistant epilepsy and seizure control after CPAP treatment- a double blind, placebo controlled prospective trial

Neurosurgery

Use of de-cellularised bovine pericardium as dural substitute. The study has reached preclinical stage and animal trials are in progress.

Pathology

During the year, 3 major lipid antigens of Mycobacterium tuberculosis bacilli were isolated and characterized. These include cord factor (Trehalose 6, 6' dimycolate), lipoarabinomannan and sulpatides. With these antigens immunoassays such as ELISA were standardized for the diagnosis of tuberculous meningitis, tuberculous pleural effusion and tuberculous lymphadenitis. The role of cord factor in in vitro chemotaxis of neutrophils from patients with pulmonary tuberculosis and tuberculous meningitis were evaluated.

An experimental study was initiated to induce pulmonary granuloma in naïve and lymphopenic mice with cord factor antigen of M tuberculosis: Lymphopenia were induced with the corticosteroids (cortisone acetate). The naïve mice showed well formed pulmonary granulomas following cord factor administration while with the lymphopenic mice did not show any pulmonary granuloma.

A specific immunoassay was developed to estimate the cord factor in intracranial tuberculoma.

A simple dot- immunobinding for the detection of cord factor antigen in body **f** uids is being developed.

The role of cord factor of M. tuberculosis and its role in the immunodiagnostic and prognosis in pulmonary tuberculosis: (a) Cord factor antigen can be demonstrated in the clinical speciemens (sputum, pleural f uid, CSF and sera) of patients with tuberculosis. (b) The concentration of cord factor antigen is directly proportional to the disease severity(c) cord factor antigen is not present in patients with non tuberculous pulmonary diseases and hence the detection of cord factor has a role in the diagnosis of tuberculosis.

Trehalose 6, 6'dimycolate (TDM) induced pulmonary granuloma in naive and lymphopenic mice is shown in the following figure: (a) Cytospin smear showing viable peritoneal macrophages (toludine blue stain, \times 400); (b) perivascular aggregation of lymphomononuclear cells in the lung (H&E stain, \times 250); (c) discrete aggregation of lymphomononuclear cells and few histiocytic cells in the lung (H&E, \times 250); (d) showing well-formed cohesive histiocytic granulomas in lung (H&E \times 250); (e) showing a granuloma located in the sub-pleural region (H&E \times 100); (f) showing TDM positive cells in the lung granuloma (ABC immunoassaying, \times 250).



Cord factor of M. tuberculosis and its role in the immunopathogenesis of murine tuberculosis:

Cord factor antigen in optimal concentrations induced granuloma formation in lungs in experimental models (mice). The cord factor also promoted chemotaxis of peritoneal macrophages in invitro. Hence cord factor play an important role in the immunopathogenesis of tuberculosis. However under the infuence of immunosuppression cord factor did not promote invitro chemotaxis and granuloma formation. The results this experimental observation may have a direct clinical relevance. Patients with immunosuppressant such as AIDS do not manifest granuloma formation and tuberculous lesions in lungs of patients with HIV resemble closely with the lesions seen in lymphopenic mice.

A new finding of lipofuscinosis of the lung was identified in some of the patients reporting to the hospital.

Externally Funded Research Projects

SI. No	Principal Investigator	Project Title	Funded By	Total cost	Duration	Status
1	Dr. G.Srinivas	Isolation, Characterization of Gliomasphere forming cells from Glioblastoma Multiforme: Correlation with Prognostic Factors and Treatment Outcome	DBT	Rs. 32,84,000/-	2 years	Ongoing
2	Dr. S. Harikrishnan	Feasibility study for establishing nationwide network of registries on management of acute coronary event (MACE REGISTRY)	ICMR	Rs. 2,85,890/-	1 year	Pliot phase
3	Dr. S. Harikrishnan	Coronary Artery Disease in the Young	KSCSTE	Rs. 13,00,000/-	3 years	Ongoing
4.	Dr. S. Harikrishnan	Coronary Artery Disease and Its Risk Factors Prevalence Study (CSI Kerala CRP Study)	Cardiological Society of India, Kerala Chapter	Rs.8,22,835 /-	1 year	Ongoing
5.	Dr. Narayanan Namboodiri	Atrial Fibrillation Registry	IHRS - Indian Heart Rhythm Society	Rs.1,00,000/-	1 year	Ongoing
6.	Dr. S. Harikrishnan	Does non-regression of pulmonary hypertension following balloon mitral valvotomy correlate with Bmpr2 mutations?	PVRI – Pulmonary vascular research Institute, Canterbury, UK	RS.2,65,650/-	1 year	Ongoing
7	Dr. S. Harikrishnan	<u>U</u> se of a <u>M</u> ultidrug <u>P</u> ill <u>In</u> <u>R</u> educing cardiovascular Events(UMPIRE)	Imperial College, London	Rs. 1,392,500/-	2 years	Ongoing
8.	Dr. S. Harikrishnan	Comprehensive heart failure intervention program	ICMR	Rs. 5,415,301/-	2 years	Ongoing
9.	Dr. K. Shivakumar	Molecular basis of cardiac fibroblast resistance to oxidative stress	DBT	Rs 45,00,000/-	3 years	Ongoing
10	Dr. K Shivakumar	Regulation of the cardiac fibroblast cell cycle by p44/42 MAPK	ICMR	Rs.18,68,571/-	3 years	Ongoing
11	Dr. R Renuka Nair	Modulation of energy metabolism in prevention of cardiac remodeling: Stimulation of peroxisome proliferator-activated alpha receptor	LSRB	Rs. 18, 00,000/-	3 years	Ongoing
12	Dr. R. Renuka Nair	Autocrine and paracrine mechanisms in human resident cardiac stem cell signaling following hypoxic injury	KSCSTE	Rs.16,00,000/-	3 years	Ongoing

Hospital Wing

13	Dr. C. Kesavadas	Self-Regulation of Broca's Area (right inferior frontal gyrus) using Real time fMRI in Post Stroke Aphasia patients	DBT	Rs. 9,00,000/-	2 years	Second year
14	Dr. C. Kesavadas	Neurobiological Marker for Population Differences: A Neuroeconomic Investigation with Anxiety & Depression Patients contrasted with Normal Population	DBT	Rs.7,00,000/-	2 years	Ongoing
15	Dr. R. Ashalatha	Improving localization in lesion negative focal epilepsy: Can EEG-FMRI predict the epileptogenic zone and the likelihood of post-operative seizure freedom?	KSCSTE	Rs.14,85,000/-	3 years	Ongoing.
16	Dr. R. Ashalatha	EEG-FMRI as a tool in pre surgical evaluation of Medically refractory epilepsy	DBT	Rs.9,00,000/-	3 years	Ongoing
17	Dr. R. Ashalatha	Can EEG-FMRI predict the epileptogenic zone and the likelihood of post-operative seizure freedom?	DST	Rs.21,25,200/-	3 years	Ongoing
18	Dr. Asha Kishore	Cerebellum and Cortical Plasticity – The Case of Dystonia" (Indo-French Collaborative Project.	ICMR and INSERM (Paris, France)	Rs.7,00,000/-	2 years	Ongoing
19	Dr. Asha Kishore	Developing experimental therapeutics using Transcranial magnetic stimulation for Movement disorders (Indo-French collaborative project): Cerebellum and Cortical Plasticity	Association Center for Neurological Research of the Sal Peteriere	Rs 7,00,000/-	2 years	Ongoing
20	Dr. Asha Kishore	Protocol SP921: A multicenter, randomized, double-blind, placebo controlled, 5-arm, parallel- group trial to assess the study drug transdermal system dose response in subjects with advanced-stage Parkinson's disease.	UCB Bioscience GmbH Funding agency	Rs.10,00,000/-	1 year	Completed
21	Dr. Asha Kishore	Protocol 28850: Open label trial to determine the long term safety of the study drug in Parkinson's disease patients.	Merck Serono	Rs.10,00,000/-	1 year	ongoing
22	Dr. Asha Kishore	Protocol P04938: A phase 3, 12- week, double blind, double-dummy, placebo and active controlled efficacy and safety study of the study drug in subjects with moderate to severe Parkinson's disease	Schering-Plough	Rs. 10,00,000/-	1 year	ongoing

23	Dr. Asha Kishore	Protocol P05664: A Phase III, double blind, placebo and active controlled, dose – range – finding efficacy and safety study of the study drug in subjects with early Parkinson's disease	Schering-Plough	Rs. 5,00,000/-	1 year	Ongoing
24	Dr. P.N Sylaja	Diabetes, prediabetes and insulin resistance in patients with recent transient ischemic attack and ischemic stroke	NIH	\$ 15,000/-	10 months	Ongoing
25	Dr. P.N. Sylaja	Indo-US Collaborative Stroke Registry and Infrastructure Development	DBT-NIH	\$ 60,000/-	2 years	Ongoing
26	Dr. P. S. Mathuranath	Multi-centric Indo-US collaborative project, the Kerala-Einstein study	National Institute of Health (NIH) USA	\$82,759/-	5 years	Ongoing
27	Dr. Kamalesh K. Gulia	The effects of maternal sleep deprivation (restriction) on cognition in the offspring in an animal model	DST-CSI funded project	Rs. 42,47,000/-	3 years	Ongoing
28	Dr. Kamalesh K. Gulia	To investigate the effects of short- and long-term administration of alpha- asarone on oxidative stress and anxiety alleviation in insomnia model in rats	CSIR	Rs 24,22,000/-	3 years	on going
29	Dr. Kamalesh K. Gulia	To investigate the role of rapid eye movement (REM) sleep during development in regulation of sexual arousal and erectile events in adult rats	DST	Rs. 10,68,000/-	3 years	Ongoing
30	Mr.Mendlow, Professor of Neurosurgery, Regional Neurosciences Centre, New Castle Upon Tyne, UK (Principal International Investigator)	Multicentric multinational randomised controlled surgical Otrial in intracerebral haemorrhage (STICH II),	Sponsored by stroke association and medical research council, University of New Castle, UK.	Rs. 82,293/-	2.5 years	Ongoing
31	Dr.V.V.Radhakrishnan	The role of cord factor of M tuberculosis and its role in the immunodiagnostic and prognosis in pulmonary tuberculosis	KSCSTE	Rs.5,63,200/-	2 years	ongoing
32	Dr.V.V.Radhakrishnan	Cord factor of M tuberculosis and its role in the immunopathogenesis of murine tuberculosis	DST	Rs.12,49,600/-	2 years	ongoing
33	Dr.V.V.Radhakrishnan	Development of an immunodiagnostic system suited to laboratories in developing countries	DBT	Rs.17,03,000/-	3 years	ongoing

Biomedical Technology Wing

a. Newly Initiated Projects

Title	Principal Investigator	Funding Agency	Total Project Cost (in Rs)	Duration
Visible light induced insitu gelling Multifunctional Hydrogels as Potential Wound Dressings	Dr. C. Radhakumary	DBT	39.79 lakhs	3 years
Cell Sheet Engineering on Electrospun Scaffolds for Efficient Cell Supply in Skin Tissue Engineering	Dr. P.R. Anil Kumar	DST Fast Track	19.44 lakhs	3 years
Home based vital signs monitor for screen- ing of sleep disorders	Dr. Niranjan D. Khambete	DST	29.28 lakhs	2 years

b. Ongoing Projects

Title	Principal Investigator	Funding Agency	Total Project Cost	Duration
Development of Calcium Sulfate Based Injectable Bone Substitute	Dr. Manoj Komath	DST (SERC)	12.03 lakhs	2 years
Development of nanodevices for DNA delivery and cell transfection using Elastin Like Polymers (ELPs) coupled to cell interaction motifs	Dr. Chandra P. Sharma	Indo Spanish DST project	26.14 lakhs	3 years
Pulsed laser Ablation of Bioactive Ceramic Composite on Titanium Bone Implants	Dr. H.K.Varma	KSCSTE	6.35 lakhs	3 years
Synthesis of oxide based magnetic nanoparticles for biocompatibility studies, magnetic hyperthermia and MRI applications.	Dr. H.K.Varma	DST	16.39 lakhs	3 years
Development of Coronary Stent System	Mr. C.V. Muraleedharan	NMITLI, CSIR	184 lakhs	6 Years
Development of iron oxide Nanoparticle probes for organ specific molecular MR imaging	Dr. R.S. Jayasree	BRN, DAE	28.63 lakhs	
Development of smart dental composites consisting of calcium containing resins and fillers	Dr.P.P. Lizymol	KSCSTE	14.65 lakhs	3 years
Quantum dots for cardio-vascular Applica- tions	Dr.Diksha Painuly	DST	22 lakhs	3 years
Molecular and immunotoxi-cological effects of Dextran coated Ferrite and Hydroxylapitite nanomaterials'	Dr. P.V. Mohanan	DST	49.39 lakhs	3 years
In Vitro alternative test system development for Ocular Irritation	Dr. P.V. Mohanan	ICMR	40.11 lakhs	3 years
Development of neurons from adult stem cells for the application of regenerative medicine	Dr. Lissy Krishnan	SERC, DST	29 lakhs	3 years

Facility for micro/nanoparticles based biomaterials for Advanced Drug Delivery Systems (FADDS)	Dr. Chandra P. Sharma	DST	554.79 lakhs	4 years
Ex vivo evaluation of Left Ventricular Assist Devices (LVAD) VSSC-SCTIMST joint project	Mr. D.S. Nagesh	VSSC, Trivandrum	30 lakhs	
Development of a Dura Substitute by Electrospinning of -Caprolactone-Co- Lactide Polymers	Dr.P. Ramesh	KSCSTE	9.58 lakhs	4 years
In vitro and Preclinical evaluation of curcumin released from biodegradable drug carriers	ICMR	ICMR	15 lakhs	
Development of National GLP Guidelines & Identification and selection of National Regulatory Guidelines for Testing and Evaluation of Medical Devices	Dr. P.V. Mohanan	National GLP Compliance Monitoring Authority,DST	10.77 lakhs	18 months
Development of hemostatic scaffold for wound care	Dr. Lissy K. Krishnan	CSIR	22 lakhs	3 years
Development of neurons from adult stem cells for the application of regenerative medicine	Dr. Lissy K. Krishnan	DST	29 lakhs	3 years
Bioengineered hybrid skin substitutes for burn wounds	Dr. Lissy K. Krishnan	KSCSTE	27 lakhs	3 years
In vitro, and Preclinical Evaluation of Curcumin Released from Biodegradable Fibrin Matrix	Dr. Lissy K. Krishnan	ICMR	15 lakhs	
Role of transforming growth factor – alpha in neuronal growth and regeneration	Dr.Anoopkumar Thekkuveettil	STEC	14.96 lakhs	3 years
Dispensable and biodegradable polymeric bone cement for minimally invasive treatment of bone diseases – product validation	Dr. M. Jayabalan	DST	32.07 lakhs	3 years
Program support for a Lead program on Centre of excellence in Tissue engineering (COE) program of the (extended for 2 more years)	Dr. Prabha D. Nair – Team Leader & P.I	DBT	499 lakhs	5 years
Individual project under the COE program - Tissue engineering of cartilage using biomimetic scaffolds under dynamic conditions – (extended for 2 more years)	Dr. Prabha D. Nair	DBT		
Musculoskeletal Tissue engineering	Dr. Prabha D. Nair, SCTIMST and Prof M.Kassem, Odense University	Indo-Danish project jointly funded by the Danish Ministry of Science and Technology and DBT India	637.89 lakhs	3 year
Epithelial-mesenchymal interactions in tissue engineered hybrid artificial lung role of angiogenic factors	Dr. A.Maya Nandkumar	DBT	46.101 lakhs	3 years

Differentiation of foetal progenitor cells and fabrication of a prototype of bioartificial liver	Dr. T.V. Kumary	DBT	59.56 lakhs	1 year
Development and Feasibility study of Polymeric Scaffolds for Tissue culture under Microgravity	Dr.P.R. Anil Kumar (Co-investigator)	Indian Institute of Space Science and Technology, Trivandrum	25.00 lakhs	3 year
Medical Device Retrieval Programme	Dr. Mira Mohanty	DBT	48.65 lakhs	3 years
Atlas of tissue response to Biomaterials	Dr. Mira Mohanty	DST	5.78 lakhs	1 year
Cell based tissue engineered fabrication of osteochondral grafts	Dr. Annie John	DBT (ANCETE)	54.57 lakhs	5 years
Tissue engineering of a carrier free corneal endothelial construct towards transplantation for endothelial keratoplasty.	Dr. Bernadette K. Madathil	DST, (Women scientist scheme, WOS-A)	24.80 lakhs	2 years

INDUSTRY sponsored projects 2011-12

d. Ongoing projects

Title	Principal Investigator	Funding Agency	Total Project Cost	Duration
Setting up a mission mode programme for medical instrumentation and devices development	Dr.V. Kalliyana Krishnan	DST	28 lakhs	2 years
Evaluation of molecular toxicity of newly developed materials intended for biomedical application	Dr. P.V. Mohanan	ICMR	18.44 lakhs	3 years
Development of decellularised animal tissue for cardiovascular application'	Dr. S.R. Krishnamanohar/ Dr. P.R. Umashankar	DBT		
Bone Tissue Engineering using adipose stromal cells on 3D porous bioactive ceramic scaffolds	Dr. Annie John	DBT (ANCETE)	35.00 lakhs	1 year
Bioconjugation of nanomaterials and their applications in cancer therapy	Co-investigator- Dr. Annie John (Collaboration with University of Kerala)	DBT, (Nanoscience & Nanotechnology Task Force)	25.00 lakhs	3 years
Development of improved tilting disc heart valve	Mr. C.V. Muraleedharan	NMITLI, CSIR	94.2 lakhs	4 years

b. Ongoing Projects

Title	Principal Investigator	Funding Agency	Total Project Cost	Duration
Development of intrauterine drug releasing system	Dr.V. Kalliyana Krishnan	HLL Lifecare Ltd., Trivandrum	40 lakhs	4 years

INSTITUTE Technology Development Fund Projects 2011-12

e. Newly Initiated projects

Title	Principal Investigator	Duration	Total project cost (Rs in lakhs)
Toxicological evaluation of a new dental reatorative composite containing Diphenyl [2,4,6-trimethyl benzoyl] phosphine oxide [TPO] as photoinitiator	Dr.V.Kalliyana Krishnan	1 year	9 .11 lakhs
Production scale-up of Calcium phosphate Cement (Chitra- CPC)	Dr. Manoj Komath	1 year	4.30 lakhs
Prototyping of sking graft substitues for wound healing applications using cholecyst - derived extracellular matrix	Dr. T.V. Anilkumar	2 years	9 lakhs
n vivo evaluation of the efficacy of oral heparin nanoparticles in rabbit models	Dr. Chandra P. Sharma	10 months	1.98 lakhs
Development of Titanium nitride coatings for medical applications	Mr. Sujesh Sreedharan	2 years	2.35 lakhs

f. Ongoing projects

Title	Principal Investigator	Duration	Total project cost
A pilot project on implementation of a medical device safety network portal suitable for Indian scenario	Mr. Arun Anirudhan	2 years	8.53 lakhs
Preclinical animal evaluation of decellularised bovine pericardium as dura substitute.	Dr. Girish Menon	18 months	6.87 lakhs
Development of bioactive bone cement based on organically modified ceramic resin	Dr. P.P. Lizymol	2 years (Jan 2010 – Sep 2012)	6.33lakhs
RAPID Antibiotic sensitivity kit for UTI	Dr. A. Maya Nandkumar		1.95 lakhs
Development of Mandibular Advancement Device for the Treatment of Obstructive Sleep Apnea	Dr. Roy Joseph	2 years	9.99 lakhs
Evaluation of functional efficacy of recombinant TGF alpha and VEGF proteins	Dr. Anoopkumar Thekkuveettil	2 years	9.76 lakhs
Clinical application of cryo preserved homograft valves in cardiovascular surgery	Dr. K. Jayakumar	2 years	8 lakhs

Achutha Menon Centre for Health Science Studies

S. No	Principal Investigator/ Responsibility	Project Title	Funded By	Total cost	Duration	Status
1	K. R. Thankappan, P. S. Sarma S. Sivasankaran Yamini Thankachi G.K. Mini Sreedevi Padmajam	Building Capacity for Tobacco Cessation in India and Indonesia	Fogarty International Centre of the National Institutes of Health	US \$ 472,500	Five years Up to 30 June, 2013	Ongoing
2	K. R. Thankappan S. Sivasankaran Ravi Prasad Varma Rekha M. Ravindran C. U. Thresia	Community Interventions for Health	Oxford Health Alliance	US \$ 690,000	Five Years Up to 31 December 2012	Ongoing

3	K. R. Thankappan Sony Jacob	Partnership for Better Health	European Commission through the BRAC school of Public Health Bangladesh	Euro 180,455	Four years up to 31 October 2012	Ongoing
4.	Prof. Brian Oldenburg, Australia Prof. Khalid Kadir, Malaysia Prof. Edwin Fisher, USA Prof. K. R. Thankappan, India Dr. Prasad Katalunda, Sri Lanka	Asian Collaboration for Excellence in Non- Communicable Diseases (ASCEND)	Fogarty International Centre of the National Institutes of Health, USA	US \$ 1.0343 Million	Five years up to June 30, 2015	Ongoing
5	K. R. Thankappan S. Sivasankaran T. Sathish Neena Philip Anoop Velayudhan	Kerala Diabetes Prevention Program	National Medical and Health Research Council, Australia	AU \$ 1.03 Million	Five years up to June 30, 2015.	Ongoing
6	Mala Ramanathan V. Raman Kutty	Prevalence of Type II diabetes in a rural Community: Identification of the Contributing Economic and Socio- cultural factors		1.15 lakhs	Two years until October 2012	Ongoing
7	V. Raman Kutty Mala Ramanathan	Impact of type 2 Diabetes on women's lives and wellbeing.	Women Component plan of DST	19.85 lakhs	Two years until July 2012	Ongoing
8	Biju Soman Manju Nair S. Harikrishnan	Capacity Building for Women Health workers	Women Component Plan of DST	10 lakhs	Two years up to July 2012	Ongoing
9	Biju Soman K. R. Thankappan P. S. Sarma	A longitudinal study in the tsunami affected areas of Kerala	University of San Francisco, USA	40 lakhs	Four years up to June 30, 2011	Completed
10	K. Srinivasan P.S. Sarma	Workload of Public Health Nurses and Other Women Health Workers	Women Component Plan of DST	20 lakhs	Two years up to December 2011	Completed
11	V. Raman Kutty Mala Ramanathan	Capacity building for Safe Motherhood Programmes	Centre for Studies in Ethics and Rights, Mumbai	11. 36 lakhs	Up to March 31, 2012	completed



SCIENTIFIC PUBLICATIONS



Journal Articles

- Abraham AA. Short term research projects in lowresource settings. Indian J Med Ethics 2011; 8:187-188.
- Anilkumar TV, Harikrishnan VS, Vineetha VP, Thulaseedharan NK, Sreeja KR, Deepa R, Fernandez AC. Immunohistochemistry and confocal microscopy of rat mammary gland sirrhous carcinoma. Indian J Vet Pathol. 2011; 35: 108-110
- Arun M, Silja PK, Mohanan PV. Evaluation of hydroxyapatite-bioglass and hydroxyapatite-ethyl vinyl acetate composite extracts on antioxidant defense mechanism and genotoxicity: An in vitro study. Tox Mech Methods. 2011; 21: 561-566
- Baheti NN, Radhakrishnan A, Radhakrishnan K. A critical appraisal on the utility of long-term video-EEG monitoring in older adults. Epilepsy Res 2011;97:12-19.
- Bahuleyan B, Menon GR, Sharma M, Nair S. Exophytic third nerve schwannoma mimicking a mesial temporal intra-axial lesion: case report. Childs Nerv Syst 2012;28:481-484.
- Bahuleyan B, Menon GR, Easwer H, Sharma M, Nair S. Symptomatic posterior fossa and supratentorial subdural hygromas as a rare complication following foramen magnum decompression for Chiari malformation Type I. J Neurosurgery 2011;114:510-513.
- Baldawa SS, Bele K, Menon G, George CV, Abraham M, Nair S. Susceptibility-weighted imaging : a new tool for detection of intratumoral bleeding and subarachnoid hemorrhage-report of two cases. Clin Neuroradiol. 2012;22(3):257-61.
- Baldawa SS, Easwer HV, Nair S, Menon G.R, Mesencephalothalamic Giant Virchow-Robin Space Causing Obstructive Hydrocephalus. Neurosurgery Quarterly 2011;21:214–218.
- Baldawa SS, Pendharkar H, Menon GR, Nair SR. Thrombosed giant cavernous carotid artery aneurysm secondary to cervical internal carotid artery dissection: An unusual entity. Indian J Radiol Imaging. 2011;21:225-227
- Banerjee S, Mohanan PV. Inf ammatory response to pyrogens determined by a novel ELISA method using

human whole blood. J. Immunol.Methods 2011; 369: 146–153.,

- Bansal AR, Radhakrishnan K. Primary reading epilepsy. C.P.Panayiotopoulos (ed,), Atlas of Epilepsies, Springer-Verlag London Limited 2010: 1109-1113.
- Baskaradoss JK, Geevarghese A, Kutty VR. Maternal periodontal status and pre-term delivery: a hospital based case control study. J Periodontal Res. 2011; 46:542-549.
- Behari M, Bhattacharyya KB, Borgohain R, Das SK, Ghosh B, Kishore A, Krishnan S, Mridula KR, Muthane U, Pal PK, Sankhla C, Shukla G. Diagnosis of Parkinson's disease. Ann Indian Acad Neurol. 2011 Jul; 14(Suppl 1):S2-6.
- Bhat M, Ramesha KN, Nirmala C, Sarma PS, Thomas SV. Knowledge and practice profile of obstetricians regarding epilepsy in women in Kerala state, India, Ann Indian Acad Neurol 2011; 14:169-171.
- Bhattacharjya C, Kannan S. Prevalence of Non-Sterile occupational injuries among students of modern Medicine in Assam. International Journal of Medical Toxicology and Legal Medicine. 2011;14(12):59-67.
- Bijulal S, Krishnamoorthy KM, Sivasankaran S.Retroaortic coronary artery: possible contraindication for device closure of atrial septal defect. Pediatr Cardiol 2011; 32:1001-1003.
- Boopalan PRJVC, Sabareeswaran A, Livingston A, Mohanty M, Chittaranjan SB. Pulsed electromagnetic field therapy results in healing of full thickness articular cartilage defect. International Orthopaedics ;(SICOT) 2011; 35:143-148
- Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Haworth SG, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Adatia I. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.Pulm Circ. 2011;1:286-298.
- Chandra V, Swetha G, Muthyala S, Jaiswal AK, Bellare JR, Nair PD, Bhonde RR. Islet-like cell aggregates generated from human adipose tissue derived stem cells ameliorate experimental diabetes in mice. PLoS One. 2011;6(6):1-12(e20615).

- Chatterjee N, Koshy T, Misra S, Suparna B Changes in left ventricular preload, afterload and cardiac output in response to a single dose of mannitol in neurosurgical patients undergoing craniotomy: A transesophageal echocardiographic study" J Neurosurg. Anesth. 2012; 24: 25–29
- Chaurasia AK, Harikrishnan S, Bijulal S, Krishnamoorthy KM, Sivasankaran S, Tharakan JA. Usefulness of Doppler derived end diastolic f ow gradient across the patent ductus arteriosus in selecting coils for ductal occlusion. Pediatr Cardiol. 2012; 33:290-294.
- Cherian A, Radhakrishnan A, Parameswaran S, Varma R, Radhakrishnan K. "Do sphenoidal electrodes aid in surgical decision making in drug resistant temporal lobe epilepsy"? Clinical Neurophysiology 2012;123: 463-470
- Chinchure S, Thomas B, Wangju S, Jolappara M, Kesavadas C, Kapilamoorthy TR, Radhakrishnan VV Mean intensity curve on dynamic contrast-enhanced susceptibility-weighted perfusion MR imaging--review of a new parameter to differentiate intracranial tumors. J Neuroradiol. 2011;38:199-206.
- Chinchure S, Kesavadas C. Neuroimaging in epilepsy in tropics. Neuroimaging Clin N Am. 2011; 21: 867-877.
- Chinchure SD, Pendharkar HS, Gupta AK, Bodhey N, Harsha KJ. Adult onset moyamoya disease: Institutional experience. Neurol India. 2011; 59: 733-738.
- Das A, Radhakrishnan A. A case of PANDAS with Kleine-Levin type periodic hypersomnia. Sleep Medicine 2012; 13: 319–320
- Das A, Radhakrishnan A Teaching NeuroImages: Floppy eyelids in obstructive sleep apnea syndrome. Neurology 2011;29: 77 (22):e130-1.
- Das A, Shabeesh B, Banerjee M, Radhakrishnan K. Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective. Indian Journal of Human Genetics 2011; 17(suppl 1): S12- S21
- Abraham AA, Jithesh V. The Kerala Experience in Palliative Care: An Ethical Exploration from the Public Health Perspective. Asian Bioethics Review 2012; 4:14-28.
- Dawlee S, Jayabalan M. Studies on inherently radiopaque acrylate copolymers for biomedical applications. J Applied Polymer Sci. 2012;125(3):2252–2261.

- Dawlee S, Jayabalan M. Development of segmented polyurethane elastomers with low iodine content exhibiting radiopacity and blood compatibility. Biomed Mater. 2011;6(5):055002.
- Dayananda L, Kesavadas C, Thomas B, Neelima R, Radhakrishnan VV. Atypical clinical and imaging manifestation in neurocysticercosis Ann Indian Acad Neurol. 2011;14: 295-297.
- Durgadas CV, Nair LV, Sharma, CP, Sreenivasan K. Sensing of Lead ions using glutathione mediated End to End Assembled Gold Nanorod chains. Sens. Actuators B: Chemical 2011; 156: 791-797.
- Durgadas CV, Sharma CP, Sreenivasan K. Fluorescent and superparamagnetic hybrid quantum clusters for magnetic separation and imaging of cancer cells from blood. Nanoscale. 2011; 3: 4780-4787.
- Edwin BT, Nair PD. Invitro evaluation of wound healing property of Hemigraphics alternate (Burm F. T Anders) using fibroblast and endothelial cells. Biotechnol. Biosci. Res. Asia 2011; 8:1-6.
- Finosh GT, Jayabalan M. Regenerative Therapy and Tissue Engineering for the Treatment of End-Stage Cardiac Failure New Developments and Challenges. Biomatter 2012; 2:1 1–14.
- Flisser E, Thomas SV, Sarma PS, Sukumaran SC. Polytherapy increases the risk of infertility in women with epilepsy, Neurology 2011; 76:1442.
- Fonn S, Ravindran TKS. The macroeconomic environment and sexual and reproductive health: a review of trends over the last 30 years. Reproductive Health Matters 2011; 19: 11-25
- Francis BF, Shenoy SJ, Babu SS, Varma HK, John A. Short-term studies using ceramic scaffolds in lapine model for osteochondral defect amelioration. Biomed. Mater 2012; 7: doi:10.1088/1748-6041/7/3/035005
- Ganesh G, Shenoy SJ, Umashankar PR. Long duration anaesthetic regimen for major surgical procedure in goats. Indian Vet. J 2011; 88: 20-21.
- Geetha CS, Sabareeswaran A, Mohanan PV. Preclinical evaluation of titanium . Toxicol Mech Methods 2012; 22:144-150.
- Gopal R, Harikrishnan S, Sivasankaran S, Ajitkumar VK, Titus T, Tharakan JM. Once weekly Azithromycin in secondary prevention of rheumatic fever, Indian Heart J 2012; 6401:12-15

- Gopalakrishnan CV, Dhakoji A, Nair S. Epidermoid cyst of the brainstem in children: case based update. J Child Neurol. 2012; 27:105-112
- Gopalakrishnan CV, Dhakoji A, Nair S. Hemimasticatory spasm following surgery for vestibular schwannoma. Movement disorders 2011; 26: 2481-82.
- Gopalakrishnan CV, Shrivastava A, Nair S. Calcification in vestibular schwannoma: Report of two cases and review of the literature. Neurology India 2011;59:642-645.
- Gulia KK. Sleep to survival: Emerging role of Preoptic Area networking. Sleep Biological Rhythms. 2011; 9: 251-252.
- Gulia KK. Dynamism in Activity of the Neural Networks in Brain is the Basis of Sleep-Wakefulness Oscillations. Front Neurol. 2012;3:38.
- Gupta D, Kuruvilla A. Vascular parkinsonism: what makes it different? Postgrad Med J. 2011; 87: 829-836
- Gupta SK, Krishnamoorthy K, Tharakan JA, Sivasankaran S, Sanjay G, Bijulal S, Anees T. Percutaneous closure of patent ductus arteriosus in children: Immediate and short-term changes in left ventricular systolic and diastolic function. Ann Pediatr Cardiol 2011; 4: 139-44.
- Harikrishnan S, Bijulal S, Krishnakumar N, Ajithkumar VK.Combined mitral and pulmonary valvotomy with Inoue balloon in rheumatic quadrivalvular disease. J Heart Valve Dis. 2011;20:112-113.
- Harikrishnan S, Bimal F, Ajithkumar V, Bhat A, Titus T, Tharakan J. Percutaneous treatment of congenital coronary arteriovenous fistulas. J Interv Cardiol. 2011; 24: 208-215
- Harikrishnan.S, Ed Percutaneous Mitral Valvotomy :. Jaypee brothers; New Delhi. 2012
- Hingwala DR, Chatterjee S, Kesavadas C, Thomas B, Kapilamoorthy TR. Applicatiins of 3D CISS sequence for problem solving in neuroimaging. Indian J Radiol Imaging. 2011;21: 90-97.
- Hingwala DR, Thomas B, Kesavadas C, Kapilamoorthy TR. Suboptimal contrast opacification of dynamic head and neck MR angiography due to venous stasis and ref ux: technical considerations for optimization. Am J Neuroradiol. 2011;32:310-314.
- Huffman MD, Rao KD, Pichon-Riviere A, Zhao D,

Harikrishnan S, Ramaiya K, Ajay VS, Goenka S, Calcagno JI, Caporale JE, Niu S, Li Y, Liu J, Thankappan KR, Daivadanam M, van Esch J, Murphy A, Moran AE, Gaziano TA, Suhrcke M, Reddy KS, Leeder S, Prabhakaran D. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011;6(6):1-10(e20821).

- Iyer RS, Rekha M, Kumar TS, Sarma PS, Radhakrishnan K. Primary care doctors' management behavior with respect to epilepsy in Kerala, Southern India. Epilepsy Behav 2011:21:137-142.
- Jagtap S, Nair M.D., Harsha KJ, Sureshbabu S, Komath M, SMA Shibli, Varma HK. Biomimetic deposition of hydroxyapatite on titanium with help of sol–gel grown calcium pyrophosphate prelayer. Materials Research Innovations.2011;15: 178-184.
- Jeemon P, Prabhakaran D, Huffman MD, Ramakrishnan L, Goenka S, Thankappan KR, Mohan V, Joshi PP, Mohan BV, Ahmed F, Ramanathan M, Ahuja R, Chaturvedi V, Lloyd-Jones DM, Reddy KS; Sentinel Surveillance in Industrial Populations Study Group. Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). BMJ Open. 2011;1(1):1-9(e000068).
- John A, Mani S, Sandeep G, Babu SS, Lal AV, Varma HK. Osteogenesis of a bioactive ceramic calcium phospho silicate composite system in goat femur defect. Int. J Appl. Ceram. Technol. 2011; 8: 491–500
- Jolapara M, Patro SN, Kesavadas C, Saini J, Thomas B, Gupta AK, Bodhey N, Radhakrishnan VV Can diffusion tensor metrics help in preoperative grading of diffusely infiltrating astrocytomas? A retrospective study of 36 cases. Neuroradiology. 2011; 53: 63-68.
- Joseph N, Anil Kumar PR, Prasad T, Joseph L, Sreenivasan K, Kumary TV. Intelligent Thermoresponsive Substrate from Modified Over Head Projection Sheet as a Tool for Construction and Support of In vitro Corneal Cell Sheet. Tissue Engineering Part C: Method 2011; 17: 181-191
- Jospeh N, Anilkumar PR, Kumary TV. Tunable stimuli responsive polymer for cell sheet engineering. In: Regenerative Medicine and Tissue Engineering; From Cells to Organs / Book 2. Intech Open; 2011:503-12.
- Kasar PA, Kumar SR, Kutty RV. Somatic growth

following congenital heart surgery in economically underprivileged children. Heart Asia. 2011; 3: 135-139

- Kate M, Thomas B, Kuruvilla A, Nair MD, Iyer RS. A 6-year old girl with progressive ataxia. J Clin Neurosci. 2012;19(2):299, 340
- Kaur S, Harikrishnan VS, Shenoy SJ, Radhakrishnan NS, Uruno A, Sugawara A, Kartha CC. Transfection of Endothelial Nitric Oxide Synthase Gene Improves Angiogenic Efficacy of Endothelial Progenitor Cells in Rabbits with Hindlimb Ischemia. J Clinic Experiment Cardiol. 2011;2(6):1-6(1000140).
- Kesavadas C, Thomas B, Pendharakar H, Sylaja P.N. Susceptibility weighted imaging: does it give information similar to perfusion weighted imaging in acute stroke?. J Neurol. 2011;258:932-934.
- Kishore A, Joseph T, Velayudhan B, Popa T, Meunier S. Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease. Clin Neurophysiol. 2012; 123: 822-828.
- Komath M, Rajesh P, Muraleedharan CV, Varma HK, Reshmi R, Jayaraj MK. Formation of hydroxyapatite coating on titanium at 200 C through pulsed laser deposition followed by hydrothermal treatment. Bull. Mater. Sci.2011; 34: 389–399
- Kottayil BP, Jayakumar K, Dharan BS, Pillai VV, Ajitkumar V, Menon S, Sanjay G, Anomalous origin of left coronary artery from pulmonary artery in older children and adults: direct aortic implantation. Ann Thorac Surg, 2011; 91: 549-553.
- Krishnan LK. Design of a Biomimetic Niche for Adult Progenitor Cell Selection and Differentiation. In: Adult Stem Cell Standardization. Nardo PD (ed) River Publishers (Denmark) 2011; pp149-166.
- Krishnan S, Sarma G, Sarma P S, Kishore A. Do nonmotor symptoms in Parkinson's disease differ from normal aging? Mov. Disord. 2011; 26: 2110-2113.
- Krishnan V, Krishnan A, Remya R, Ravikumar KK, Nair AS; Shibili SMA; Sukumaran K, Kumar JK, Varma HK. Development and evaluation of two PVD coated beta titanium orthodontic archwires for f uoride induced corrosion protection. Acta Biomaterialia 2011; 7: 1913-1927.
- Kumar KP, Paul W, Sharma CP. Green Synthesis of Gold Nanoparticles with Zingiber officinale Extract: Characterization and Blood Compatibility. Process Biochemistry; 2011; 46: 2007-2013.

- Kumar MS, Sarma PS, Thankappan KR. Community based group intervention for tobacco cessation in rural Tamil Nadu, India: a cluster randomized trial. J Substance Abuse Treatment. 2012;43: 53-60.
- Kuruvilla A, Aguwa A, Lee AW, Xavier AR. Anomalous origin of the middle meningeal artery from the posterior inferior cerebellar artery. J Neuroimaging. 2011; 21: 269-272.
- Kuruvilla A, Bhattacharya P, Rajamani K, Chaturvedi S. Factors associated with misdiagnosis of acute stroke in young adults. J Stroke Cerebrovasc Dis. 2011; 20: 523-527.
- Kuruvilla A, Norris GM, Xavier AR. Acute endovascular recanalization therapy in wake-up stroke. J Neurol Sci. 2011; 300: 148-150.
- Kuruvilla A, Wattamwar PR. Kinaesthetic ipsilateral and crossed extensor plantar response: A new way to elicit upgoing toe sign (Babinski response)? Ann Indian Acad Neurol. 2011;14: 198-199.
- Lakshmy R, Mathur P, Gupta R, Shah B, Anand K, Mohan V, Desai NG, Mahanta J, Joshi PP, Thankappan KR. Measurement of cholesterol and triglycerides from a dried blood spot in an Indian Council of Medical Research-World Health Organization multicentric survey on risk factors for non-communicable diseases in India. J Clinical Lipidology. 2012; 6:33-41.
- Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Haworth SG. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011.Pulm Circ. 2011; 1:280-285
- Lizymol PP, Mohanan PV, Sabareeswaran A, Krishnan KV. Biological evaluation of a new organically modified ceramic based dental restorative resin. J Appl Polymer Sci. 2012;125:620–629.
- Mandilya A, NamboodiriN, Sreedharan SE, Sylaja . Sinus arrest complicating acute posterior cerebral artery stroke. Neurol India. 2011; 59:772-773.
- Manju S, Muraleedharan CV, Rajeev A., Jayakrishnan A, Joseph R. Evaluation of alginate dialdehyde crosslinked gelatin hydrogel as a biodegradable sealant for polyester vascular graft. J Biomed Mater Res. Part B: Applied Biomaterials 2011; 98B: 139-149
- Manju S, Sharma CP, Sreenivasan K. Targeted Co administration of Sparingly Soluble Paclitaxel and

Curcumin into Cancer Cells by Surface Engineered Magnetic nanoparticles. J. Mater. Chemistry; 2011; 21: 15708–15717

- Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sc. 2011;359: 318-325.
- Manju S, Sreenivasan K. Detection of Glucose in synthetic tear f uid using dually functionalized Gold Nanoparticles. Talanta 2011; 85: 2643–2649.
- Manju S, Sreenivasan, K. Enhanced drug loading onto Magnetic nanoparticles by Layer by Layer Assembly using Drug conjugates: Blood compatibility evaluation and Targeted drug Delivery into Cancer cells. Langmuir. 2011; 27: 14489–14496.
- Mathai A, Neelima R, Harikrishnan VS, Radhakrishnan VV : trahelose 6-6' dimycolate(cord factor antigen) induced pulmonary granuloma in naïve and lymphopenic mice. Infect Dis Immun. 2012;4: 29-35.
- Mathai A, Neelima R, Harikrishnan VS, Radhakrishnan VV : Utility of cord factor antigen of Mycobacterium tuberculosis for the laboratory diagnosis of tuberculous meningitis. Int Res J Microbiol. 2011; 2: 167-172
- Mathai A, Neelima R, Harikrishnan VS, Radhakrishnan VV: An immunoassay using cord factor antigen of Mycobacterium tuberculosis for the confirmatory diagnosis of intracranial tuberculoma. J Infect Dis Immun 2011; 3: 64-67.
- Mathews A, Colombus S, Krishnan VK, Krishnan LK. Vascular tissue construction on poly(ε-caprolactone) scaffolds by dynamic endothelial cell seeding: effect of pore size. J Tissue Eng Regen Med. 2012;6(6):451-61.
- Megha KB, Banerjee S, Mohanan. PV. Investigation of interleukin - 1β release from cryopreserved blood stimulated with endotoxin. Cryobiology. 2011; 63:273-278.
- Menon G, Gopalakrishnan CV, Rao BR, Nair S, Sudhir J, Sharma M. A single institution series of cavernomas of the brainstem. J Clin Neurosci. 2011;18:1210-1214.
- Mohanan PV, Banerjee S, Geetha CS. Detection of pyrogenicity on medical grade polymer materials using rabbit pyrogen, LAL and ELISA method. J Pharmaceut. Biomed. Analysis 2011; 55: 1170–1174.
- Mohanan PV, Lizymol PP. Cytogenetic Evaluation of the Physiological Saline Extract of a Newly Developed

Dental Material ORMO-48.Toxicol Intl; 2011;18: 155-159

- Mohanan PV, Mavely L, Pandya A. Toxicity and Haemostatic potential of Poly [β- (1, 4)- 2-amino-2deoxy-D-glucosamine] based haemostatic material on albino rabbits. Toxicol Mechanisms Meth 2011; 21: 25–30.
- Mondal T, Sunny MC, Khastgir D., Varma HK, Ramesh P. Poly (I-lactide-co-ε-caprolactone) microspheres laden with bioactive glass ceramic and alendronate sodium as bone regenerative scaffolds. Mat Sci. Eng C: Mater Biol Applicat. 2012; C32: 697-706.
- Morris VB, Sharma CP. Folate mediated l-arginine modified oligo (alkylaminosiloxane) graft poly (ethyleneimine) for tumor targeted gene delivery. Biomaterials. 2011; 32: 3030-3041.
- Morris VB, Sharma CP. Polymeric nanoparticles for delivery of drugs and genes in cancer, in Nanotechnology In: Diagnostics and Treatment of Cancers Banerjee R (ed), Narosa Publishing House Pvt. Ltd., 2012; pp 127-158.
- Mukundan LM, Nirmal R, Thomas LV, Sajeev US, Nair PD. Retrieval of rat aortic smooth muscle cells as intact cell sheet for regenerative medicine: a cost effective approach using photo polymerization. Biotechnol Lett. 2011; 10: 1-7
- Nair BP, Sharma CP. Poly(lactide-co-glycolide)laponite-F68 nanocomposite vesicles through a singlestep double-emulsion method for the controlled release of doxorubicin. Langmuir. 2012;28(9):4559-64.
- Nair KK, Namboodiri N , Thajudeen A, Valaparambil AK, Tharakan JM. .An unusual mechanism of sustained right atrial tachycardia. Indian Pacing Electrophysiol J. 2011; 11:169-172.
- Nair KKM, Sivadasanpillai H , Thajudeen A, Tharakan JM, Titus T, Ajitkumar V, Sivasankaran S, Namboodiri N, Bijulal S, Sanjay G. Comparative Study on Safety, Efficacy and Midterm results of Balloon Mitral Valvotomy Performed with Triple Lumen and Double Lumen Mitral Valvotomy Catheters. Catheterisation and Cardiovascular Interventions , 2012 DOI: 10.1002/ccd.24284
- Nair P, Aloysious N. Perspectives of Islet Cell Transplantation as a Therapeutic Approach for Diabetes Mellitus. In: Regenerative Medicine and Tissue Engineering; From Cells to Organs / Book 2 ISBN 978-953-307-688-1

- Nair PA, Ramesh P. Synthesis and characterization of poly(urethane-ether)s from calcium salt of p-hydroxybenzoic acid. J Appl. Polymer Sci. 2011;122: 1946-1952.
- Nair PD, Aloysious N: Perspectives of Islet Cell Transplantation as a Therapeutic Approach for Diabetes Mellitus In: Primary Hypoparathyroidism; Classic Image AJNR. 2011
- Nair S, Gopalakrishnan CV, Vikas V, Menon G. Techniques of Facial nerve preservation in vestibular schwannoma surgery. Medimond Monduzzi Editore International Proceedings Division; ISBN 978-88-7587-609-8:2011: 55-60.
- Nair S, Rao BRM, Menon G. Petroclival-Premeatal meningiomas: Reverting back to conventional retrosigmoid approach. Medimond Monduzzi Editore International Proceedings Division; ISBN 978-88-7587-609-8:2011: 45-53.
- Nair S, Remya NS, Remya S, Nair PD. A biodegradable in situ injectable hydrogel based on chitosan and oxidized hyaluronic acid for tissue engineering applications. Carbohydrate Polymers 2011; 85: 838– 844.
- Nazeer Shaiju S, Ariya S, Asish R, Salim Haris P, Anita B, Arun Kumar G, Jayasree RS. Habits with killer instincts: in vivo analysis on the severity of oral mucosal alterations using autof uorescence spectroscopy. J Biomed Opt. 2011 Aug;16(8):087006.
- Neelima R, Eswer HV, Kapilamoorthy TK, Hingwala DR, Radhakrishnan VV: Embryonal tumor with multilayered rosettes: Report of two cases with a review of literature. Neurology India 2012; 60: 96-99.
- Neelima R, Gopalakrishnan CV, Thomas B, Radhakrishnan VV: Glioblastoma multiforme with epithelial differentiation. Neurology India. 2011; 59: 918-920.
- Oloyo AK, Sofola OA, Nair RR, Harikrishnan VS, Fernandez AC, Anigbogu CN. Testosterone relaxes abdominal aorta in male Sprague–Dawley rats by opening potassium (K+) channel and blockade of calcium (Ca2+) channel. Pathophysiology. 2011;18: 247–253.
- Pandian JD, Jyotsna R, Singh R, Sylaja PN, Vijaya P, Padma MV, Venkateswaralu K, Sukumaran S, Radhakrishnan K, Sarma PS, Mathew R, Singh Y. Premorbid Nutrition and Short Term Outcome of

Stroke: A Multicentre Study from India, J Neurol Neurosurg Psychiatry 2011; 82:1087-1092.

- Patil A, Cherian A, Iype T, Sandeep P. Nocardial brain abscess in an immunocompetent individual. Neurology India 2011; 59(5):779-782.
- Paul A, Antony M, Mathai J, Appukuttan PS. High polymeric IgA content facilitates recognition of microbial polysaccharide-natural serum antibody immune complexes by immobilized human galectin-1. Immunology Letters 2011:136:55-60
- Paul W, Chandra P Sharma. Synthesis and Characterization of Alginate coated Zinc Calcium Phosphate Nanoparticles for Intestinal Delivery of Insulin. Process Biochemistry 2012;47: 882-886.
- Paul W, Sharma CP. Blood Compatibility Studies of Swarna Bhasma (Gold Bhasma), an Ayurvedic Drug. International J Ayurveda Research 2011; 2: 14-22.
- Phadnis SM, Joglekar MV, Dalvi MP, Muthyala S, Nair PD, Ghaskadbi SM, Bhonde RR, Hardikar AA. Human bone marrow-derived mesenchymal cells differentiate and mature into endocrine pancreatic lineage in vivo. Cytotherapy 2011;13:279-293.
- Priya S, Babykutty S, Roshan DVG, Nair RS, Srinivas P, Srinivas G. Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-κB. European J Pharmaceut. Sci.. 2012; 45: 581-591.
- Priya S, Babykutty S, Srinivas P, Srinivas G. Aloe emodin induces G2/M cell cycle arrest, and apoptosis via activation of caspase- 6 in human colon cancer cells. Pharmacology 2012; 89: 91-98.
- Radhakrishnan A, James JS, Kesavadas C, Thomas B, Bahuleyan B, Abraham M, Radhakrishnan K. Utility of diffusion tensor imaging tractography in decision making for extratemporal resective epilepsy surgery. Epilepsy Research 2011; 97:52-63.
- Radhakrishnan A, Menon RN, Radhakrishnan K. Coexistence of idiopathic generalized epilepsy among surgically treated patients with drug-resistant temporal lobe epilepsy. Epilepsy Res 2011;96:151-157.
- Radhakrishnan A, Menon RN, Hariharan S, Radhakrishnan K. The evolving electroclinical syndrome of "epilepsy with ring chromosome 20" Seizure 2012; 21: 92- 97.

- Radhakrishnan VV. 'Pathogenesis of brain tumors' In: Neurosurgery -IIIrd edtion, Tandon PN. Ramamurthy B. (ed), Volume II- Jaypee Brothers Medical Publishers. New Delhi. 2012; 1366-1376
- Radhakumary C, Nair PD, Nair RCP, Mathew S. Chitosan-graft-poly(vinyl acetate) for hemodialysis applications. J Appl Polymer Sci. 2012;125(3):2022–33.
- Radhakumary C, Nandkumar MA, Nair PD. Hyaluronic acid-g-poly(HEMA) copolymer with potential implications for lung tissue engineering. Carbohydrate Polymers. 2011; 85: 439-445
- Radhakumary C, Sreenivasan K. Synthesis and evaluation of pH responsive silica-polymer hybrid nano capsules. Soft Materials 2011; 9: 347–358.
- Radhakumary C, Sreenivasan K. Naked eye detection of glucose in urine using Glucose Oxidaze immobilized Gold Nano Particles. Anal. Chem 2011; 83: 2829–2833.
- Radhakumary C, Sreenivasan, K. Gold nanoparticles generated through "Green Route" bind Hg2+ with a concomitant blue shift in plasmon absorption peak. Analyst 2011; 136: 2959-2962.
- Ragaseema VM, Rosemary MJ, Nandakumar MA, Krishnan.KV, Krishnan L. Silver Nanoparticle Impregnated Poly (e-Caprolactone) Scaffolds: Optimization of Antimicrobial and Noncytotoxic Concentrations. Tissue Engineering Part A; 2011; 17: 439-449.
- Ragaseema VM, Unnikrishnan S, Kalliyana Krishnan V, Krishnan LK. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. Biomaterials. 2012 Apr;33(11):3083-92.
- Raghavendra S, Kumar RS, Kuruvilla A. Pseudoseizures. In: Kumar A, editor. Epilepsy-A Review. Patna, India,2010:619-638.
- Raj V, Jaime R, Astruc D, Sreenivasan K. Selective in vitro binding of cholesterol by Digitonin Conjugated Gold Nanoparticles. Biosensor and Bioelectronics. 2011; 27: 197–200.
- Rajesh P, Komath M, Muraleedharan CV, Varma HK. Pulsed laser deposition of hydroxyapatite on titanium substrate with titania interlayer. J. Mater. Sci. Mater. Med; 2011; 22: 497-505
- Rajesh P, Muraleedharan CV, Komath M, Varma HK. Laser surface modification of titanium substrate

for pulsed laser deposition of highly adherent hydroxyapatite. J Mater Sci Mater Med. 2011; 22: 1671–1679.

- Rajesh R, Rekha MR, Chandra P Sharma. Evaluation of lauryl chitosan graft polyethyleneimine as a potential carrier of genes and anticancer drugs. Process Biochemistry; 2012; 47:1079-1088.
- Ramanathan M, Jesani A. The legacy of scandals and non-scandals in research and its lessons for bioethics in India. (Editorial) Indian JMedical Ethics. 2012; 9: 4-6
- Ramesha KN, Mooney T, Sarma PS, Radhakrishnan K. Long-term seizure outcome and its predictors in patients with recurrent seizures during the first year after temporal lobe resective epilepsy surgery. Epilepsia 2011;52(5):917-924.
- Rathore C, Kesavadas C, Ajith A, Sasikala A, Sarma SP, Radhakrishnan K. Cost-effective utilization of single photon emission computed tomography (SPECT) in decision making for epilepsy surgery. Seizure 2011;20:107-114.
- Rathore C, Radhakrishnan K. What causes seizures in patients with calcified neurocysticercal lesions? Neurology 2012; 78:612-613.
- Rathore C, Panda S, Sarma SP, Radhakrishnan K. How safe is it to withdraw antiepileptic drugs following successful surgery for mesial temporal lobe epilepsy? Epilepsia 2011; 52:627-635.
- Rathore C, Sarma SP, Radhakrishnan K. Prognostic importance of serial postoperative EEGs after anterior temporal lobectomy. Neurology 2011; 76:1925 -1931.
- Rathore C, Thomas B, Kesavadas C, Radhakrishnan K. Calcified neurocysticercosis lesions and hippocampal sclerosis: Potential dual pathology? Epilepsia 2012;53 (4):e60-e62, 2012.
- Ravindran TKS, Fonn S. Are social franchises contributing to universal access to reproductive health services in low-income countries? Reproductive Health Matters 2011, 19: 85-101
- Ravindran TKS, Nair MR. Gender in the HLEG Report: Missed opportunity. Economic and Political Weekly 2012; XLVII (8): 70-73
- Rekha MR, Sharma CP. Modification of chitosan nanoparticles for improved gene delivery. Nanomedicine 2012; 7: 5-8.

- Rekha MR., Sharma CP. Hemocompatible pullulanpolyethyleneimine conjugates for liver cell gene delivery: In vitro evaluation of cellular uptake, intracellular trafficking and transfection efficiency. Acta Biomaterialia 2011; 7: 370-379.
- Sailaja GS, Ramesh P. Varma HK. Effect of surface functionalization on the physicomechanical properties of a novel biofunctional copolymer. J Applied Polymer Sci 2011; 6: 3509–3515.
- Saini J, Chatterjee S, Thomas B, Kesavadas C. Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Acta Radiol. 2011;52:1159-1168
- Sajeesh S, Sharma CP. Mucoadhesive hydrogel microparticles based on poly (methacrylic acid-vinyl pyrrolidone)-chitosan for oral drug delivery. Drug Delivery 2011; 18: 227-235.
- Sajeesh S, Sharma CP. Mucoadhesive hydrogel microparticles based on poly (methacrylic acid-vinyl pyrrolidone)-chitosan for oral drug delivery. Drug Delivery 2011; 18: 227-235
- Sandhyamani S. Gross Lung Pathology- A Color Atlas. Kulshrestha R, Vaideeswar P, Amonkar G, Gruber-Moesenbacher U, Popper HH. Vidyanilayam Publisher, Delhi, 2011.
- Saramma PP, Krishnakumar K, Dash PK, Sarma PS. Alcohol-based hand rub and ventilator-associated pneumonia after elective neurosurgery: An interventional study, Indian J Critical Care Med. 2011; 15: 203-208.
- Saramma PP, Sarma PS, Thomas SV. Women with Epilepsy have poorer knowledge and skills in child rearing than women without epilepsy. Seizure 2011; 20: 575-579.
- Sathish T, Kannan S, Sarma PS, Razum O, Thankappan KR. Incidence of hypertension and its potentially modifiable risk factors in rural Kerala, India: a community-based cohort study. International Journal of Cardiology. 2011;152: S95-S96
- Sen A, Kesavadas C. Intermittent herniation of brain: a rare cause of intermittent cerebrospinal fuid rhinorrhea. Neurol India. 2011; 59:131-132.
- Shah S, Siddappa S, Patra V, Sandhyamani S, Unnikrishnan M. 'String of beads or bunch of grapes' : A case report of renal artery fibromuscular dysplasia. International J Case Reports Images. 2012; 3: 12-15.

- Shelma R, Sharma CP. Development of lauroyl sulfated chitosan for enhancing hemocompatibility of chitosan. Colloids and Surface B: Biointerfaces; 2011; 84: 561-570.
- Shelma R, Sharma CP. Development of lauroyl sulfated chitosan for enhancing hemocompatibility of chitosan. Colloids and Surface B: Biointerfaces. 2011; 84: 561-570.
- Singh G, Manikandan S, Neema PK. Endotracheal tube fixation in neurosurgical procedures operated in prone position. J Anaesthesiol Clin Pharmacol. 2011; 27: 574-575
- Soman B Rheumatic Heart Disease an epidemiological mystery. In: S. Harikrishnan (ed). Percutaneous Mitral Valvotomy. 2012 Jaypee Brothers New Delhi:. 7-12
- Sonia TA, Sharma CP. In vitro evaluation of N-(2hydroxy) propyl-3-trimethyl ammonium chitosan for oral insulin delivery. Carbohydrate Polymers. 2011; 84: 103-109.
- Sonia TA, Sharma CP. Chitosan and its Derivatives for Drug Delivery Perspective. Adv Polym Sci. 2011; 243: 23–54.
- Sonia TA, Rekha MR, Sharma CP. Bioadhesive hydrophobic chitosan microparticles for oral delivery of insulin: In vitro characterization and in vivo uptake studies. J Applied Polymer Science 2011; 119: 2902-2910
- Sreedharan SE, Sarathchandran P, Menon G, Chellenton J, Sylaja PN. Intracranial hypertension with polyradiculopathy - early CSF diversion to optimize neurological recovery. Br J Neurosurg. 2012;26(4):558-60.
- Strother L, Mathuranath P S, Aldcroft A, Lavell C, Goodale M A, Vilis T. Face inversion reduces the persistence of global form and its neural correlates. PLoS ONE 2011; 6(4): e18705.
- Sudhakar M, Rana R VR, Mohanty M, Mohanan PV, Nair PD. The reversal of diabetes in rat model using mouse insulin producing cells A combination approach of tissue engineering and macroencapsulation. Acta Biomaterialia. 2011; 7: 2153-2162.
- Sudhir BJ, Gopalakrishnan CV, Chinchure S., Prabhu AS. Floating fat globule within an arachnoid cyst. Indian J Radiol Imaging. 2011;21:228-230
- Sureshbabu S, Komath M, Shibli SMA, Varma HK. Biomimetic deposition of hydroxyapatite on titanium

with help of sol–gel grown calcium pyrophosphate prelayer. Materials Research Innovations.2011; 15: 178-184.

- Thajudeen A, Namboodiri N, Valaparambil AK, Nair KK, Tharakan JM.Unusual Response of an Accessory Atrioventricular Connection to Adenosine. J Cardiovasc Electrophysiol. 2012; 23: 223-224
- Thasneem YM, Sajeesh S, Sharma CP. Effect of Thiol Functionalization on the Hemo-Compatibility of PLGA Nanoparticles. J Biomedical Materials Research: Part A; 2011; 99:607-617.
- Thomas B, Lingegowda D, Kesavadas C, Sylaja PN. Direct visualization of thrombus load in MCA in acute stroke on susceptibility weighted imaging. Neurol India. 2011;59:943
- Thomas JJ, Rekha MR, Sharma CP. Unraveling the Intracellular Efficacy of Dextran-Histidine Polycation as an Efficient Nonviral Gene Delivery System. Mol. Pharmaceutics-ACS journal. 2012; 9: 121–134.
- Thomas LV, Nair PD. Citric acid-co-polycaprolactone triol Polyester - a biodegradable elastomer for Soft tissue engineering. Biomatter. 2011; 1: 81 – 90
- Thresia CU, Mohindra KS. Public Health Challenges in Kerala and Sri Lanka. Economic and Political Weekly 2011, XLVI: 99-107.
- Umashankar P.R., Arun T, Kumari TV. Short duration glutaraldehyde crosslinking of decellularised bovine pericardium improves biological response. J Biomed Mater Res A 2011; 97: 311-320.
- Umashankar PR., Mohanan PV, Kumari TV. Gluteraldehyde treatment elicits toxic response

compared to decellularisation in bovine pericardium. Toxicology International. 2012;19:51-58.

- Vaghela V, Hingwala DR, Kapilamoorthy TR, Kesavadas C, Thomas B Spontaneous intracranial hypo and hypertensions: an imaging review. Neurol India. 2011; 59:506-512.
- Velayudhan S, Ramesh P, Varma HK. Mechanical properties of hydroxyapatite filled ethylene vinyl acetate copolymer: effect of particle size and morphology. J Applied Polymer Scienc. 2011; 119: 1594-1601.
- Venugopal B, Fernandez FB, Babu SS, Harikrishnan VS, Varma H, John A. Adipogenesis on biphasic calcium phosphate using rat adipose-derived mesenchymal stem cells: in vitro and in vivo. J Biomed Mater Res A. 2012;100(6):1427-37.
- Victor SP, Sharma CP. Tryptophan complexed hydroxyapatite nanoparticles for immunoglobulin adsorption. J Materials Science: Materials in Medicine; 2011; 2: 2219-2229.
- Victor SP, Sreenivasan K, Chandra P. Sharma. Use of Quartz crystal nanobalance to study the binding and stabilization of Albumin and Doxycycline on a thin layer of Hydroxyapatite, Applied Surface Science 2011; 258: 1666-1669.
- Vijayan B, Gopala S, Kishore A. LARK2 G2019S mutation does not contribute to Parkinson's disease in South India. Neurol India. 2011; 59:157-60.
- Wattamwar PR, Doshi SA, Thomas B, Nair MD, Kuruvilla A. Hypertrophic pachymeningitis in a patient with Takayasu arteritis:One more association ? Ann Indian Acad Neurol. 2012 ; 15: 56-59.



Honours, Awards & Visitors



ANNUAL REPORT 2011-12-

Honours and Awards

- Smt.Sudarsa. K, Ward Sister-B, NeuroSurgery ICU , who has received the prestigious "National Florance Nightingale Award" by the honourable President of India.
- Dr. K. Radhakrishnan, Director, received the prestigious "Asian and Oceanian Outstanding Achievement Epilepsy Award" by the Commission on Asian and Oceanian Affairs (CAOA) of the International League Against Epilepsy (ILAE).
- Dr. Shashidhar K. P., Senior Resident, Cardiovascular and Thoracic Surgery Department who has Won the "Ist Best Poster Award " during the INDOVASC 2012 Held at Bangalore on 23rd to 25th March 2012.
- Dr. Shunmugha Sundaram & Dr. Kiron S., Senior Residents, Cardiology Department who has Won the "Ist Prize in Echo Quiz " during the 3rd Annual Conference of Indian College of Cardiology Held at Kozhicode.
- Dr. Anil Kumar P.R., Scientist 'C', Division of Implant Biology, BMT Wing who has received "The SAB Young Bioengineer Award 2011" by the Society of Applied Biotechnology (SAB) during the Second National Conference on Biotechnology, Bioinformatics and Bioengineering held at Kolhapur on 24th and 25th February 2012.
- Dr. Thomas Koshy, Professor, Anesthesiology has been Awarded Honarary IACTA Fellowship Award (FIACTA) and Honarary Transesophageal Echocardiography Fellowship By Indian Association of Cardiovascular and Thoracic Anesthesiologists (IACTA).
- Dr. C. Kesavadas, Additional Professor, Department of Imaging Sciences & Interventional Radiology was awarded the Dr.M.L.Aggarwal Memorial Oration Award 2012 at the 65th Annual Scientific Meeting of the Indian Radiological and Imaging Association held in Hyderabad for the topic of oration was "Advanced Magnetic Resonance Imaging of Brain Neoplasms -Moving Closer to Physiology & Pathology".
- Dr. R.Ashalatha, Associate Professor, Department of Neurology was awarded the "Bio Scientist Career Award-2011" by DBT for developing the state-of-the-

art investigations in the treatment of drug resistant epilepsy.

- Dr. Prakash Muthusami, Senior Resident, Department of Imaging Sciences & Interventional Radiology won the "Certificate of Merit" for the work entitled "Diffusion Tensor imaging (DTI) and tractography of the language pathways" at the 97th Annual Scientific meeting of the Radiological Society of North America (RSNA), held between 28TH November to 3rd December 2011 at Chicago.
- Mr. G.T. Finosh, Ph.D. student in the Biomedical Technology Wing winning the Young Scientist Award Studies on biosynthetic hydrogels for tissue engineering - effect of free water on cell penetration and survival. at the 24th Kerala Science Congress held from 29th to 31st January 2012 organized by the Kerala State Council for Science and Technology & Environment at Kottayam.
- Ms. Ashna U., Junior Research Fellow (JRF) in the Biomedical Technology Wing winning the Best Poster Award Surfactant gene mRNA modulations in three dimensional cultures of alveolar cells. At the 24th Kerala Science Congress held from 29th to 31st January 2012 organized by the Kerala State Council for Science and Technology & Environment at Kottayam.
- Dr. Thomas Titus, Professor of Cardiology has been awarded FRCP (Edinburgh) from the Royal College of Physicians, Edinburgh.
- Dr. Noshir H. Wadia, former President, SCTIMST was awarded Padma Bhushan on the eve of 63rd Republic Day.
- Dr. Shiny Velayudhan, Scientist C (Adhoc) from the Division of Tissue Engineering & Regeneration Technologies (DTERT) won the MAHE Award for the best paper presented by a scientist/academic faculty : "A novel, higly sensitive cell based meatabolic assay using honeycomb micro-porous polymer membranes"During 22nd National Conference of the Society for Biomaterials and Artificial Organs, SBAOI & STERMI (India), Jan 6-8, 2012 at Rajalakshmi Engineering College, Chennai.

- Mr. Willi Paul, Jr. Scientific Officer-B, Division of Biosurface Technology has won the Best Oral Presentation Award for Faculty for the paper "Thermosensitive curcumin stabilized gold nanoparticles: Adelivery system for cancer thearapy"During the International Conference on Biomaterials Implant Devices and Tissue Engineering, BIDTE-2012 organized jointly by Rajalakshmi Engineering College, Chennai, Society for Biomaterials and Artificial Organs, India and Society for Tissue Engineering and Regenerative Medicine at Rajalakshmi Engineering College, During January 6-8, 2012.
- Ms. Susan M.Alex, PhD Student, (Guide Dr. C.P. Sharma) Biosurface Technology Division has won the Bajpai-Saha Award (First Prize) for the paper "Ligand targeted polyamine substitution in chitosan for efficient nanoparticles mediated gene delivery" During the International Conference on Biomaterials Implant Devices and Tissue Engineering, BIDTE-2012 organized jointly by Rajalakshmi Engineering College, Chennai, Society for Biomaterials and Artificial Organs, India and Society for Tissue Engineering and Regenerative Medicine at Rajalakshmi Engineering College, during January 6-8, 2012.
- Ms. Sidhy Viha CV, Bajpai-Saha Award (Stem Cells and Regenerative Medicine) for the paper presentation entitled "Functional Evaluation of a Polysaccharide-Protein Hydrogel as a Packed Bed Scaffold for Liver Tissue Engineering" co-authored by Ms. Sarika PR, Mr. Sajin Raj RG, Dr. Nirmala Rachel James and Dr. Anil Kumar PR in the in the International Conference on Biomaterials Implant Devices And Tissue Engineering during 6-8 January 2012 at The Rajalekshmi Engineering College, Chennai.
- Dr. Prakash Muthuswami, PDCC resident in the Department of Imaging Sciences & Interventional Radiology was awarded the "Certificate of Merit" at the Annual Scientific meeting of the Radiological Society of North America (RSNA - one of the most important international Radiology meeting), November 28
 December 3, 2011 at Chicago for the work titled "Diffusion Tensor imaging (DTI) and tractography of language pathways".
- Dr. Sujit Abajirao Jagtap, Senior Resident, Department of Neurology, First Prize for the poster entitled:

"Landau-Kleffner Syndrome: natural history and long term outcome" at the Pediatric Epilepsy Symposium organized by the Pediatric Epilepsy Society, Hyderabad, Andhra Pradesh on 5th and 6th November 2011.

- Dr.Gayathri Easwer, working as Institute Research Fellow - A has been awarded IMA KMJ Best Paper Research Award for her publication titled "Incidence of Hypothyroidism in Coastal and non Coastal areas of Kerala in age group 20-25 years". Kerala medical Journal. July(4) .141-148, 2011
- Dr. Meera R, fellow in Cardiac Electrophysiology won the best scientific paper award for the presentation on "Utility of implantableloop recorders in the evaluation of syncope - an initial experience" in the annual conference of Kerala chapter of Cardiological Society of India, held in Kollam on 30th October 2011.
- Dr.Satyajeet Misra, Assistant Professor of Anaesthesiology has won the "KPR Young Anaesthesiologist Award 2011" during the 35th Annual Kerala State Conference of ISA , Held at Kerala, Kollam on 8-10-2011
- The 18th National Vascular Society of India Conference (VSICON 2011), was held at Taj Lands End, Mumbai from 29th September to 1st October 2011. SCTIMST winning in the following events.
- Dr.Prakash Muthusami and Dr.Divyata Hingwala, Senior residents in the Department of Radiology were awarded the second & third prize for the Poster presentation at the Annual Conference of Indian Society of Neuroradiology held at PGI, Chandigarh from 22nd to 25th September 2011. The titles of the papers are: "Diffusion tensor metrics in elucidating brain tumor microstructure" & "Delineation of the optic radiations using diffusion tensor imaging and tractography"
- Dr. Ramshekhar N. Menon, Assistant Professor of Neurology has won the "Best Paper on Epilepsy Award" during the 19th Annual Conference of Indian Academy of Neurology (IANCON-2011), Held at Pune from 22nd to 25th September 2011 for the paper "Utility of Flouro-Deoxy Glucose Positron Emission Tomography (FDG-PET) in deciding Surgical Candidacy in Patients with Drug-resistant Partial Epilepsy".
- Dr. Shiva Kumar, Scientist 'G' Division of Cellular &

Molecular Cardiology Selected for the Prestigious Award "Amrut Mody Unichem Prize - 2008" By the Indian Council of Media Research in recognition of the Outstanding Contribution in Biomedical Research.

- Mr.Vishnu S.P., Apprentice Trade Fitter, Division of Clinical Engineering Won the "Gold Medal and selected As the Best Craftsman During the All India Skill Competition For Craftsman held at Kanpur on january 2011 Under the Craftsman Training Scheme.
- Dr. Rohan Vijay Ainchwar, Illrd year Cardiology Senior Resident won the First Prize in the National level Quiz competition conducted during the 3rd annual conference of the Arrhythmia-Heart Failure Academy held in Madras Medical Mission, Chennai on 3rd and 4th, September 2011.
- Dr. Srujal Shah & Dr. Vikram Patra, IIIrd year Vascular surgery Senior Residents, SCTIMST have won the first prize & "First Rolling Trophy" of Vascular Society of india (VSI) during the 4th mid term conference of VSI held at Goa from 01/07/11 to 03/07/11.



Administration




Message from the Deputy Director

The responsibility of the Administration encompasses organizing and supporting the major activities of the institute, in particular the patient's total medical care in the Hospital Wing as well as overseeing research & technology development programs at the Biomedical Technology Wing. It integrates the various functions and services. Therefore, it is a multifaceted organization having the integrated role of a R & D institution, a medical university & hospital and public health study center comprising many departments, types of personnel, and services. A public not-for-profit superspeciality hospital is run by the Institute as envisaged in the SCTIMST Act 1980. A number of departments perform support functions that help with diagnosis and treatment and also technology development work. It requires highly trained employees, efficient systems and controls, necessary supplies, adequate equipment and facilities, and, of course, physicians/surgeons and scientists & engineers and other technical & supporting staff. It is a patient caring, people-oriented research institution and it has a similar structure and hierarchy of authority as any other large public sector medical and research institution. The apex policymaking body is the Institute Body and the executive body is the Governing Body (GB).

In order to meet the objectives of the Institute, the Administration coordinates activities and creates polices so that all areas of the Institute staff functions efficiently. The Administration recruits, hires and train hospital staff such as doctors, scientists, engineers, nurses and other para-medical and scientific/technical staff for the entire staff requirements of the institute and evaluates the current employees. It always puts in place policies and procedures and make sure that they are adhered to by the staff. Also develop short-term and long-term programs for institute growth and for research and technology development activities, besides overseeing hospital/research operations by supervising other officials and managing budgets and financial operations.

For the physical health sector management and related activities, non-medical administrative services are absolutely. The Director and other senior officers lead these administrative services and is directly responsible for the day-to-day operations of the facility. The Finance & Accounts Division manages financial activities including the hospital's admitting and discharge functions, records charges to a patient's account, and handles accounts receivables. The finance department advises the Director on financial policy and long-range planning, establishes procedures for accounting functions, receives and deposits all monies received by the hospital, and approves the payments of salaries and other expenditures.

Evaluating the staff on a periodical basis and judging the level of their performance and also developing policies and procedures that facilitate the efficiency of daily operations are entrusted with the Administration. These procedures can include how to organize staff work schedules or paperwork. It reviews, implements and analyzes the budget of the institute overall and the budgets of different areas of the Institute to make sure they are realistic and stringently followed. At times, it acts as a moderator for staff complaints and tries to resolve the grievances arising out of patient care services. In addition to a great deal of paperwork and daily administrative tasks, the administration also thinks about the future of the institute and come up with short-range and long-range plans for its growth and development. The administration is always responsible and supports for attaining and maintaining patient care, safety, medical education, research and technology development activities and other service goals. It also ensures that Institute objectives are met through the process of selection, development, organization, motivation, management, evaluation and the promotion of human resources.

The Administration complies with government regulations set out for the Institute and its staff. In an effort to complete this duty, the administration monitors the organization's service and delivery system at all times to ensure optimal operation. Recruitment of employees, training, functioning, setting the salaries and benefits of employees and managing employee-employer relations, are some of the primary duties of the Administration. Staff requirements for each section of the hospital, such as clinical and diagnostic departments, administration & accounts, equipments & building maintenance, logistics, ambulance, nursing, diagnostic labs, paramedics, and R & D staff for the Biomedical Technology development wing are being timely met with. Recruitment guidelines are drawn up for job applicant screenings, as well as, for the recruiting of junior and senior level positions. The Senior and Junior Staff Selection Committees actively participate in the selection of doctors, surgeons, scientists, engineers and undertakes responsibilities in facilitating the selection process and creates offer letters and employment contracts. During the year 2011-12, Personnel Department has conducted 12 interviews for filling up Permanent posts, 97 for. temporary/leave substitute positions, 34 project appointment positions besides handling the internal promotional cases of 117 employees under vacancy oriented and f exible complementing promotion schemes. Service Records/Books of an average of 1304 employees (932 permanent employees and 372 project and temporary staff) are maintained and updated and their requirements are met promptly. Running a superspeciality hospital even without bystanders, the institute is able to maintain nursing and para-medical staff ratio well below the national average. The administrative staff strength is also maintained within 10 percent of the total staff strength of the institute, which is a national record in comparison to similar other institutions.

P.B. Sourabhan

ADMINISTRATIVE BODIES

INSTITUTE BODY

Dr. R. Chidambaram (President)

Principal Scientific Advisor to the Government of India 318, Vigyan Bhavan Annexe Maulana Azad Road, New Delhi - 110 011.

Prof. P. J. Kurien Hon'ble Member of Parliament (Rajya Sabha)

302, Brahmaputra B.D. Marg, New Delhi - 110 001.

Dr. Shashi Tharoor

Hon'ble Member of Parliament (Lok Sabha) TC 14/506, Nandavanam Road Vikas Bhavan P.O, Thiruvananthapuram - 695 033.

Dr. Rajan Sushant

Hon'ble Member of Parliament (Lok Sabha) 2, North Avenue,New Delhi – 110 001.

Dr. T. Ramasami

Secretary to Government of India Department of Science & Technology Technology Bhavan, New Mehrauli Road New Delhi - 110 016.

Dr. R. K. Srivastava

Director General of Health Services Ministry of Health & Family Welfare Nirman Bhavan, Maulana Azad Road New Delhi – 110011.

Secretary to the Govt. of India

Ministry of Health & Family Welfare Ministry of Health and Family Welfare Nirman Bhavan, Maulana Azad Road, New Delhi - 110011

Secretary to the Govt. of India

Department of Higher Education Ministry of Human Resource Development Shastri Bhawan, New Delhi – 110001.

Financial Adviser to the Govt. of India

Department of Science and Technology Technology Bhavan, New Mehrauli Road New Delhi - 110 016.

Dr.Rajeev Sadanandan IAS

Secretary to the Govt. of Kerala Department of Health & Social Welfare Secretariat, Thiruvananthapuram - 695 001.

Dr. V.N. Rajasekharan Pillai

Executive Vice President Kerala State Council for Science, Technology & Environment, Sasthra Bhavan, Pattom Thiruvananthapuram – 695 004.

Prof. A. Jayakrishnan

Vice Chancellor University of Kerala Thiruvananthapuram – 695 034.

Prof. R. C. Deka

Director All India Institute for Medical Sciences Ansari Nagar, New Delhi – 110029.

Dr. Baldev Raj

(Former Director, Indira Gandhi Centre for Atomic Research (IGCAR)) President, PGS Institutions PGS College of Technology Peelamadu, Coimbatore-641004

Dr. Jairup Singh

Vice Chancellor Central University of Punjab Bathinda, Punjab – 151 001.

Prof. P. Balaram

Director Indian Institute of Science Bangalore - 560 012.

Prof. Bakhtaver S. Mahajan

Professor (Retired), Homi Bhabha Centre for Science Education, TIFR, Mumbai. 10 Rohini CHS, Sector 9A, Navi Mumbai – 400 703.

Prof. Jayaprakash Muliyil

Professor & Head Community Health Department Christian Medical College Bagayam, Vellore – 632002.Tamil Nadu.

Prof. Ashok Misra

Chairman Intellectual Ventures India #701, Raheja Paramount, 138 Residency Road Bangalore – 560 025.

Dr. K.A. Dinshaw

(Former Director, Tata Memorial Hospital) 201, Samudra Setu, Saher Agiary Lane Bhulabhai Desai Road Mumbai - 400 026.

Dr. K. Radhakrishnan

Director Sree Chitra Tirunal Institute for Medical Sciences and Technology Thiruvananthapuram - 695 011

Dr. G. S. Bhuvaneshwar

Head, Biomedical Technology Wing Sree Chitra Tirunal Institute for Medical Sciences and Technology Poojappura, Thiruvananthapuram - 695 012

GOVERNING BODY

Dr.R. Chidambaram Principal Scientific Advisor to the Government of India 318, Vigyan Bhavan Annexe Maulana Azad Road New Delhi - 110 011.

Dr.T. Ramasami Secretary to Government of India Department of Science & Technology, Technology Bhavan, New Mehrauli Road New Delhi - 110 016.

Dr. R.K. Srivastava Director General of Health Services Ministry of Health & Family Welfare, Nirman Bhavan, Maulana Azad Road New Delhi - 110 001

Dr.Baldev Raj (Former Director,IGCAR,Kalpakkam) President, PGS Institutions, PGS College of Technology Peelamadu, Coimbatore-641004

Dr. V.N. Rajasekharan Pillai Executive Vice President Kerala State Council for Science, Technology & Environment Sasthra Bhavan, Pattom Thiruvananthapuram - 695 004.

Dr. K.A. Dinshaw, (Former Director, Tata Memorial Hospital) 201, Samudra Setu, Saher Agiary Lane Bhulabhai Desai Road, Mumbai - 400 026.

Top of Form Dr.K.Radhakrishnan Director Sree Chitra Tirunal Institute for Medical Sciences and Technology Thiruvananthapuram - 695 011

Dr.G.S. Bhuvaneshwar Head, Biomedical Technology Wing Sree Chitra Tirunal Institute for Medical Sciences and Technology Poojappura, Thiruvananthapuram - 695 012

Shri.O.S.Neelakantan Nair Engineer 'G' (Sr.Grade), Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology Poojappura, Thiruvananthapuram - 695 012

STANDING COMMITTEES

Academic Committee Prof.K.Radhakrishnan (Chairman) Director SCTIMST, Thiruvananthapuram.

ANNUAL REPORT 2011-12-

Prof.A.Jayakrishnan Vice Chancellor University of Kerala, Thiruvananthapuram

Prof.Jayaprakash Muliyil Professor of Community Medicine Christian Medical College, Vellore

Dr.M.Radhakrishna Pillai Director Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram.

Dr.G.K.Suraishkumar Professor of Biotechnology, I.I.T., Madras.

Dr.G.S.Bhuvaneshwar Head, BMT Wing, SCTIMST Poojappura, Thiruvananthapuram

Dr.J.M.Tharakan Dean (Academic Affairs) & HOD, Cardiology, SCTIMST

Dr.Suresh Nair N. Professor of Neurosurgery, SCTIMST

Dr.K.R.Thankappan Professor, AMCHSS, SCTIMST

Dr. C.P. Sharma Scientist 'G', SCTIMST

Dr.Rupa Sreedhar Professor of Anaesthesiology, SCTIMST

Dr.Prabha D. Nair Scientist 'G', SCTIMST

Dr.A.V.George Registrar, SCTIMST (Convener)

Building Committee

Dr.K.Radhakrishnan (Chairman) Director SCTIMST, Thiruvananthapuram

Secretary to the Government of Kerala Health & Family Welfare Thiruvananthapuram

Shri. K.N. S Nair Head, Engineering Maintenance Division VSSC (Retd) "Deepti", Kazhakuttan, Thiruvananthapuram

Dr. G. S. Bhuvaneshwar Head, BMT Wing, SCTIMST Poojappura, Thiruvananthapuram **Financial Advisor** SCTIMST, Thiruvananthapuram

A member to be co-opted by the Director as and when necessary

Finance Committee

Dr.K.Radhakrishnan (Chairman) Director SCTIMST, Thiruvananthapuram

Dr. T. Ramasami Secretary to the Govt. of India Ministry of Science and Technology Technology Bhavan New Delhi – 110016

Financial Advisor Department of Science & Technology New Delhi - 110 016

Dr. G.S. Bhuvaneshwar Head, BMT wing, SCTIMST

Financial Advisor (Ex-Officio Convenor) SCTIMST, Thiruvananthapuram

Senior Staff Selection Committee

Dr.K.Radhakrishnan (Chairman) Director SCTIMST, Thiruvananthapuram

Dr. G. S. Bhuvaneshwar Head, BMT Wing, SCTIMST, Poojappura Thiruvananthapuram

Prof. Jayaprakash Muliyil Professor & Head of Community Medicine Christian Medical College, Vellore

Nominee of the Secretary Department of Science & Technology Govt. of India, New Delhi - 110 016

A Senior Professor of SCTIMST

An External Expert nominated by the President of the Institute

Junior Staff Selection Committee

Medical Superintendent SCTIMST Thiruvananthapuram **Dr. G. S. Bhuvaneshwar** Head, BMT Wing, SCTIMST, Poojappura Thiruvananthapuram

Shri. P. B. Sourabhan Deputy Director (Admn) SCTIMST, Thiruvananthapuram

Nursing Superintendent SCTIMST, Thiruvananthapuram

Dr. Kalliyana Krishnan V Scientist 'G', BMT Wing

Representative of Academic Wing of the Institute nominated by the Director of the Institute

Institutional Ethics Committee

Chairman-IEC Shri.Justice M .R. Hariharan Nair 'LIVRA-57', Link Valley Kakkanad, Eranakulam ,Cochin-682030

Members Dr.K. Radhakrishnan Director SCTIMST, Thiruvananthapuram-695011

Smt. J. Lalithambika I AS (Retired)

"Abhilash", Golf links Road Thiruvananthapuram-695041 Dr. P.G. Premila 7 C, Kowdiar Manor, Jawahar Nagar Thiruvananthapuram-695041

Dr.Meenu Hariharan

"Abha" ,20/1677,no-8 Sasthri Nagar, Karamana Thiruvananthapuram-695002

Dr.K.A. Kumar "Koikkal" T.C. 13/598, Near Ulloor Bridge Pattom Palace P.O.Thiruvananthapuram-695004

Dr.Mohan D.Gupte ICMR Chair Epidemiology Ex-Director,National Institute of Epidemiology (ICMR) Chennai – 600 777.

Dr. Rema M. N (Former DME and Professor and Head of the Dept.of Pharmacology) "Manjush", Puthupally Lane Trivandrum-695011, Dr. S.N.Pal Director (Engineering) HSCC (India) limited E-6 (A), Sector –1NOIDA (U.P)-201301

Dr.Seema Bhaskar State Project Director Kerala Mahila Samakhya Society, Women's College Lane, Vazhuthacaud, Thiruvananthapuram-695014

Dr.G.S.Bhuvaneshwar Head, B.M.T. Wing Satelmond Palace Poojappura, Thiruvananthapuram-695012

Dr. Girish Menon Additional Professor Dept. of Neurosurgery, SCTIMST

Member Secretary, IEC Dr.Anoop Kumar T Scientist 'F', Molecular Medicine SCITMST, BMT Wing, Poojappura Thiruvananthapuram-695012

Co-ordinator, IEC **Ms.Sreepriya C.S** Executive Secretary to the Director.cum. Ethics Committee Co-ordinator SCTIMST, Thiruvananthapuram-695011

Technology Development Committee

Dr K. Radhakrishnan – Chairman Director, SCTIMST **Dr Baldev Raj** Former Directror IGCAR, Kalpakkam

Dr K. Balasubramanian Director, NFTDC, Hyderabad

Dr R. Krishna Kumar Professor IITMadras, Chennai

Dr S Radhakrishnan Formerly Scientist-G NCL, Pune

Dr M. Radhakrishna Pillai Director RGCB, Thiruvananthapuram

Dr K.G.Rajendran Formerly Vice President USV Ltd, Mumbai

Dr K. Jayakumar HOD and Sr Prof CVTS SCTIMST

Dr Sanjeev Thomas Prof. of Neurology SCTIMST

Dr V Kalliyanakrishnan Scientist-G BMT Wing, SCTIMST

Dr G S Bhuvaneshwar- Convenor Head, BMT Wing

OTHER INTERNAL WORKING COMMITTEES

Biosafety Committee

Dr. Mira Mohanty, Associate Head, BMT Wing- Chairperson

- Dr Renuka Nair- Scientist G (Senior Grade), Div. of Cellulat & Molecular Cardiology
- Dr. Lissy Kalayana Krishnan- Scientist G, Thrombosis Research Unit
- Dr. P. Ramesh Scientist F, Polymer Processing
- Dr. Kavita Raja Professor, Division of Microbioology
- Dr. Jawahar SK- Administrative Medical Officer and Biosafety Officer.
- Dr. Satheesh Mundayoor Rajiv Gandhi Center for Biotechnology, DBT nominee
- Dr. Moinak Banerjee- Rajiv Gandhi Center for Biotechnology, External expert.
- Dr. A. Maya Nandkumar, Scientist E- Secretary and Convener

Hospital Management Committee

Dr. R. Sankarkumar, Medical Superintendent, SCTIMST Dr. Jagan Mohan Tharakan, HOD, Dept. of Cardiology Dr. Muralidharan Nair, HOD, Dept. of Neurology Dr. Suresh Nair, HOD, Dept. of Neurosurgery Dr. Jayakumar K, HOD, Dept. of CVTS Dr. Kapilamoorthy. T R., HOD, Dept. of IS & IR Dr Ramesh Chandra Rathod, HOD, Dept. of Anesthesiology Dr. S. K. Jawahar, Administrative Medical Officer Smt. Sudhamani Amma, Nursing Superintendent i/c Mr. N. G. Thampi, SMRO

Hospital Infection Control Committee

Dr. R. Sankarkumar, Medical Superintendent Dr. Jayakumar K,HOD, Dept. of CVTS Dr. Suresh Nair,HOD, Dept. of Neurosurgery Dr. Kavita Raja, HOD,Dept. of Microbiology Dr. Jaisy Mathai, HOD, Dept. of Transfusion Medicine Dr. Sanjeev V. Thomas, Professor, Dept. of Neurology Dr. Thomas Koshy, Addl. Professor, Dept. of Anesthesiology Dr. Harikrishnan S, Addl Professor, Dept. of Cardiology Dr. Kesavadas C, Addl Professor, Dept. of IS &IR Dr. S. K. Jawahar, Adminsitrative Medical Officer-Convener Dr. Baiju S. Dharan, Assoc. Professor, Dept. of CVTS Dr. Krishnakumar K, Assoc. Professor, Dept. of Neurosurgery Mr. Mohanlal G, Scientist G, DCE

Hospital Transfusion Committee

Dr. Jaisy Mathai, Scientist G Dept of Transfusion Medicine	Chiarperson
Dr. Shrinivas V.G, Additional Prof, Anaesthesiology	Member
Dr. Vivek.V.Pillai, Assistant Prof, CVTS	Member
Dr. Krishnakumar,Assistant Prof., Neurosurgery	Member
Dr. Bijulal.S,Assistant Prof, Cardiology	Member
Dr. Anugya Bhatt,Scientist C, Thrombosis Research unit	Member
Smt. Sudhamoni Amma, i/c. Nursing Superintendent	Member
Dr.Sathyabhama.S,Scientist F Dept. of Transfusion Medicine	Convener

Institutional Animal Ethics Committee (IAEC)

Dr. G.S.Bhuvaneswar, Head, BMT Wing, (Chairman) Dr. Renuka Nair, Head, Cellular & molecular Cardiology, Biological Scientist Dr. T.V. Kumary, Scientist G. Dr. P.R.Umashankar, Scientist E, Veterinarian Dr. Annie John, Scientist E, Biological Scientist (Member Secretary, IAEC) Dr. Robin D Culas – Main CPCSEA Nominee Dr. Arun George - Link CPCSEA Nominee Mr. A.G.Babu - Non Scientific Socially Aware Member Dr. K.R.Chandra Mohan Nair – Scientist from Outside the Institute

Institutional Committee for Stem Cell Research and Therapy (ICSCRT) Shri. Justice M.R. Hariharan Nair (Chairman)

'LIVRA-57' Link Valley, Kakkanad, Ernakulam , Cochin- 682030

Dr. K. Radhakrishnan Director, SCTIMST, Thiruvananthapuram- 695011

Prof. T.S.Ganesan Chairman Cancer Institute & Institute of Molecular Medicine, Amrita Institute of Medical Sciences, Kochi – 682041

Dr. Vikram Mathews Professor of Clinical Hematology, Christian Medical College, Vellore 632004

Dr. K. Jayakrishnan KJK Hospital, Nalanchira, Thiruvananthapuram,

Dr. Jackson James Scientist-E1, Neurobiology Division, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram - 695014

Dr. Seema Bhaskar State Program Director, Kerala Mahila Samakhya Society, Women's College Lane, Vazhuthacaud, Thiruvananthapuram

Dr. R. Renuka Nair Scientist 'G' (Senior Grade), Division of Cellular & Molecular Cardiology, SCTIMST, Thiruvananthapuram-11

Dr. Lissy K. Krishnan Scientist 'G', Thrombosis Research Unit, BMT Wing, SCTIMST, Thiruvananthapuram - 12

Dr. Prabha D. Nair (Convener) Scientist G, Division of Tissue Engineering and Regeneration Technology, BMT Wing, SCTIMST, Thiruvananthapuram - 12

Dr. Anoop Kumar T. Memer Secretary, IEC, & Scientist 'F', Molecular Medicine, BMT Wing, SCTIMST, Thiruvananthapuram-12

Ms. Sreepriya.C S Coordinator, Exe. Secretary to the Director-cum-EC.Co., SCTIMST, Thiruvananthapuram-11

Library Committee

- Dr. Jaganmohan Tharakan, Dean and HOD, Cardiology(Chairman) Dr. Sanjeev Thomas, Professor, Neurology Dr. Kavita Raja, Professor, Microbiology Dr. Lissy K. Krishnan, Scientist 'G', BMT Wing
- Dr. S. Harikrishnan, Additional Professor, Cardiology

Shri. Nagesh D.S., Scientist 'F', BMT Wing
Dr. K. Srinivasan, Associate Professor, AMCHSS
Dr. Venkateshwaran S., Sr. Resident, DM Cardiology
Dr. Sohini Banerjee, MPH Student
Ms. Saumya Gopalan, DNN I Year Student
Mr. Suhesh M.S., DBBT Student
Shri. Jayachandra Das, Librarian-cum-Infmn. Officer(Convener)

Official Language Implementation Committee

Director (Chairman) Dy. Director, Admn Dr. C.P. Sharma, Scientist G(Sr.Grade) Mrs. Shiny George Ambat, FA Dr. Kamalesh K. Gulia, Scientist D Dr. Anugya Bhatt, Scientist C Dr. Narendra K. Bodhey, Associate Professor Dr. P.P. Saramma, Senior Lecturer Dr. Usha Kandaswamy, Sr.MSW Registrar (Convener)

Research and Publication Cell

Dr. R. Renuka Nair, Scientist G, (Sr.Grade)	Associate Dean(R&P Cell)
Dr. Sundari Ravindran T.K, Professor	Member
Dr. Sreenivasan K, Scientist G	Member
Dr. Harikrishnan S, Additional Professor	Member
Dr. Rathore Chaturbhuj Gopal Singh, Assistant Professor	Member
Dr. Srinivas G, Scientist D	Member
Dr. Kamalesh K. Gulia, Scientist D	Member
Dr. K. Srinivasan, Associate Professor	Convener

Supporting Staff

Shri Balram S, Scientist F Shri Suresh Kumar B, Engineer C Shri Lijikumar G, Chief Technician MI Smt. Vasanti S, Artist MI Smt. Thankamoni S, (Till Feb 2012) Shri Phil Roy, Manager, Project Cell

Technical Management Committee

Dr. G.S.Bhuvaneswar, Head, BMT Wing(Chairman) Dr. C.P.Sharma, Scientist 'G', Sr.Grade Mr. D.S.Nagesh, Scientist 'G' Dr. Ramesh.P, Scientist 'F' Dr. Annie John, Scientist 'E' Dr. H.K.Varma, Engineer 'F' Mr. C.V.Muraleedharan, Scientist 'G' Mr. Balram.S, Scientist 'F' Mr. O.S.Neelakantan Nair, Scientist 'G' Dr. Sreenivasan.K, Scientist 'G' Dr. Maya Nandkumar, Scientist 'E' Dr. Mira Mohanty, Scientist 'G', Sr.Grade Dr. Kumary.T.V, Scientist 'G' Dr. Mohanan.P.V, Scientist 'G' Dr. Lissy.K.Krishnan, Scientist 'G' Dr. P.R.Umashankar, Scientist 'G' Mrs. Helen Joseph, Stores & Purchase Officer Gr.II Mr. Prasanna Kumar.K, Security Officer Mr. Selvaraj Kumar.A, Administrative Officer Gr.II Mr. Jayachandra Das.S, Librarian cum-Information Officer

Technical Advisory Committee (TAC)

Technical Advisory Committee for Studies on Medical Devices:

Dr. G.S. Bhuvaneshwar, Head, BMT Wing (Chairman) Shri. C.V. Muraleedharan, Scientist 'G', BMT Wing Dr. Girish Menon, Additional Professor, Neurosurgery Dr. Anoop Kumar T., Scientist 'F', BMT Wing (Member Secretary)

Technical Advisory Committee for Clinical Studies (not including medical devices):

- Dr. V.Mohankumar, Emeritus Professor, Sleep Disorder Center (Chairman)
- Dr. R.Sankar Kumar, Medical Supdt. & Sr.Professor of CVTS
- Dr. T.V.Kumari, Scientist G, BMT Wing
- Dr. Thomas Koshy, Professor, Anaesthesiology
- Dr. C.Kesavadas, Additional Professor, IS & IR
- Dr. K.Srinivasan, Associate Professor, AMCHSS
- Dr. Narayan Namboodiri, Associate Professor, Cardiology
- Dr. Chaturbhuj Gopal Singh Rathore, Assistant Professor, Neurology
- Dr. K.Sivakumar, Scientist G, Cellular & Molecular Cardiology (Member Secretary)

Technical Advisory Committee for Studies on Public Health:

- Dr. V. Ramankutty, Professor, AMCHSS (Chairman)
- Dr. S. Sivasankaran, Additional Professor, Cardiology
- Dr. Lissy K. Krishnan, Scientist 'F', BMT Wing
- Dr. Mala Ramanathan, Additional Professor, AMCHSS (Member Secretary)

Complaints Committee for redressal of complaints on Sexual harassment of working women

- Dr. Rupa Sreedhar, Professor (Chairperson) Dr. Renuka Nair, Scientist 'G' (Senior Grade) Dr. Mala Ramanathan, Addl. Professor Dr. Lissy K. Krishnan, Scientist 'G'
- Ms. Sudhamani Amma S., Nursing Supdt. i/c.
- Smt. Nalini Nayak, Secretary, SEWA, Thiruvuananthapuram

Right to Information

(Published as required under section 41(b), Chapter II of Right to Information Act, 2005.) Dr. Kavita Raja Professor & 1st Appellate Authority, Department of Microbiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Medical College P.O., Thiruvananthapuram-695011, Land Phone: 0471-2524222 (O); 0471-2322300 (Res)

Dr. R . Renuka Nair

Transparency Officer, Scientist G(Sr.Grade) Head of the Division, Cellular & Molecular Cardiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Medical College P.O., Thiruvananthapuram-695011 Phone: 0471-2524505, Email - renuka@sctimst.ac.in

Dr. S.K. Jawahar Administrative Medical Officer, Principal Public Information Officer, SCTIMST, TVM -11, Ph:0471-2524150 Email jawahar@sctimst.ac.in

Shri. Sundar Jayasingh S.

Asst. Public Information Officer, (Academic Affairs), Deputy Registrar, SCTIMST, TVM-11, Ph:0471-2524140 Email -jsingh@sctimst.ac.in

Sri. N.G. Thampi

Asst. Public Information Officer (Patient Information), Senior Medical Records Officer, SCTIMST, TVM-11, Phone:0471-2524436, Email -thampi@sctimst.ac.in

Sri. S. Balram

Asst. Public Information Officer, (Technology), Engineer, Technology Business Division, BMT Wing, Poojappura, SCTIMST, TVM-12, Ph: 0471-2340801, Email - balrams@sctimst.ac.in

Vigilance officer

Dr. Jaisy Mathai (Part Time Vigilance Officer) Scientist G, Department of Transfusion Medicine , SCTIMST



Statement of Accounts

Balance Sheet Income & Expenditure Account Schedules Forming Part of Accounts Receipt & Payments Accounts of the year 2011-2012 Provident Fund Account for the year ended 31.03.2012 Accounts of NCMMR, Trivandrum Separate Audit Report



BALANCE SHEET AS AT 31st MARCH 2012

		2011-12	2010-2011
CORPUS/CAPITAL FUND AND LIABILITIES	Schedules	[Rs.]	[Rs.]
CAPITAL FUND	1	2768668378.88	2883685259.78
RESERVES & SURPLUS	2	408563899.45	355187993.70
EARMARKED ENDOWMENT FUNDS	3	236774177.31	172537198.05
SECURED LOANS & BORROWINGS	4	0.00	0.00
CURRENT LIABILITIES & PROVISIONS	7	132100430.22	139199588.22
TOTAL		3546106885.86	3550610039.75
ASSETS			
FIXED ASSETS	8	1469191220.49	1394143045.27
INVESTMENTS FROM EARMARKED ENDOWMENT FUNDS	9	517764355.45	488222189.70
CURRENT ASSETS , LOANS, ADVANCES ETC	11	1559151309.92	1668244804.78
MISCELLANEOUS EXPENDITURE (TO THE EXTENT NOT WRITTEN OFF)		0.00	0.00
TOTAL		3546106885.86	3550610039.75
SIGNIFICANT ACCOUNTING POLICIES	24		
CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS	25		

S/d-FINANCIAL ADVISOR S/d-DIRECTOR

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31st MARCH 2012

INCOME	Schedules	2011-12	2010-2011
		[Rs.]	Rs.
Income from Sales / Services	12	394775138.50	321602172.40
Grants Received from Govt of India(Non Plan)	13	239495165.00	258676264.00
Fees/Subscription	14	5053867.00	7024222.00
Income from Investments	15	27294531.45	29729323.00
(Income on Investment from earmarked/endow.Funds transferred to Funds)			
Income from Royalty, Publication etc	16	2302598.00	877864.00
Interest Earned	17	78409570.91	74043322.57
Other Income	18	4296687.70	4779831.30
Total		751627558.56	696732999.27
EXPENDITURE			
Establishment Expenses	20	873490403.25	666986582.60
Other Administrative Expenses	21	458779828.98	413918436.44
Bank Charges	23	118974.00	114518.25
Depreciation (Net Total at the year-end-corresponding to Schedule 8)		143965460.78	134965510.39
Total		1476354667.01	1215985047.68
Balance being Excess Expenditure over Income		724727108.45	519252048.41
Add: Transfer to Special Reserve Account		59744954.45	53580274.00
BALANCE BEING DEFICIT CARRIED TO CAPITAL FUND		784472062.90	572832322.41
SIGNIFICANT ACCOUNTING POLICIES	24		
CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS	25		

S/d-FINANCIAL ADVISOR S/d-DIRECTOR

SCHEDULES		
	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
SCHEDULE 1 - CORPUS/CAPITAL FUND		
Balance as at the beginning of the year	4056247692.39	3853369086.38
Less Depreciation up to the end of the previous year	1172562432.61	1037596922.19
Net balance at the beginning of the year	2883685259.78	2815772164.19
Add: Plan Grants received from Government of India	670504835.00	641323736.00
Add: Grants received from Others for Capital Assets(WCP)	0.00	0.00
Add:Contribution towards Corpus/Capital Fund	0.00	0.00
Deduct: Balance of net expenditure transferred from the Income and Expenditure Account	784472062.90	572832322.41
Less:Value of Assets Written off during the year	1049653.00	578318.00
DeductTransfer to BMT/Add Transfer from CHO	0.00	0.00
BALANCE AS AT THE YEAR-END	2768668378.88	2883685259.78
SCHEDULE 2-RESERVES AND SURPLUS:		
1. Capital Reserve:		
As per last Account		
Addition during the year		
Less:Deduction during the year		
2. Revaluation Reserve:		
As per last Account		
Addition during the year		
Less: Deductions during the year		
3. Special Reserves:		
As per last Account	355187993.70	310546070.70
Addition during the year (Current year transfer+Decrease in provision)	53375905.75	44641923.00
Less: Deductions during the year		
4. General Reserve:		
As per last Account		
Addition during the year		
Less: Deductions during the year		
TOTAL	408563899.45	355187993.70

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
SCHEDULE 3-EARMARKED/ENDOWMENT FUNDS		
a) Opening balance of the funds		
b) Additions to the funds:		
i. Donations/grants		
ii. Income from Investments made on account of funds		
iii. Other additions (Specify nature)		
TOTAL (a+b)		
c) Utilisation / Expenditure towards objective of funds		
i. Capital Expenditure		
- Fixed Assets		
- Others		
Total (Detailed Schedule Attached)		
ii. Revenue Expenditure		
- Salaries, Wages and allowances etc.	236774177.31	172537198.05
- Rent		
- Other Administrative expenses		
Total	236774177.31	172537198.05
TOTAL (c)		
NET BALANCE AS AT THE YEAR-END (a+b+c)	236774177.31	172537198.05

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FL	JND-WISE BREAK			
DDOL	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR	ODENING	ADDITION	S TO FUND	TOTAL	
Code		BALANCE	GRANTS	OTHER RECEIPTS		
5000	PROJ-MISCELLANEOUS	856396.00	4264092.00	0.00	5120488.00	
5008	DR.C.KESAVADAS	10916.00	0.00	0.00	10916.00	
5033	MPH PROGRAMME	1480.00	0.00	0.00	1480.00	
5040	PROJ. DR.ASHA VIJAYARAGHAVAN	1156818.70	0.00	0.00	1156818.70	
5055	GRANT/ROCKFELLER FOUNDATION, USA	686120.00	0.00	0.00	686120.00	
5065	M.D.PHARMA(DR,ASHA)	398586.50	0.00	0.00	398586.50	
5078	PROJECT GRANT/DR MALA RAMANATHAN	5810.00	0.00	0.00	5810.00	
5082	T V HEMALATHA/HEALTHAWARENESS PROGRAM	127537.00	0.00	0.00	127537.00	
5088	DOUBLE BLIND PLACEBO CONT. PARALLEL	63023.00	0.00	0.00	63023.00	
5091	EURO REG. OF EPILEPSY & PREGNANCY	71796.00	0.00	0.00	71796.00	
5094	KERALA STATE AIDS CONTROL SOCIETY	45517.00	0.00	0.00	45517.00	
5100	AMC/MAC ARTHUR FOUNDATION/02-70546	46315.05	0.00	0.00	46315.05	
5103	CLINICAL TRIAL/QUINTAILSPEC/DR.RADHAKRISHNAN	318638.00	0.00	0.00	318638.00	
5108	EVAL.SUB-TYPES DEMENTIA/DR.MATHURA	15800.50	0.00	0.00	15800.50	
5110	TOBACCO CESSATION & RESEARCH / DR.THANKAP	2001013.94	6012518.00	22967.00	8036498.94	
5111	DIFFUSION WEIGHTED IMAGING/DR.GUPT	-26226.00	143582.00	2197.00	119553.00	
5119	STAKE HOLDER-PERCEPT/INST.REV BO	151589.73	0.00	0.00	151589.73	
5128	INDENT. OF MACOBACTERIAL/DST/ V.V.RADHAKRISHN	136107.00	0.00	0.00	136107.00	
5130	TELE-HEALTH & MEDICAL EDUCATION/JAWAHAR	924464.00	300000.00	0.00	1224464.00	
5133	COMMUNITY BASED INTERVENTION/WHO	215059.00	0.00	0.00	215059.00	
5135	A 16-WEEK, DOUBLE BLIND/ASHA KISHORE	1719592.00	0.00	0.00	1719592.00	
5137	MECHANISM OF ANTICANCER/DAE, BRS	2761.00	0.00	0.00	2761.00	
5139	A 24 WEEK, MULTICENTER/DR. MATHURANATH	2927181.28	773493.50	0.00	3700674.78	
5140	HARVARD SCHOOL OF PUBLIC HEALTH	91794.32	0.00	0.00	91794.32	
5142	BANKING FOR BETTER HEALTH-MEDISAVE	240383.36	0.00	0.00	240383.36	
5146	DEVELOPMENT OF SPECT	67151.00	0.00	0.00	67151.00	
5147	DEVELOPMENT OF SPECT	39137.00	0.00	0.00	39137.00	
5150	PROTOCOL 6002-INT 001	389796.60	0.00	0.00	389796.60	
5153	DEV REF. MANUAL FOR	155802.00	0.00	0.00	155802.00	
5155	COMM BASED DETECTION	308058.00	0.00	20306.00	328364.00	
5156	TSUNAMI PROJECT	539120.50	0.00	0.00	539120.50	
5159	NCD RISK FACTOR	71123.00	0.00	0.00	71123.00	
5160	BRAIN MAPING & BASIC NEUROGENETIC/DR.P.S MATHURANATH	0.00	0.00	185925.00	185925.00	
5161	DOSE RANGING STUDY:CGHR	2134719.00	3253.00	0.00	2137972.00	
5167	PROJ/SURVIVAL MECHANISM	209319.00	0.00	0.00	209319.00	
5168	PROJ/VERMEER STUDY	1922742.00	0.00	0.00	1922742.00	
5170	dr.asha kishore	2415076.00	0.00	0.00	2415076.00	
5172	C.KESAVADAS	79902.00	0.00	0.00	79902.00	
5173	DR.DINESH NAYAK	772311.00	0.00	0.00	772311.00	

		UTILISATION						
CAPITAL EXPE	NDITURE	REVENUE EXPENDITURE						
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUMABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
0.00	0.00	0.00	2991177.00	215762.00	787408.00	3994347.00	3994347.00	1126141.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10916.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1480.00
0.00	0.00	0.00	0.00	0.00	10697.00	10697.00	10697.00	1146121.70
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	686120.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	398586.50
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5810.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	127537.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	63023.00
0.00		0.00	0.00	0.00	0.00	0.00	0.00	71796.00
0.00	0.00	0.00	0.00	0.00	3957.00	3957.00	3957.00	41560.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	46315.05
0.00	0.00	0.00	0.00	0.00	4001.00	4001.00	4001.00	314637.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15800.50
0.00	0.00	0.00	1842555.00	334167.00	975060.00	3151782.00	3151782.00	4884716.94
0.00	0.00	0.00	0.00	0.00	119553.00	119553.00	119553.00	0.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	151589.73
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	136107.00
0.00	0.00	0.00	149597.00	0.00	42699.00	192296.00	192296.00	1032168.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	215059.00
0.00	0.00	0.00	40000.00	0.00	9390.00	49390.00	49390.00	1670202.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2761.00
0.00	0.00	0.00	311435.00	158211.00	103263.00	572909.00	572909.00	3127765.78
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	91794.32
0.00	0.00	0.00	0.00	0.00	86472.00	86472.00	86472.00	153911.36
0.00	0.00	0.00	0.00	0.00	56125.00	56125.00	56125.00	11026.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	39137.00
0.00	0.00	0.00	30000.00	0.00	0.00	30000.00	30000.00	359796.60
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	155802.00
0.00	0.00	0.00	0.00	0.00	119049.00	119049.00	119049.00	209315.00
0.00	0.00	0.00	130935.00	0.00	0.00	130935.00	130935.00	408185.50
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	71123.00
24738.00	0.00	24738.00	0.00	0.00	33.00	33.00	24771.00	161154.00
0.00	0.00	0.00	132398.00	0.00	29703.00	162101.00	162101.00	1975871.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	209319.00
0.00	0.00	0.00	171430.00	0.00	220398.00	391828.00	391828.00	1530914.00
0.00	0.00	0.00	200324.00	0.00	217491.00	417815.00	417815.00	1997261.00
0.00	0.00	0.00	0.00	0.00	79902.00	79902.00	79902.00	0.00
0.00	0.00	0.00	129209.00	0.00	2411.00	131620.00	131620.00	640691.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FL	JND-WISE BREAK U			
PROL	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITION	s to fund	TOTAL	
Code		BALANCE	GRANTS	OTHER RECEIPTS		
5174	CHANGES IN SLEEP WAKEFULNESS-Dr.Mohanku.	139062.00	0.00	0.00	139062.00	
5175	SURGICAL TRAIL IN LOBAR INTRACEREBRAL	39125.27	0.00	0.00	39125.27	
5176	WOMENT COMPONANT PLAN	59065.25	0.00	0.00	59065.25	
5180	DR.KANNAN SRINIVASAN	18308.00	0.00	0.00	18308.00	
5181	DR.ASHA KISHORE	-14350.00	0.00	0.00	-14350.00	
5182	DR.SANJEEV.V.THOMAS	4463816.00	0.00	14001.00	4477817.00	
5183	DR.K.R.THANKAPPAN	11723513.92	0.00	85110.00	11808623.92	
5184	DR.JAWAHAR	1958204.00	0.00	0.00	1958204.00	
5187	DR.SANJEEV.V.THOMAS	181383.00	0.00	0.00	181383.00	
5188	DR.K.RADHAKRISHNAN	361822.00	398242.00	0.00	760064.00	
5189	DR.HARIKRISHNAN	1012.00	0.00	0.00	1012.00	
5190	DR.MALARAMANATHAN	76339.00	0.00	0.00	76339.00	
5191	DR.ASHA KISHORE	670946.00	0.00	0.00	670946.00	
5192	DR.K.R.THANKAPPAN	344696.50	0.00	0.00	344696.50	
5193	DR.MALARAMANATHAN	78537.00	0.00	0.00	78537.00	
5194	DR.K.R.THANKAPPAN	378589.00	2341235.00	0.00	2719824.00	
5196	DR.SHIVKUMAR	160030.00	511000.00	10000.00	681030.00	
5198	DR.RENUKA NAIR	13418.00	1417950.00	0.00	1431368.00	
5199	DR.JAYAKUMAR	271712.00	800000.00	14677.00	1086389.00	
5201	DR.ASHA KISHORE	2170617.50	2050896.00	0.00	4221513.50	
5202	DR.JAYASREE	-24043.00	0.00	24043.00	0.00	
5203	STUDY IN MRI - ISIR	0.00	27365.00	54416.00	81781.00	
5205	DR.SURESH NAIR	229876.00	49635.00	0.00	279511.00	
5207	DR.JAYSREE/A.K.GUPTA	6692.00	0.00	0.00	6692.00	
5208	DR.K.SRINIVASAN	437863.00	0.00	0.00	437863.00	
5209	DR.S.HARIKRISHNAN	20540.00	0.00	0.00	20540.00	
5210	DR.K.R.THANKAPPAN	993906.00	0.00	0.00	993906.00	
5212	DR.S.HARIKRISHNAN	397020.00	577796.00	0.00	974816.00	
5213	AMC FUND	1475000.00	0.00	0.00	1475000.00	
5214	DR.ASHA GOPINATHAN	338526.00	350000.00	0.00	688526.00	
5215	DR.V.V.RADHAKRISHNAN	252414.00	135123.00	5000.00	392537.00	
5216	DR.ASHA KISHORE	776652.60	511065.50	5000.00	1292718.10	
5217	DR.K.SRINIVASAN	1399716.50	0.00	0.00	1399716.50	
5219	DR.BIJU SOMAN	1745968.00	0.00	0.00	1745968.00	
5220	DR.BIJU SOMAN	897060.00	0.00	0.00	897060.00	
5221	DR.V.RAMANKUTTY	1582542.00	0.00	0.00	1582542.00	
5224	DR.C.KESAVADAS	300000.00	0.00	0.00	300000.00	
5226	DR.G.SRINIVAS	1323000.00	0.00	13464.00	1336464.00	
5227	DR.MURALIDHARAN NAIR	134129.00	356762.00	0.00	490891.00	
5228	DR.S.HARIKRISHNAN	130756.00	368000.00	0.00	498756.00	

	UTILISATION							
CAPITAL EXPE	NDITURE	TURE REVENUE EXPENDITURE						
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUMABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
29894.00	0.00	29894.00	28054.00	31500.00	297.00	59851.00	89745.00	49317.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	39125.27
 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	59065.25
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18308.00
 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-14350.00
 0.00	0.00	0.00	1352617.00	52695.00	331925.00	1737237.00	1737237.00	2740580.00
 0.00	0.00	0.00	1789070.00	1312506.00	2342202.00	5443778.00	5443778.00	6364845.92
0.00	0.00	0.00	0.00	0.00	328032.00	328032.00	328032.00	1630172.00
 0.00	0.00	0.00	0.00	0.00	797.00	797.00	797.00	180586.00
0.00	0.00	0.00	33000.00	0.00	512841.00	545841.00	545841.00	214223.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1012.00
 0.00	0.00	0.00	30000.00	0.00	4129.00	34129.00	34129.00	42210.00
0.00	0.00	0.00	0.00	436302.00	82.00	436384.00	436384.00	234562.00
0.00	0.00	0.00	0.00	0.00	25521.00	25521.00	25521.00	319175.50
 0.00	0.00	0.00	0.00	0.00	6741.00	6741.00	6741.00	71796.00
0.00	0.00	0.00	373226.00	0.00	1135387.00	1508613.00	1508613.00	1211211.00
121012.00	0.00	121012.00	25968.00	141810.00	76973.00	244751.00	365763.00	315267.00
295576.00	0.00	29 5576.00	397284.00	222264.00	304439.00	923987.00	1219563.00	211805.00
0.00	0.00	0.00	340259.00	0.00	101638.00	441897.00	441897.00	644492.00
0.00	0.00	0.00	96452.00	0.00	292133.00	388585.00	388585.00	3832928.50
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.00	0.00	0.00	0.00	0.00	12452.00	12452.00	12452.00	69329.00
0.00	0.00	0.00	0.00	0.00	61167.00	61167.00	61167.00	218344.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6692.00
0.00	0.00	0.00	0.00	0.00	328.00	328.00	328.00	437535.00
0.00	0.00	0.00	6250.00	0.00	0.00	6250.00	6250.00	14290.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	993906.00
0.00	0.00	0.00	67097.00	365186.00	7672.00	439955.00	439955.00	534861.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1475000.00
0.00	0.00	0.00	420000.00	0.00	96027.00	516027.00	516027.00	172499.00
0.00	0.00	0.00	0.00	45150.00	48856.00	94006.00	94006.00	298531.00
0.00	0.00	0.00	137742.00	0.00	32601.00	170343.00	170343.00	1122375.10
0.00	0.00	0.00	192710.00	0.00	196645.00	389355.00	389355.00	1010361.50
0.00	0.00	0.00	177904.00	0.00	97484.00	275388.00	275388.00	1470580.00
0.00	0.00	0.00	43226.00	0.00	18616.00	61842.00	61842.00	835218.00
0.00	0.00	0.00	180000.00	0.00	453386.00	633386.00	633386.00	949156.00
0.00	0.00	0.00	0.00	44588.00	392.00	44980.00	44980.00	255020.00
466879.00	0.00	466879.00	210340.00	209300.00	220000.00	639640.00	1106519.00	229945.00
0.00	0.00	0.00	176613.00	0.00	124203.00	300816.00	300816.00	190075.00
0.00	0.00	0.00	69032.00	0.00	88858.00	157890.00	157890.00	340866.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FL	JND-WISE BREAK U			
PROJ	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITIONS TO FUND		TOTAL	
Code		BALANCE	GRANTS	OTHER RECEIPTS		
5229	DR.C.KESAVADAS	560839.00	0.00	0.00	560839.00	
5230	DR.SUNDARI RAVINDRAN	76862.25	421077.25	0.00	497939.50	
5231	DR.V.V.RADHAKRISHNAN	628047.00	0.00	28688.00	656735.00	
5232	DR.ASHA KISHORE	434383.00	0.00	88204.00	522587.00	
5233	DR. BEJOY THOMAS/DR.C.KESAVADAS	106822.00	0.00	0.00	106822.00	
5234	DR.R.ASHA LATHA	1058333.00	0.00	0.00	1058333.00	
5235	REGULATION OF THE CARDIAC FIBROBLAST C	0.00	636190.00	0.00	636190.00	
5237	KERALA DIABETES PREVENTION PROGRAM(K-DPP	0.00	1473790.41	0.00	1473790.41	
5238	IMPROVING LOCALIZATION IN LESION NEGA	0.00	300000.00	0.00	300000.00	
5239	BUILDING THE ASIAN NCD RESEARCH NETWORK.	0.00	0.00	35752.00	35752.00	
5240	AUTOCRINE AND PARACRINE MECHANISMS IN	0.00	911334.00	0.00	911334.00	
5241	DEVELOPMENT OF LIPID ANTIGEN BASED	0.00	671000.00	0.00	671000.00	
5243	STEROIDS IN CARDIAC SURGERY	0.00	545886.00	0.00	545886.00	
5244	MOLECULAR BASIS OF CARDIAC FIBROBLAST	0.00	2553000.00	0.00	2553000.00	
5245	IMPROVING LOCALIZATION IN LESION N	0.00	1253400.00	0.00	1253400.00	
5247	A PHASE 3, 12-WEEK, DOUBLE BLIND, PLA	0.00	161775.00	0.00	161775.00	
5248	A PHASE 3, DOUBLE BLIND, PLACEBO AND A	0.00	161775.00	0.00	161775.00	
5249	CNRS-INDO-FRENCH PROJECT	0.00	683850.00	100000.00	783850.00	
5250	DIABETES, PREDIABETES AND INSU	0.00	37000.00	0.00	37000.00	
5251	NEUROBIOLOGICAL MARKER OF POPULATION D	0.00	380000.00	0.00	380000.00	
5253	INDO-SWISS SYMPOSIUM ON COHORT	0.00	800000.00	0.00	800000.00	
5255	PRIVATIZATION OF HEALTHCARE	0.00	353882.50	0.00	353882.50	
5256	HEALTHY LIFE STYLE		672903.00	0.00	672903.00	
5257	PULMONARY HYPERTENSION, BMPRII	0.00	287448.00	0.00	287448.00	
6054	PROJ/DR RADHAKRISHNAN NEUROLOGY	544284.54	0.00	8800.00	553084.54	
6055	MOVEMENT/DR. ASHA KISHORE	58819.00	0.00	0.00	58819.00	
6057	PUBLISHING JOURNAL ARTICLE/DR. THANKAPPAN	93412.00	0.00	0.00	93412.00	
6058	ATHIYANOOR SCT ACTION/DR.K.R.T	21006.00	0.00	0.00	21006.00	
6064	SPEECH THERAPY	-612931.00	0.00	0.00	-612931.00	
6065	COMPREHENSIVE CENTRE FOR SLEEP DIS ORD.	-226179.00	0.00	268711.00	42532.00	
6066	DR.SANJEEV V THOMAS	50000.00	0.00	0.00	50000.00	
6067	DR.JAGANMOHAN THARAKAN	103160.00	0.00	0.00	103160.00	
6068	DR.SAJITH.S	150000.00	0.00	0.00	150000.00	
6069	DR.SYAM.K	31520.00	0.00	0.00	31520.00	
6070	DR.BEJOY THOMAS/DR.GAYATHRI.P	150000.00	0.00	0.00	150000.00	
6071	DR.S.K.JAWAHAR	136071.00	0.00	0.00	136071.00	
6072	COMPREHENSIVE STROKE CARE	-681730.00	0.00	0.00	-681730.00	
6073	DR.KIRON.S	50000.00	0.00	0.00	50000.00	
6074	DR.DIVYATA FANJENDR HINGWALA	50000.00	0.00	0.00	50000.00	
6075	DR.BIJULAL.S	150000.00	0.00	0.00	150000.00	

	UTILISATION							
CAPITAL EXPE	NDITURE	REVI	ENUE EXPENDITU	JRE				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUMABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
0.00	0.00	0.00	154209.00	0.00	184872.00	339081.00	339081.00	221758.00
0.00	0.00	0.00	0.00	0.00	497939.50	497939.50	497939.50	0.00
0.00	0.00	0.00	119761.00	156447.00	118956.00	395164.00	395164.00	261571.00
0.00	0.00	0.00	179188.00	0.00	245793.00	424981.00	424981.00	97606.00
0.00	0.00	0.00	0.00	0.00	84949.00	84949.00	84949.00	21873.00
0.00	0.00	0.00	110001.00	0.00	43207.00	153208.00	153208.00	905125.00
176323.00	0.00	176323.00	116556.00	194606.00	17055.00	328217.00	504540.00	131650.00
0.00	0.00	0.00	280000.00	0.00	401941.00	681941.00	681941.00	791849.41
0.00	0.00	0.00	0.00	0.00	26055.00	26055.00	26055.00	273945.00
0.00	0.00	0.00	0.00	0.00	35752.00	35752.00	35752.00	0.00
0.00	0.00	0.00	42774.00	762094.00	66.00	804934.00	804934.00	106400.00
0.00	0.00	0.00	0.00	42806.00	78776.00	121582.00	121582.00	549418.00
0.00	0.00	0.00	0.00	0.00	10506.00	10506.00	10506.00	535380.00
0.00	0.00	0.00	0.00	259887.00	7760.00	267647.00	267647.00	2285353.00
1800.00	0.00	1800.00	113177.00	0.00	5305.00	118482.00	120282.00	1133118.00
0.00	0.00	0.00	12069.00	0.00	56427.00	68496.00	68496.00	93279.00
0.00	0.00	0.00	0.00	0.00	40459.00	40459.00	40459.00	121316.00
0.00	0.00	0.00	0.00	0.00	800.00	800.00	800.00	783050.00
 0.00	0.00	0.00	0.00	0.00	21077.00	21077.00	21077.00	15923.00
 0.00	0.00	0.00	38400.00	0.00	18083.00	56483.00	56483.00	323517.00
0.00	0.00	0.00	0.00	0.00	569827.00	569827.00	569827.00	230173.00
 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	353882.50
 0.00	0.00	0.00	0.00	0.00	546.00	546.00	546.00	672357.00
0.00	0.00	0.00	0.00	0.00	319.00	319.00	319.00	287129.00
 0.00	0.00	0.00	110310.00	0.00	0.00	110310.00	110310.00	442774.54
 0.00	0.00	0.00	80000.00	58500.00	3800.00	142300.00	142300.00	-83481.00
0.00	0.00	0.00	65000.00	0.00	15710.00	80710.00	80710.00	12702.00
 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	21006.00
0.00	0.00	0.00	143062.00	0.00	0.00	143062.00	143062.00	-755993.00
0.00	0.00	0.00	766200.00	57121.00	242399.00	1065720.00	1065720.00	-1023188.00
 0.00	0.00	0.00	0.00	0.00	42900.00	42900.00	42900.00	7100.00
 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	103160.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	150000.00
 0.00	0.00	0.00	0.00	0.00	29390.00	29390.00	29390.00	2130.00
0.00	0.00	0.00	0.00	76062.00	77.00	76139.00	76139.00	73861.00
0.00	0.00	0.00	97742.00	0.00	685.00	98427.00	98427.00	37644.00
0.00	0.00	0.00	3596033.00	556678.00	40968.00	4193679.00	4193679.00	-4875409.00
0.00	0.00	0.00	0.00	0.00	24981.00	24981.00	24981.00	25019.00
0.00	0.00	0.00	0.00	0.00	25010.00	25010.00	25010.00	24990.00
0.00	0.00	0.00	0.00	0.00	15006.00	15006.00	15006.00	134994.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FU	JND-WISE BREAK	JP		
PROJ Code	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR	OPENING	ADDITION	s to fund	TOTAL	
Code		BALANCE	GRANTS	OTHER RECEIPTS		
6076	SCANNING THE MEDICAL RECORDS AS PART	0.00	795000.00	40.00	795040.00	
6077	TAC	-10000.00	0.00	0.00	-10000.00	
6078	DESIGN & DEVELOPMENT OF MINIMALLY INV	0.00	90000.00	0.00	90000.00	
7101	ADVANCES TO PI	-80257.00	0.00	1486380.00	1406123.00	
7102	AMT.PAYABLE TO PROJECT STAFF	4618.00	0.00	115457.00	120075.00	
2721	ADVANCE FOR SUPPLIES PROJECT	-223910.00	0.00	744482.00	520572.00	
	TOTAL	59429364.81	34581319.16	3333620.00	97344303.97	
	EARMARKED FUNDS					
1014	NEW PENSION SCHEME	61060548.00		44872732.00	105933280.00	
1301	EMPLOYEES PENSION FUND	-7667131.35		234584769.00	226917637.65	
1075	PATIENT WELFARE FUND	1914090.35		359497.00	2273587.35	
1077	INSTITUTIONAL ETHICS COMMITTEE FUND	3938845.00		2136833.00	6075678.00	
1078	DR. RICHARD A CASH & DR K MOHANDS AWARD	15000.00		44457.00	59457.00	
1080	STAFF BENEVOLENT FUND	2472762.25		2498954.00	4971716.25	
1079	VICE CHANCELLORS CONFERENCE FUND	178233.00			178233.00	
1081	CONTINUUM - SPECIAL CME PUBLICATION FUND	51707.00			51707.00	
		61964054.25	0.00	284497242.00	346461296.25	

			UTILISATION					
CAPITAL EXPE	INDITURE	REV	ENUE EXPENDITU	JRE				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUMABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
0.00	0.00	0.00	431216.00	0.00	121799.00	553015.00	553015.00	242025.00
0.00	0.00	0.00	120000.00	0.00	0.00	120000.00	120000.00	-130000.00
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	90000.00
0.00	0.00	0.00	0.00	0.00	1410303.00	1410303.00	1410303.00	-4180.00
0.00	0.00	0.00	0.00	0.00	117922.00	117922.00	117922.00	2153.00
0.00	0.00	0.00	0.00	0.00	1189545.00	1189545.00	1189545.00	-668973.00
1116222.00	0.00	1116222.00	18851602.00	5733642.00	15536401.50	40121645.50	41237867.50	56106436.47
		0.00			94917459.00	94917459.00	94917459.00	11015821.00
		0.00			113846641.00	113846641.00	113846641.00	113070996.65
		0.00			83498.00	83498.00	83498.00	2190089.35
		0.00			270825.00	270825.00	270825.00	5804853.00
		0.00			15000.00	15000.00	15000.00	44457.00
		0.00			4273993.00	4273993.00	4273993.00	697723.25
		0.00			9796.00	9796.00	9796.00	168437.00
		0.00				0.00	0.00	51707.00
0.00	0.00	0.00	0.00	0.00	213417212.00	213417212.00	213417212.00	133044084.25
						TOTAL		189150520.72

NAME OF GRANTEL/PRINCIPAL INVESTIGATOR PROJECT SUSPENSEADDITIONS VINDADDITIONSTOTAL5000PROJECT SUSPENSE473001.004760592.000\$233593.005057DYNAMIC ORTHOPAEDIC PVT LTD, HYDROXY28787.550.0000.0028787.555089DETEC & TREAT OF CANCER BY LASER3959.0010000.0028787.5550810DEFE CA TREAT OF CANCER BY LASER30944.00150000.001150000.0070010MISCELENEOUS PROJECT30944.013737995.75493551.00-4231546.7570120DYCJSAHAJANAND VASCUJDR.AURTHUR3737995.75493551.00-2537.007004PROJ.ES.T.D. R.P.V. MOHANAN2537.400.00012551.257005PROJ.ES.T.D. R.P.V. MOHANAN3551.250.0000.0021382.007006PROJ.ES.T.D. R.P.V. MOHANAN3537.400.0001213382.007006PROJ.ES.T.D. R.P.V. MOHANAN313876.000.0001213382.007007PROJ.ES.T.D. R.P.V. MOHANAN313876.000.0001213382.007018RMITU, PROJECT C.S.I.R399311.900.00010.00017010DST-RAB: CUNICALLYSIG-SHAPE OF HEVA14002.807378.000.0013988.007011DST-RAB: CUNICALLYSIG-SHAPE OF HEVA13674.000.00010.00017011DST-RAB: CUNICALLYSIG-SHAPE OF HEVA13674.000.00013088.007012DST-DROME CRO REDECAL APPLICATION<		SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FU	ND-WISE BREAK UP			
PROJE DEFENSE OTHERS 5057 DYNAMIC ORTHOPAEDIC PVT LTD, HYDROXY 28787.55 0.00 0.00 28787.55 5059 DETEC & TREAT OF CANCER BY LASER 3959.00 0.000		NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITIONS T	O FUND	TOTA	L
5000 PROJECT SUSPENSE 473001.00 74760592.00 5.233593.00 5057 DYNAMIC ORTHOPAEDIC PYT LTD, HYDOXY 28787.55 0.000 28787.55 5089 DETEC & TREAT OF CANCER BY LASER 3959.00 0.000 0.000 150000.00 7000 MISCELLENE ROTEINS ON THE ENDOTHE 30944.09 0.000 4231546.75 7001 PROJSAHAJANAND VASCUJCR.AURTHUR 373795.75 493551.00 0.00 4231546.75 7002 D.TOMS LABORATORY, Dr. K.KRISHNAN 13876.00 0.00 13876.00 0.00 13876.00 7003 PROJED.S.T. DR.YM MCHANAN 2537.40 0.00 0.0 1355.00 7004 PROJENJ.S.T. DR.YM MCHANAN 2537.40 0.00 0.0 13656.00 7005 PROJECT.DYNAMIC ORTHOPAEDICS 13656.00 0.00 213382.00 0.00 13656.00 7006 PROJE D.S.T. D.S.NAGESH 213382.00 0.00 1.702.75 7010 398311.90 0.000 13674.00 7014 DST-BSDMC FOR MEDICICLA PPUICATION 111500.0 0.00 <td>PROJ Code</td> <td></td> <td>OPENING BALANCE</td> <td>GRANTS</td> <td>OTHER RECEIPTS</td> <td></td> <td></td>	PROJ Code		OPENING BALANCE	GRANTS	OTHER RECEIPTS		
5057 DYNAMIC ORTHOPAEDIC PVT LTD, HYDROXY 28787.55 0.00 0.00 28787.55 5089 DETC & TREAT OF CANCER BY LASER 3959.00 0.000 0 33959.00 6045 ROLE OF PLATELET PROTEINS ON THE ENDOTHE 0.00 15000.00 0 15000.00 7001 MISCELLENCOUS PROJECT 30344.09 0.00 0 4231546.75 7002 D.TOMS LABORATORY, Dr. K.RISHNAN 13876.00 0 2537.40 7004 PROJED, ST. DR.P.V. MOHANAN 2537.40 0.00 21382.00 7005 PROJECT, DYNAMIC ORTHOPAEDICS 13656.00 0.00 213382.00 7006 PROJE ST. D.S. NAGESH 213382.00 0.00 39311.90 7008 CHITOSAN BASED WAINED DRESSING 7702.75 0.00 39388.00 7011 DST-BE SUMOK FOR MEDICAL APPLICATION 11604.00 0.00 13674.00 7014 AUROLAB,RARVIND EYE HOSPITAL 13674.00 11604.00 - 39388.00 7015 TK HEAT THORAE	5000	PROJECT SUSPENSE	473001.00	4760592.00	-	5233593.00	
5089DETEC & TREAT OF CANCER BY LASER3959.000.000.000.00150000.000.006045ROLE OF PLATELET PROTEINS ON THE ENDOTHE0.00150000.001.0030944.0970010PRO;SAHAJANAND VASCU;DR.AURTHUR3737995.75493551.000.00423156.7570020D.TOMS LABORATORY, Dr. K.RISHNAN13876.000.000.0012837.0070040PRO;J.S.T. DR.P.V. MOHANAN2537.400.0000.0013656.0070051PRO;D.S.T. DR.P.V. MOHANAN551.250.0000.0013656.0070060PRO;D.T. DS. NAGESH13656.000.000139301.0013656.0070070CHITOSAN BASED WAINED DRESSING7702.750.0000.0021382.0070110DST-FAS CLINICALLY/SIG:SHAPE OF HEVA140028.0011500.000.00021382.00701210DST-BASCH KEDICAL APPLICATION113674.000.00013674.00701311ITK-HEALTHCARE.DEVELOPMENT OF VALV39888.000.00013674.0070141AUROLAB,ARAVIND EYE HOSPITAL13674.000.00013674.0070151ITK-HEALTHCARE.DEVELOPMENT OF VALV39888.000.00013684.0070161INDO-GERMAN COMMITTEE MEETING-DST5407.000.00013694.0070171HINDUSTAN LATEX.EVALU;BLOOD BAG120438.500.0000.0001488.0070162DST.IRANJANOSB8.000.000171.002522.0070173BISUROALVANANP385.000.0000.0001580.00	5057	DYNAMIC ORTHOPAEDIC PVT LTD, HYDROXY	28787.55	0.00	0.00	28787.55	
6045 ROLE OF PLATELET PROTEINS ON THE ENDOTHE 0.00 15000.00 15000.00 1 7000 MISCELLENCOUS PROJECT 30944.09 0.00 - 30944.09 7001 PRO,SAHAJANAND VASCU,DR.AURTHUR 3737995.75 493551.00 - 4231546.75 7002 Dr.TOMS LABORATORY, Dr. K.KRISHNAN 13876.00 - 13876.00 - 13876.00 7004 PROJ.D.S.T. D.R.P.V. MOHANAN 2537.40 0.00 - 213382.00 7005 PROJECT.DYNAMIC ORTHOPAEDICS 13656.00 0.00 - 213382.00 7006 PROJ. S.T. D.S. NAGESH 213382.00 0.00 - 39311.00 7008 NIMTU, PROJECT C.S.L.R 39931.00 - 39381.00 0.00 21382.00 7011 DST-FA8: CLINICALLYSIG:SHAPE OF HEVA 140028.00 7702.75 0.00 - 39888.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00 - 39888.00 7015 TIK HEALTHCARE.DEVELOPMENT OF VALV 39888.00 0.00 - <td>5089</td> <td>DETEC & TREAT OF CANCER BY LASER</td> <td>3959.00</td> <td>0.00</td> <td></td> <td>3959.00</td> <td></td>	5089	DETEC & TREAT OF CANCER BY LASER	3959.00	0.00		3959.00	
7000 MISCELLENEOUS PROJECT 30944.09 0.00 0 30944.09 7001 PRO;SAHAJANAND VASCU;DR.AURTHUR 3737995.75 493551.00 0 4231546.75 7002 Dr.TOMS LABORATORY, Dr. K.KRISHNAN 13876.00 0.000 0 13876.00 7003 PROJ:D.S.T. DR.P.V. MOHANAN 2537.40 0.000 0 551.25 7004 PROJ:D.S.T. DR.P.V. MOHANAN 551.25 0.000 0 551.25 7005 PROJECT:DYNAMIC ORTHOPAEDICS 13656.00 0.000 0 213382.00 7006 PROJ: D.S.T. D.S.NAGESH 213382.00 0.000 0 399311.00 7008 NIMITI, PROJECT C.S.I.R 399311.90 0.000 213826.00 0.000 7011 DST-FAB: CLINCALLYSIG:SHAPE OF HEVA 140028.00 7378.00 0.000 213826.00 7012 DST-DBSOMC FOR MEDICAL APPLICATION -11500.00 0.000 1.3674.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 39881.00 0.000 342806.00 7015 TK.H	6045	ROLE OF PLATELET PROTEINS ON THE ENDOTHE	0.00	150000.00		150000.00	
7001 PRO;SAHAJANAND VASCU;DR.AURTHUR 3737995.75 493551.00 4231546.75 7002 Dr.TOMS LABORATORY, Dr. K.KRISHNAN 13876.00 0.00 13876.00 7003 PROJ:D.S.T. DR.P.V. MOHANAN 2537.40 0.00 551.25 7004 PROJ:ATMRE;DR LISSY KRISHNAN 551.25 0.00 551.25 7005 PROJECT.DYNAMIC ORTHOPAEDICS 13656.00 0.00 213382.00 7006 PROJECT.DYNAMIC ORTHOPAEDICS 1399311.90 0.00 213382.00 7008 NMITLI, PROJECT C.S.I.R 399311.90 0.00 7702.75 7011 DST-ABS CLINICALLYSIG:SHAPE OF HEVA 140028.00 73798.00 0.00 21382.00 7012 DST-BBSOMC FOR MEDICAL APPLICATION -11367.00 0.000 1.13674.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00 39888.00 7015 TTK-HEALTHCARE.DEVELOPMENT OF VALV 39888.00 0.00 34886.00 7016 INDOLG	7000	MISCELLENEOUS PROJECT	30944.09	0.00		30944.09	
7002 Dr. TOMS LABORATORY, Dr. K.KRISHNAN 13876.00 0.00 13876.00 7003 PROJ.D.S.T. DR.P.V. MOHANAN 2537.40 0.00 2537.40 7004 PROJ.ATMRF.DR LISSY KRISHNAN 551.25 0.00 551.25 7005 PROJECT.DYNAMIC ORTHOPAEDICS 13656.00 0.00 213382.00 7006 PROJ.D.S.T. D.S.NAGESH 213382.00 0.00 393311.90 7008 NMITU, PROJECT C.S.LR 399311.90 0.00 393311.90 7010 DST-AB. CLINICALLY/SIG:SHAPE OF HEVA 140028.00 73798.00 0.00 213826.00 7011 DST-AB. CLINICALLY/SIG:SHAPE OF HEVA 140028.00 73798.00 0.00 213826.00 7012 DST-DSOMC FOR MEDICAL APPLICATION -11500.00 0.00 11307.00 0.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 13874.00 0.00 39888.00 7015 TK HEALTHCARE, DEVELOPMENT OF VALV 39888.00 0.00 342806.00 7016 <td>7001</td> <td>PRO;SAHAJANAND VASCU;DR.AURTHUR</td> <td>3737995.75</td> <td>493551.00</td> <td></td> <td>4231546.75</td> <td></td>	7001	PRO;SAHAJANAND VASCU;DR.AURTHUR	3737995.75	493551.00		4231546.75	
7003 PROJ:D.S.T. DR.P.V. MOHANAN 2537.40 0.00	7002	Dr.TOMS LABORATORY, Dr. K.KRISHNAN	13876.00	0.00		13876.00	
7004 PROJATMRE.DR LISSY KRISHNAN 551.25 0.00	7003	PROJ:D.S.T. DR.P.V. MOHANAN	2537.40	0.00		2537.40	
7005 PROJECT:DYNAMIC ORTHOPAEDICS 13656.00 0.00	7004	PROJ:ATMRF:DR LISSY KRISHNAN	551.25	0.00		551.25	
7006 PROJ: D.S.T. D.S.NAGESH 213382.00 0.00 213382.00 7008 NMITLI, PROJECT C.S.I.R 399311.90 0.00 399311.90 7009 CHITOSAN BASED WAINED DRESSING 7702.75 0.00 7702.75 7011 DST-FAB: CLINICALLY/SIG:SHAPE OF HEVA 140028.00 73798.00 0.00 213826.00 7012 DST-DBSOMC FOR MEDICAL APPLICATION -11500.00 0.00 11507.00 0.00 7014 AUROLAB, ARAVIND EYE HOSPITAL 13674.00 0.00 39888.00 7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 5407.00 7017 HINDUSTAN LATEX.EVALU:BLOOD BAG 1204338.50 29885.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHN:EDU:SH 218719.00 124087.00 69847.00 7020 IFCPAR-DAJAYAKRISHNAN 18800 0.000 0.00 188.00 7021 DST-IBEPSBC-DR.SHARMA 79385.00 0.000 79385.00 <	7005	PROJECT: DYNAMIC ORTHOPAEDICS	13656.00	0.00		13656.00	
7008NMITLI, PROJECT C.S.I.R399311.900.00399311.907009CHITOSAN BASED WAINED DRESSING7702.750.007702.757011DST-FAB: CLINICALLY/SIG:SHAPE OF HEVA140028.0073798.000.00213826.007012DST-DBSOMC FOR MEDICAL APPLICATION-11500.000.0011500.000.007014AUROLAB,ARAVIND EYE HOSPITAL13674.000.0013674.007015TTK.HEALTHCARE.DEVELOPMENT OF VALV39888.000.005407.007016INDO-GERMAN COMMITTEE MEETING-DST5407.000.005407.007017HINDUSTAN LATEX.EVALU/BLOOD BAG1204338.5029885.001503194.507018ALL INDIA COUNCIL FOR TECHNI:EDU:SH218719.00124087.000.0034280.007020IFCPAR-DRJAYAKRISHNAN188.000.000.00188.007023DST-IBEPDSEC-DR.SHARMA79385.000.0079385.007024DEV.HYDRO-CEPHALUS-HINDUSTAN LATEX45510.000.000.0088054.007025STED-DR T V KUMARY-INVITRO5089.000.000.006876.007031DBT/DR P V MOHAN/DEV INVITROPYRO880564.000.000.0029166.007033BIOFUNCTIONAL EVALUATION DR. UMASANKER72581.000.0072581.007034DST. DR. NIRMALA RACHEL14664.000.000.014664.007035DST-H.K.VARMA29153.000.0072581.00 </td <td>7006</td> <td>PROJ: D.S.T. D.S.NAGESH</td> <td>213382.00</td> <td>0.00</td> <td></td> <td>213382.00</td> <td></td>	7006	PROJ: D.S.T. D.S.NAGESH	213382.00	0.00		213382.00	
7009 CHITOSAN BASED WAINED DRESSING 7702.75 0.00 7702.75 7011 DST-FAB: CLINICALLY/SIG:SHAPE OF HEVA 140028.00 73798.00 0.00 213826.00 7012 DST-DBSOMC FOR MEDICAL APPLICATION -11500.00 0.000 11500.00 0.000 7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00 39888.00 7015 TTK.HEALTHCARE.DEVELOPMENT OF VALV 39888.00 0.00 39888.00 7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 5407.00 7017 HINDUSTAN LATEX.EVALU:BLOOD BAG 1204338.50 298856.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI:EDU:SH 218719.00 124087.00 0.00 342806.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 69847.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7024 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 0.00 68876.0	7008	NMITLI, PROJECT C.S.I.R	399311.90	0.00		399311.90	
7011 DST-FAB: CLINICALLY/SIG:SHAPE OF HEVA 140028.00 73798.00 0.00 213826.00 7012 DST-DBSOMC FOR MEDICAL APPLICATION -11500.00 0.00 11500.00 0.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00	7009	CHITOSAN BASED WAINED DRESSING	7702.75	0.00		7702.75	
7012 DST-DBSOMC FOR MEDICAL APPLICATION -11500.00 0.00 11500.00 0.00 7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00 13674.00 7015 TTK.HEALTHCARE,DEVELOPMENT OF VALV 39888.00 0.00 39888.00 7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 5407.00 7017 HINDUSTAN LATEX, EVALU: BLOOD BAG 1204338.50 298856.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI: EDU: SH 218719.00 124087.00 0.000 342806.00 7019 DST.NIRANJAN 69847.00 0.000 0.00 188.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.000 188.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.000 1711.00 2522.00 7024 DEV.HEART VALVE-DST.MURALEE 811.00 0.000 1711.00 2522.00 7025 STED-DR T V KUMARY-INVITRO 5089.00 0.000 6876.00 1701.00 80564.00	7011	DST-FAB: CLINICALLY/SIG:SHAPE OF HEVA	140028.00	73798.00	0.00	213826.00	
7014 AUROLAB,ARAVIND EYE HOSPITAL 13674.00 0.00 0 13674.00 7015 TTK.HEALTHCARE.DEVELOPMENT OF VALV 39888.00 0.00 0 39888.00 7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 0 5407.00 7017 HINDUSTAN LATEX.EVALU.BLOOD BAG 1204338.50 298856.00 0 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI:EDU.SH 218719.00 124087.00 0.000 342806.00 7019 DST.NIRANJAN 69847.00 0.000 342806.00 1 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.000 188.00 7021 DST-LIFEDPSEC-DR.SHARMA 79385.00 0.00 188.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.000 1711.00 2522.00 7024 DEV.HEART VALVE-DST.MURALEE 811.00 0.000 6876.00 10.00 6876.00 7031 DBH/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 6876.00 10.000 29166.00 <tr< td=""><td>7012</td><td>DST-DBSOMC FOR MEDICAL APPLICATION</td><td>-11500.00</td><td>0.00</td><td>11500.00</td><td>0.00</td><td></td></tr<>	7012	DST-DBSOMC FOR MEDICAL APPLICATION	-11500.00	0.00	11500.00	0.00	
7015 TTK.HEALTHCARE.DEVELOPMENT OF VALV 39888.00 0.00 39888.00 7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 5407.00 7017 HINDUSTAN LATEX.EVALU:BLOOD BAG 1204338.50 298856.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI:EDU:SH 218719.00 124087.00 0.00 342806.00 7019 DST.NIRANJAN 69847.00 0.00 69847.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 188.00 188.00 7021 DST-LBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 1711.00 2522.00 7024 DEV.HEART VALVE-DST.MURALEE 811.00 0.000 6876.00 0.000 6876.00 7025 DED-DR T V KUMARY-INVITRO 5089.00 0.000 6876.00 0.000 6876.00 7034 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 - <td< td=""><td>7014</td><td>AUROLAB,ARAVIND EYE HOSPITAL</td><td>13674.00</td><td>0.00</td><td></td><td>13674.00</td><td></td></td<>	7014	AUROLAB,ARAVIND EYE HOSPITAL	13674.00	0.00		13674.00	
7016 INDO-GERMAN COMMITTEE MEETING-DST 5407.00 0.00 5407.00 7017 HINDUSTAN LATEX.EVALU:BLOOD BAG 1204338.50 298856.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI:EDU:SH 218719.00 124087.00 0.00 342806.00 7019 DST.NIRANJAN 69847.00 0.00 69847.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 0.00 188.00 7023 DST-LBFDPSBC-DR.SHARMA 79385.00 0.00 45510.00 7024 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.000 45510.00 7025 DEV.HEART VALVE-DST.MURALEE 811.00 0.000 1711.00 2522.00 7026 DEV.HEART VALVE-DST.MURALEE 8816.00 0.000 6876.00 1000 7027 STED-DR T V KUMARY-INVITRO 80564.00 0.000 6876.00 1000 29166.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 0.000 29166.00 1	7015	TTK.HEALTHCARE.DEVELOPMENT OF VALV	39888.00	0.00		39888.00	
7017 HINDUSTAN LATEX.EVALU:BLOOD BAG 1204338.50 298856.00 1503194.50 7018 ALL INDIA COUNCIL FOR TECHNI:EDU:SH 218719.00 124087.00 0.00 342806.00 7019 DST.NIRANJAN 69847.00 0.00 69847.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 0.00 188.00 7021 DST-LIBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.00 6876.00 1000 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 80564.00 1000 29166.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 29166.00 14664.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 72581.00	7016	INDO-GERMAN COMMITTEE MEETING-DST	5407.00	0.00		5407.00	
7018 ALL INDIA COUNCIL FOR TECHNI:EDU:SH 218719.00 124087.00 0.00 342806.00 7019 DST.NIRANJAN 69847.00 0.00 69847.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 188.00 180.00 7021 DST-IBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.00 6876.00 100.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.000 6876.00 100.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 29166.00 124087.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.000 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035	7017	HINDUSTAN LATEX.EVALU:BLOOD BAG	1204338.50	298856.00		1503194.50	
7019 DST.NIRANJAN 69847.00 0.00 69847.00 7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 0.00 188.00 7022 DST-LBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.00 6876.00 5089.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 6876.00 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 29166.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 95433.00 7035 DST-H.K.VARMA 95433.00 0.00 95433.00	7018	ALL INDIA COUNCIL FOR TECHNI:EDU:SH	218719.00	124087.00	0.00	342806.00	
7020 IFCPAR-DR.JAYAKRISHNAN 188.00 0.00 0.000 188.00 7022 DST-LBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.000 0.00 6876.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 6876.00 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 29166.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.000 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 9246324.00	7019	DST.NIRANJAN	69847.00	0.00		69847.00	
7022 DST-LBFDPSBC-DR.SHARMA 79385.00 0.00 79385.00 7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.00 0.00 6876.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 6876.00 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 29166.00 80564.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.000 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.000 95433.00	7020	IFCPAR-DR.JAYAKRISHNAN	188.00	0.00	0.00	188.00	
7023 DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX 45510.00 0.00 45510.00 7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.000 0.00 6876.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.000 0.000 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 0.000 29166.00 7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.000 0.000 29166.00 7034 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.000 72581.00 7035 DST. H.K.VARMA 95433.00 0.000 95433.00	7022	DST-LBFDPSBC-DR.SHARMA	79385.00	0.00		79385.00	
7026 DEV.HEART VALVE-DST.MURALEE 811.00 0.00 1711.00 2522.00 7027 STED-DR T V KUMARY-INVITRO 5089.00 0.00 5089.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 80564.00 7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 - 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 - 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 - 95433.00	7023	DEV: HYDRO-CEPHALUS-HINDUSTAN LATEX	45510.00	0.00		45510.00	
7027 STED-DR T V KUMARY-INVITRO 5089.00 0.000 5089.00 7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.000 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.000 80564.00 7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.000 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.000 - 7034 DST. DR. NIRMALA RACHEL 14664.00 0.000 - 14664.00 7035 DST-H.K.VARMA 95433.00 0.000 - 95433.00	7026	DEV.HEART VALVE-DST.MURALEE	811.00	0.00	1711.00	2522.00	
7029 DONERG/LIFE SCIENCE BOARD 6876.00 0.00 6876.00 7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 80564.00 7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 - 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 - 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 - 95433.00	7027	STED-DR T V KUMARY-INVITRO	5089.00	0.00		5089.00	
7031 DBT/DR P V MOHAN/DEV INVITROPYRO 80564.00 0.00 80564.00 7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 95433.00 7036 INN/ITRO HEMO CAMPARIUTY/ DR. USSY 216221.00 0.00 216221.00	7029	DONERG/LIFE SCIENCE BOARD	6876.00	0.00	0.00	6876.00	
7032 DST. DR. ANNINE/BONE REGENERATION 29166.00 0.00 0.00 29166.00 7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 95433.00 7036 INN/ITPO HEMO CAMPAPHILITY/ DR. LISSY 216221.00 0.00 216221.00	7031	DBT/DR P V MOHAN/DEV INVITROPYRO	80564.00	0.00		80564.00	
7033 BIOFUNCTIONAL EVALUATION DR. UMASANKER 72581.00 0.00 72581.00 7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 95433.00 7036 INNUTRO HEMO CAMPAPHILITY/ DR. LISSY 216221.00 0.00 216221.00	7032	DST. DR. ANNINE/BONE REGENERATION	29166.00	0.00	0.00	29166.00	
7034 DST. DR. NIRMALA RACHEL 14664.00 0.00 14664.00 7035 DST-H.K.VARMA 95433.00 0.00 95433.00 7036 INNUTRO HEMO CAMPARIUTY/ DR LISSY 216221.00 0.00 216221.00	7033	BIOFUNCTIONAL EVALUATION DR. UMASANKER	72581.00	0.00		72581.00	
7035 DST-H.K.VARMA 95433.00 0.00 95433.00 7036 INIVITED HEMO CAMPAPILITY/ DB HISSY 216221.00 0.00 216221.00	7034	DST. DR. NIRMALA RACHEL	14664.00	0.00		14664.00	
	7035	DST-H.K.VARMA	95433.00	0.00		95433.00	
7050 INVITKU HEIVIU CAIVIPADILITT/ DK. LISST 216221.00 U.UU 216221.00	7036	INVITRO HEMO CAMPABILITY/ DR. LISSY	216221.00	0.00		216221.00	
7037 INVIVO EVALUATION/ STED/DR. LISSY 6205.00 0.00 6205.00	7037	INVIVO EVALUATION/ STED/DR. LISSY	6205.00	0.00		6205.00	
7039 JNC/ASR/DR. MOHANAN/STUDY OF ACCUTE 44684.00 0.00 44684.00	7039	JNC/ASR/DR. MOHANAN/STUDY OF ACCUTE	44684.00	0.00		44684.00	
7040 BIOMED/ C.V. MURALEEDHARAN 44000.00 0.00 44000.00	7040	BIOMED/ C.V. MURALEEDHARAN	44000.00	0.00		44000.00	
7041 CSIR-GRANT-ASHA S MATHEW,PHD STUDENT 62073.00 0.00 62073.00	7041	CSIR-GRANT-ASHA S MATHEW,PHD STUDENT	62073.00	0.00		62073.00	
7042 CSIR-GRANT-BERNADETTE K. MADATHIL,PHD 25870.00 0.00 25870.00	7042	CSIR-GRANT-BERNADETTE K. MADATHIL,PHD	25870.00	0.00		25870.00	
7043 CSIR-GRANT-SAILAJA.G.S.SRF 9067.00 192000.00 201067.00	7043	CSIR-GRANT-SAILAJA.G.S.SRF	9067.00	192000.00		201067.00	
7044 LISI NO TRIAL TRIAL MERIND 21672.65 0.00 21672.65	7044	LISI NO TRIAL TRIAL MERIND	21672.65	0.00		21672.65	
7045 NIRMALA RACHEL, CSIR 14063.00 0.00 14063.00	7045	NIRMALA RACHEL, CSIR	14063.00	0.00		14063.00	

			UTILISATION					
CAPITAL EX	PENDITURE	REVE	NUE EXPENDITUR	₹E				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUM- ABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
		0.00	0.00		3086399.00	3086399.00	3086399.00	2147194.00
		0.00	0.00		22000.00	22000.00	22000.00	6787.55
		0.00	0.00		0.00	0.00	0.00	3959.00
		0.00	3300.00		0.00	3300.00	3300.00	146700.00
		0.00	0.00		0.00	0.00	0.00	30944.09
		0.00	0.00		55668.00	55668.00	55668.00	4175878.75
		0.00	0.00		0.00	0.00	0.00	13876.00
		0.00	0.00			0.00	0.00	2537.40
		0.00	0.00		0.00	0.00	0.00	551.25
		0.00	0.00		0.00	0.00	0.00	13656.00
		0.00	0.00		20100.00	20100.00	20100.00	193282.00
0.00		0.00	0.00		103983.00	103983.00	103983.00	295328.90
		0.00	0.00		2941.00	2941.00	2941.00	4761.75
		0.00	0.00		0.00	0.00	0.00	213826.00
		0.00	0.00		0.00	0.00	0.00	0.00
		0.00	0.00			0.00	0.00	13674.00
		0.00	0.00			0.00	0.00	39888.00
		0.00	0.00		0.00	0.00	0.00	5407.00
		0.00	150767.00		192615.00	343382.00	343382.00	1159812.50
		0.00	0.00		68060.00	68060.00	68060.00	274746.00
		0.00	0.00		0.00	0.00	0.00	69847.00
		0.00	0.00	0.00	0.00	0.00	0.00	188.00
		0.00	0.00	0.00	0.00	0.00	0.00	79385.00
 		0.00	0.00		0.00	0.00	0.00	45510.00
0.00		0.00	0.00		0.00	0.00	0.00	2522.00
		0.00	0.00		0.00	0.00	0.00	5089.00
		0.00	0.00		0.00	0.00	0.00	6876.00
		0.00	0.00		1500.00	1500.00	1500.00	79064.00
		0.00	0.00	0.00	0.00	0.00	0.00	29166.00
		0.00	0.00		0.00	0.00	0.00	72581.00
0.00		0.00	0.00		0.00	0.00	0.00	14664.00
		0.00	0.00			0.00	0.00	95433.00
		0.00	0.00		19823.00	19823.00	19823.00	196398.00
		0.00	0.00			0.00	0.00	6205.00
		0.00	0.00		0.00	0.00	0.00	44684.00
		0.00	0.00			0.00	0.00	44000.00
		0.00	0.00	0.00	6100.00	6100.00	6100.00	55973.00
		0.00	0.00		0.00	0.00	0.00	25870.00
		0.00	0.00	0.00	192000.00	192000.00	192000.00	9067.00
		0.00	0.00	0.00	0.00	0.00	0.00	21672.65
		0.00	0.00	0.00	0.00	0.00	0.00	14063.00

ANNUAL REPORT 2011-12-

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FU	ND-WISE BREAK UP			
PROJ Code	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITIONS T	O FUND	TOTA	L
PROJ Code		OPENING BALANCE	GRANTS	OTHER RECEIPTS		
7047	U.G.C. GRANT- RESEARCH FELLOW	74689.00	623246.00		697935.00	
7048	CSIR GRANT- JOSENA JOSEPH	47473.00	0.00		47473.00	
7049	CSIR GRANT - MARY VARGHESE	35837.00	0.00		35837.00	
7051	CSIR GRANT - MANITHA B NAIR	12062.00	0.00		12062.00	
7052	DBT/DR.PRABHA/DEV. OF TEMP - RES - CO-OPLY	-229010.25	0.00		-229010.25	
7053	DR.SREENIVASAN/DEVEL.OF TEMP.RES.CO-OPLY	22619.00	0.00		22619.00	
7054	DST-DR.ANOOP-DIFF:EXPR:RAT BRAIN	44434.00	0.00		44434.00	
7055	CSIR-NMITLI SCHEME-C.V.MURALEEDHARAN	5338110.00	0.00		5338110.00	
7056	D.S.T.ROYJOSEPH, BONE GRAFT SUB:SPINAL	110047.00	0.00		110047.00	
7057	DST - PROJECT.DR.JAYABALAN	16071.00	0.00		16071.00	
7059	DBT-DR. PRABHA D NAIR, ISLET IMMUN	72870.00	0.00		72870.00	
7060	ICMR PROJECT/ SUDHAKAR MUTHALEE	134495.00	139600.00	0.00	274095.00	
7061	DR. UMASANKAR/PRELIMI:EVALU:BIODEGRADABLE	125923.00	0.00		125923.00	
7062	DR. LIZY-SAHAJA:EVA "STENT"INVITRO	-140253.00	0.00		-140253.00	
7063	DR.P.V.MOHAN, SHAJANAD	-10824.00	0.00		-10824.00	
7065	DR.T.V.KUMARI, DBT.BIOGENE	38713.00	0.00		38713.00	
7066	DR.B.S.GEETHA.PDF,STED	15321.00	0.00		15321.00	
7067	DBT.DR.JAYABALAN,DEV:&STUDIES	-27459.00	0.00		-27459.00	
7069	VSSC - PROJECT. D.S. NAGESH	364905.00	0.00		364905.00	
7070	CHO PROJECT - 5146 JAYASREE	-872.00	0.00		-872.00	
7071	STEC-PROJECT: DR.MAYA NANDKUMAR	-2164.00	0.00		-2164.00	
7072	SAHAJANAND MED.TECH. C.V.MURALIDHARAN	76292.00	0.00		76292.00	
7073	STUDY PROJECT:DR.P.V.MOHANAN	-95386.00	0.00	0.00	-95386.00	
7074	STUDY PROJECT: CLRI- DR.MOHAN	289303.00	0.00		289303.00	
7075	STUDY PROJECT - BIOSYNC SCI	11935.00	0.00		11935.00	
7076	ARROW INTERNATIONAL : DR.UMASHANKAR	399773.00	0.00		399773.00	
7077	UMHOU SENEMBYU:DR.UMASHANKAR	603714.00	0.00		603714.00	
7080	DBT-DR.MAYA- TISSUE ENGINEERING HYBRID	-391887.00	0.00		-391887.00	
7081	USV LTD. MUMBAI - DR.MOHAN	88349.00	0.00		88349.00	
7082	INDO-US JOINT PROJECT	878.00	0.00	0.00	878.00	
7083	ARROW HAEMO DIALYSIS	30882.00	0.00		30882.00	
7085	DR.R.V.THAMPAN - CSIR	26381.00	0.00		26381.00	
7086	HORMONE RELEASING INTRA DEVICES	-67934.00	0.00		-67934.00	
7087	CSIR - KALADHAR - BST	39103.00	0.00		39103.00	
7088	FEASIBILITY STUDY	0.00	0.00		0.00	
7089	PROJ/7089/DEV.PORTABLE SAFETY	0.00	0.00		0.00	
7090	PROJ/7090/TISSUE ENGINEERS VASCULAR	288679.00	255000.00		543679.00	
7091	PROJ/7091/NOVEL MICROPHORES	-302731.00	0.00		-302731.00	
7092	PROJ/7092/SEA FOOD	143803.00	0.00		143803.00	

			UTILISATION					
CAPITAL FX	PENDITURE	REVI		۶F				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUM- ABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
		0.00	0.00	0.00	386746.00	386746.00	386746.00	311189.00
		0.00	0.00		0.00	0.00	0.00	47473.00
		0.00	0.00	0.00	0.00	0.00	0.00	35837.00
		0.00	0.00	0.00	0.00	0.00	0.00	12062.00
		0.00	0.00		0.00	0.00	0.00	-229010.25
		0.00	0.00		0.00	0.00	0.00	22619.00
		0.00	0.00		0.00	0.00	0.00	44434.00
0.00		0.00	266748.00		601754.00	868502.00	868502.00	4469608.00
		0.00	0.00		0.00	0.00	0.00	110047.00
		0.00	0.00		1944521.00	1944521.00	1944521.00	-1928450.00
0.00		0.00	0.00		5096.00	5096.00	5096.00	67774.00
		0.00	0.00		136048.00	136048.00	136048.00	138047.00
		0.00	0.00		125682.00	125682.00	125682.00	241.00
		0.00	0.00		192987.00	192987.00	192987.00	-333240.00
		0.00	0.00		0.00	0.00	0.00	-10824.00
		0.00	0.00		0.00	0.00	0.00	38713.00
		0.00	0.00		0.00	0.00	0.00	15321.00
		0.00	0.00		0.00	0.00	0.00	-27459.00
 		0.00	194326.00		10203.00	204529.00	204529.00	160376.00
		0.00	0.00		0.00	0.00	0.00	-872.00
 		0.00	0.00		0.00	0.00	0.00	-2164.00
 		0.00	0.00		0.00	0.00	0.00	76292.00
		0.00	0.00	0.00	0.00	0.00	0.00	-95386.00
		0.00	0.00		0.00	0.00	0.00	289303.00
		0.00	0.00		0.00	0.00	0.00	11935.00
		0.00	0.00		0.00	0.00	0.00	399773.00
		0.00	0.00		0.00	0.00	0.00	603714.00
0.00	0.00	0.00	0.00		0.00	0.00	0.00	-391887.00
		0.00	0.00			0.00	0.00	88349.00
		0.00	0.00		0.00	0.00	0.00	878.00
		0.00	0.00		0.00	0.00	0.00	30882.00
		0.00	0.00		0.00	0.00	0.00	26381.00
0.00		0.00	10868.00		7225.00	18093.00	18093.00	-86027.00
		0.00	0.00		0.00	0.00	0.00	39103.00
		0.00	0.00		0.00	0.00	0.00	0.00
		0.00	0.00		0.00	0.00	0.00	0.00
		0.00	0.00		131702.00	131702.00	131702.00	411977.00
		0.00	0.00		0.00	0.00	0.00	-302731.00
		0.00	0.00		11925.00	11925.00	11925.00	131878.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FUI	ND-WISE BREAK UP			
	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITIONS T	O FUND	TOTA	L
PROJ Code		OPENING BALANCE	GRANTS	OTHER RECEIPTS		
7093	PROJ/7093/CSIR GRANT-LPA	33281.00	755486.00		788767.00	
7095	PROJ/7095/CSIR GRANT-VIOLA.B.MORRIS	34204.00	56516.00		90720.00	
7097	PROJ/7097/ACCELERATED AGEING	318243.00	0.00		318243.00	
7098	PROJ/7098/EVALN OF NTU DRUG	1355655.00	0.00		1355655.00	
7099	PROJ/7099/BCL	7011.00	0.00		7011.00	
7100	PROJ/7100/ITR PROGRAMME	31619.00	8750.00		40369.00	
7101	PROJ/7101/CSIR/SONIA.T.A	32436.00	57600.00		90036.00	
7102	PROJ/7102/CSIR/LYNDA THOMAS	24999.00	19200.00		44199.00	
7103	PROJ/7103/CSIR/VIDYARAJ	7348.00	46534.00		53882.00	
7104	PROJ/7104/CSIR/RENJITH.P.NAIR	38889.00	503000.00		541889.00	
7105	PROJ/7105/CSIR/ARJUN NAMBOODIRI	17841.00	351200.00		369041.00	
7106	PROJ/7106/CSIR/NITHYA JOSEPH	0.00	0.00		0.00	
7107	PROJ/7107/CSIR/NEENA & 2 FELLOWS	34863.00	48000.00		82863.00	
7108	PROJ/7108/CSIR/FRANCIS.B.FERNANDEZ	38957.00	327200.00		366157.00	
7109	PROJ/7109/CSIR/TARA.S	35342.00	57600.00		92942.00	
7110	PROJ/7110/CSIR/DEEPA.R	30822.00	115364.00		146186.00	
7111	PROJ/7111/CSIR/SHEEJA LIZA EASO	-808.00	221600.00		220792.00	
7112	PROJ/7112/ICMR/JASEER MOHAMMED	22041.00	250400.00		272441.00	
7113	PROJ/7113/KSCSTE/RATHIKALA	110992.00	0.00		110992.00	
7200	JOINT PROGRAME/M.TECH	3362295.00	0.00		3362295.00	
7210	PROJ/7210/CSIR/SOMA DEY	4932.00	250400.00		255332.00	
7220	COST OF ANIMAL FEED	1386419.00	90300.00		1476719.00	
7230	PROJ/7230/CSIR/MANJU.S	10212.00	336534.00		346746.00	
7240	PROJ/7240/CSIR/SUNITHA CHANDRAN	20932.00	308000.00		328932.00	
7250	PROJ/7250/CSIR/KIRAN.S.NAIR	5699.00	317445.00		323144.00	
7260	PROJ/7260/ST0X083Y09/DR.P.V.MOHANAN	410000.00	66000.00		476000.00	
7270	PROJ/7270/KSCSTE/MAYURI.P.V.	114000.00	0.00		114000.00	
7280	PROJ/7280/CSIR/SUSAN.M.ALEX	7812.00	323044.00		330856.00	
7290	PROJ/7290/CSIR/RAKHI.A	0.00	337686.00		337686.00	
7300	PROJ/7300/CSIR/ARIYA SARASWATHY	0.00	183117.00		183117.00	
8001	PROJ/8001/PROGRAM SUPPORT & TISSUE	-38291.00	2552412.00		2514121.00	
8002	PROJ/8002/PROGRAM SUPPORT & TISSUE	70428.00	1591000.00	0.00	1661428.00	
8003	PROJ/8003/PROGRAM SUPPORT & TISSUE	-119735.00	1109000.00		989265.00	
8004	PROJ/8004/PROGRAM SUPPORT & TISSUE	-65414.00	0.00	0.00	-65414.00	
8005	PROJ/8005/PROGRAM SUPPORT & TISSUE	-171788.00	1525486.00	0.00	1353698.00	
8006	PROJ/8006/BIOCONJUGATION NANO MAT.	-226843.00	0.00		-226843.00	
8007	PROJ/8007/PRODUCTS OF POLYMER	517198.00	0.00		517198.00	
8008	PROJ/8008/CSIR GRANT-PADMAJA.P.NAMBI	2990.00	204155.00		207145.00	
8009	PROJ/8009/DBT/DR.T.V.ANILKUMAR/DETISSUE	-719313.00	0.00		-719313.00	
8010	PROJ/8010/DBT/DR.NIRANJAN/IMPLATEDCONTROL	403725.00	0.00		403725.00	

			UTILISATION					
 CAPITAL EX	PENDITURE	REVI	ENUE EXPENDITUR	RE				
 FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUM- ABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
		0.00	0.00		749140.00	749140.00	749140.00	39627.00
		0.00	0.00		68648.00	68648.00	68648.00	22072.00
		0.00	0.00		0.00	0.00	0.00	318243.00
		0.00	0.00		0.00	0.00	0.00	1355655.00
		0.00	0.00		0.00	0.00	0.00	7011.00
		0.00	0.00		36290.00	36290.00	36290.00	4079.00
		0.00	0.00		87386.00	87386.00	87386.00	2650.00
		0.00	0.00		44199.00	44199.00	44199.00	0.00
		0.00	0.00		48200.00	48200.00	48200.00	5682.00
		0.00	0.00		473891.00	473891.00	473891.00	67998.00
		0.00	0.00		362220.00	362220.00	362220.00	6821.00
			0.00		0.00	0.00	0.00	0.00
		0.00	0.00		48000.00	48000.00	48000.00	34863.00
		0.00	0.00		318650.00	318650.00	318650.00	47507.00
		0.00	0.00		64050.00	64050.00	64050.00	28892.00
		0.00	0.00		118737.00	118737.00	118737.00	27449.00
		0.00	0.00		228566.00	228566.00	228566.00	-7774.00
			0.00		270232.00	270232.00	270232.00	2209.00
			0.00		106465.00	106465.00	106465.00	4527.00
		0.00	1894646.00		263673.00	2158319.00	2158319.00	1203976.00
			0.00		231160.00	231160.00	231160.00	24172.00
			0.00		819625.00	819625.00	819625.00	657094.00
			0.00		304440.00	304440.00	304440.00	42306.00
			0.00		279200.00	279200.00	279200.00	49732.00
			0.00		285303.00	285303.00	285303.00	37841.00
			130416.00		66000.00	196416.00	196416.00	279584.00
			0.00		29700.00	29700.00	29700.00	84300.00
			0.00		284473.00	284473.00	284473.00	46383.00
					263883.00	263883.00	263883.00	73803.00
					148413.00	148413.00	148413.00	34704.00
0.00		0.00	2215781.00		909552.00	3125333.00	3125333.00	-611212.00
0.00		0.00	643280.00		576327.00	1219607.00	1219607.00	441821.00
0.00		0.00	201381.00		438922.00	640303.00	640303.00	348962.00
0.00		0.00	0.00		11601.00	11601.00	11601.00	-77015.00
0.00		0.00	240708.00		782602.00	1023310.00	1023310.00	330388.00
		0.00	0.00		0.00	0.00	0.00	-226843.00
0.00		0.00	0.00		517198.00	517198.00	517198.00	0.00
		0.00	0.00		194155.00	194155.00	194155.00	12990.00
0.00		0.00	0.00		0.00	0.00	0.00	-719313.00
0.00		0.00	0.00		120033.00	120033.00	120033.00	283692.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FU	ND-WISE BREAK UP			
	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR		ADDITIONS T	o fund	TOTA	L
PROJ Code		OPENING BALANCE	GRANTS	OTHER RECEIPTS		
8011	PROJ/8011/NANOFRONT/DR.NIRANJAN/INTRAMAS	139900.00	0.00		139900.00	
8012	PROJ/8012/VSSC/DR.NIRANJAN/DESIGN STUDIES	2469340.00	0.00		2469340.00	
8013	PROJ/8013/DST/DR.C.P.SHARMA/ FADDS	5281843.00	24643.00	0.00	5306486.00	
8014	PROJ/8014/DBT/DR.ROY JOSEPH/DEVV.GRAFT	-17063.00	0.00		-17063.00	
8015	PROJ/8015/DR.ANOOPKUMAR/PROGRAMME	4566.00	0.00		4566.00	
8016	PROJ/8016/DBT/DR.UMASHANKAR/DEVEAPPLN.	111618.00	0.00	0.00	111618.00	
8017	PROJ/8017/AYUTECH/DR.UMASANKAR	365050.00	0.00		365050.00	
8018	PROJ/8018/ICMR/DR.P.V.MOHANAN	126563.00	444661.00		571224.00	
8019	PROJ/8019/STEC/DR.P.RAMESH	69661.00	215000.00		284661.00	
8020	PROJ/8020/CSIR/DR.LISSY KRISHNAN	-23920.00	634314.00		610394.00	
8021	PROJ/8021/ANGIOGENESIS EXP/DR.UMASHANKAR	171814.00	0.00		171814.00	
8022	PROJ/8022/AIR POLLUTION/SUJESH SREEDHAR	96433.00	0.00		96433.00	
8023	PROJ/8023/KSCSTE/DR.H.K.VARMA	4649.00	0.00		4649.00	
8024	PROJ/8024/IIT/DR.P.R.ANILKUMAR	-68280.00	472224.00		403944.00	
8025	PROJ/8025/	357503.00	0.00		357503.00	
8026	PROJ/8026/	-6137.00	12000.00		5863.00	
8027	PROJ/8027/DR.P.V.MOHANAN	321446.00	0.00		321446.00	
8028	PROJ/8028/DR.DIKSHA PAINULY	111903.00	921112.00		1033015.00	
8029	PROJ/8029/INDO-JAPAN	153083.00	0.00		153083.00	
8030	PROJ/STUDY/DR.UMASHANKAR	441083.00	697410.00		1138493.00	
8031	PROJ/8031	381754.00	0.00		381754.00	
8032	PROJ/8032/O.S.N.NAIR	200000.00	0.00		200000.00	
8033	PROJ/8033/DEV. OF IRON OXIDE-DR.R.S.JAYASREE	499346.00	718220.00		1217566.00	
8034	PROJ/8034/FLURO PASSIDR.ROY JOSEPH	954424.00	744525.00		1698949.00	
8035	PROJ/EVALN OF SEWING RING-DR.UMASHANKAR	57960.00	0.00		57960.00	
8036	PROJ/DEV OF CALCIUM SULPHATE-DR.MANOJ	788410.00	0.00		788410.00	
8037	PROJ/MEDICAL DEVICE RET - DR.MIRA MOHANTY	2548870.00	920000.00		3468870.00	
8038	PROJ/DEV OF MISSION PROGRAM - DR.GSB	1800000.00	0.00		1800000.00	
8039	PROJ/DISPENSABLE & BIODEGR- DR.JAYABALAN	2234348.00	0.00		2234348.00	
8040	PROJ/SYNTHESIS OF OXIDE-DR.H.K.VARMA	721952.00	0.00		721952.00	
8041	PROJ/DEV OF NANO DEVICES DNA-DR.C.P.SHARMA	1500000.00	50460.00		1550460.00	
8042	PROJ/BIOENGINEERED HYBRID -DR.LISSY KRISH	1026836.00	0.00		1026836.00	
8043	PROJ/MOLECULAR IMMUNOTOX-DR.P.V.MOHANAN	1847219.00	1500000.00		3347219.00	
8044	PROJ/TISSUE ENGINEERING-BERNADETTE	564967.00	0.00		564967.00	
8045	PROJ/COLOUR ATLAS OF TISSUE-DR.MIRA	439584.00	0.00		439584.00	
8046	PROJ/DIFF. OF ADULT PRO - DR.ASHA.S.MATHEW	739755.00	0.00		739755.00	
8047	PROJ/INVIVO GENOTOXICITY-DR.P.V.MOHANAN	646316.00	0.00		646316.00	
8048	PROJ/STUDIES DR.KAMALESH GULIA	230480.00	0.00		230480.00	
8049	PROJ/NEW VISION BIOMAT-DR.C.P.SHARMA	4530.00	0.00		4530.00	
8050	PROJ/GENOTOXICITY STUDY-DR.P.V.MOHANAN	330900.00	0.00		330900.00	

			UTILISATION					
CAPITAL EX	PENDITURE	REVE	ENUE EXPENDITUR	RE				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUM- ABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
		0.00	0.00		0.00	0.00	0.00	139900.00
		0.00	0.00		309688.00	309688.00	309688.00	2159652.00
0.00		0.00	961925.00		4344561.00	5306486.00	5306486.00	0.00
0.00		0.00	0.00		0.00	0.00	0.00	-17063.00
		0.00	0.00		0.00	0.00	0.00	4566.00
0.00		0.00	68400.00		224283.00	292683.00	292683.00	-181065.00
		0.00	0.00		0.00	0.00	0.00	365050.00
		0.00	150600.00		475815.00	626415.00	626415.00	-55191.00
			102571.00		46985.00	149556.00	149556.00	135105.00
			84929.00		223385.00	308314.00	308314.00	302080.00
			6150.00		86628.00	92778.00	92778.00	79036.00
			0.00		0.00	0.00	0.00	96433.00
			0.00		34.00	34.00	34.00	4615.00
			82662.00		267467.00	350129.00	350129.00	53815.00
			172800.00		57957.00	230757.00	230757.00	126746.00
			0.00		2524.00	2524.00	2524.00	3339.00
			76839.00		163975.00	240814.00	240814.00	80632.00
			600000.00		189729.00	789729.00	789729.00	243286.00
			0.00		63020.00	63020.00	63020.00	90063.00
			271806.00		445626.00	717432.00	717432.00	421061.00
			237600.00		556889.00	794489.00	794489.00	-412735.00
			0.00	0.00	34000.00	34000.00	34000.00	166000.00
			337155.00		412202.00	749357.00	749357.00	468209.00
			367243.00		423127.00	790370.00	790370.00	908579.00
			0.00		136560.00	136560.00	136560.00	-78600.00
			38452.00		573465.00	611917.00	611917.00	176493.00
			405703.00		2178334.00	2584037.00	2584037.00	884833.00
			0.00		601966.00	601966.00	601966.00	1198034.00
			222400.00		166609.00	389009.00	389009.00	1845339.00
			221600.00		524992.00	746592.00	746592.00	-24640.00
			0.00		1358348.00	1358348.00	1358348.00	192112.00
			239677.00		536210.00	775887.00	775887.00	250949.00
			501645.00		1259165.00	1760810.00	1760810.00	1586409.00
			420000.00		189590.00	609590.00	609590.00	-44623.00
			203200.00		257951.00	461151.00	461151.00	-21567.00
			0.00		0.00	0.00	0.00	739755.00
			165000.00		6407.00	171407.00	171407.00	474909.00
			0.00		63881.00	63881.00	63881.00	166599.00
			0.00		49391.00	49391.00	49391.00	-44861.00
			0.00		28245.00	28245.00	28245.00	302655.00

	SCHEDULE 3-EARMARKED/ENDOWMWNT FUNDS	FU	ND-WISE BREAK UP			
55.01	NAME OF GRANTEE/PRINCIPAL INVESTIGATOR	OPENING	ADDITIONS 1	TO FUND	TOTA	L
Code		BALANCE	GRANTS	OTHER RECEIPTS		
8051	PROJ/INVITRO ALTE.TEST-DR.P.V.MOHANAN	1700000.00	591724.00		2291724.00	
8052	PROJ/ROLL OF TRANFORMN GROWTH-DR.ANOOP	0.00	458333.00		458333.00	
8053	PROJ/DEVELOPMENT OF SMART/DR.LIZYMOL.PP	0.00	488334.00		488334.00	
8054	PROJ/MUSCULASKELETAL STEM CELL/DR.PDNAIR	0.00	7881000.00		7881000.00	
8055	PROJ/MUSCULASKELETAL STEM /DR.H.K.VARMA	0.00	1037000.00		1037000.00	
8056	PROJ/DR.A.C.JAYALEKSHMI	0.00	289000.00		289000.00	
8057	PROJ/INVITRO PRECLINICAL / DR.LISSY	0.00	911522.00		911522.00	
8058	PROJ/AORC FELLOWSHIP/MAYURI.P.V.	0.00	500800.00		500800.00	
8059	PROJ/CELL SHEET ENGG-DR.P.R.ANILKUMAR	0.00	808000.00		808000.00	
8060	PROJ/DEVELOPMENT OF SKIN GRAFT	0.00	2239800.00		2239800.00	
8061	PROJ/VISIBLE LIGHT INDUCED/DR.RADHAKUMARI	0.00	2189058.00		2189058.00	
8062	PROJ/ACCELERATED AREING/MR.C.V.MURALI	0.00	213728.00		213728.00	
8063	PROJ/EFFECTS OF MATERIAL SLEEP/DR.K.GULIA	0.00	2385000.00		2385000.00	
	Total	51142068.59	46471627.00	13211.00	97626906.59	

			UTILISATION					
CAPITAL EX	KPENDITURE	REV	ENUE EXPENDITU	RE				
FIXED ASSETS	OTHERS	TOTAL	SALARIES WAGES	RENT/ CONSUM- ABLES	OTHER ADM EXP	TOTAL	TOTAL EXPENDITURE	NET BALANCE
			183019.00		729927.00	912946.00	912946.00	1378778.00
			121290.00		103328.00	224618.00	224618.00	233715.00
			77742.00		88973.00	166715.00	166715.00	321619.00
			432129.00		1699831.00	2131960.00	2131960.00	5749040.00
			110400.00		168696.00	279096.00	279096.00	757904.00
			0.00		236856.00	236856.00	236856.00	52144.00
			461610.00		113625.00	575235.00	575235.00	336287.00
			0.00		409425.00	409425.00	409425.00	91375.00
			14400.00		0.00	14400.00	14400.00	793600.00
			26400.00		0.00	26400.00	26400.00	2213400.00
			0.00		0.00	0.00	0.00	2189058.00
			0.00		0.00	0.00	0.00	213728.00
			0.00		0.00	0.00	0.00	2385000.00
0.00	0.00	0.00	13317568.00	0.00	36685682.00	50003250.00	50003250.00	47623656.59
					Grand Total			236774177.31

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
SCHEDULE 4-SECURED LOANS AND BORROWINGS:		
1. Central Government		
2. State Government (Specify)		
3. Financial Institutions		
a) Term Loans		
b) Interest accured and due		
4. Banks:		
a) Term Loans-Interest accured and due		
b)Other Loans(specify)- Interest accured and due-Over draft		
5. Other Institutions and Agencies		
6. Debentures and Bonds		
7. Others(Specify)		
Against OD facility- cheques issued		
TOTAL		
SCHEDULE 5-UNSECURED LOANS AND BORROWINGS		
1. Central Government		
2. State Government (Specify)		
3. Financial Institutions		
4. Banks:		
a) Term Loans		
b)Other Loans(specify)		
5. Other Institutions and Agencies		
6. Debentures and Bonds		
7. Fixed Deposits		
8. Others(Specify)		
TOTAL		
SCHEDULE 6-DEFERRED CREDIT LIABILITIES:		
a) Acceptances secured by hypothecation of capital equipment and other assets		
b) Others		
TOTAL		
SCHEDULE 7-CURRENT LIABILITIES AND PROVISIONS		
A. CURRENT LIABILITIES		
1. Acceptances		
2. Sundry Creditors:		
a) For Goods	25773109.00	45418956.00
b) Others	1678641.00	1127360.00
3. Advances Received	33695568.93	33206734.93
4. Interest accured but not due on:	0.00	0.00

	2011-12	2010-11		
PARTICULARS	[Rs.]	[Rs.]		
a) Secured Loans / borrowings	0.00	0.00		
b) Unsecured Loans / borrowings	0.00	0.00		
5. Statutory Liabilities:	0.00	0.00		
a) Overdue	3670076.35	8186845.35		
b) Others	38297774.94	27843479.94		
6. Other current Liabilities	0.00	0.00		
TOTAL(A)	103115170.22	115783376.22		
B.PROVISIONS				
1. For Taxation	0.00	0.00		
2. Gratuity	0.00	0.00		
3. Accumulated Leave Encashment	0.00	0.00		
4. Trade Warranties/Claims	0.00	0.00		
5. Others(Specify) Audit fee	0.00	0.00		
Sinking fund contribution to invest	28985260.00	23416212.00		
TOTAL(B)	28985260.00	23416212.00		
TOTAL(A+B)	132100430.22	139199588.22		
SCHEDULE 8- FIXED ASSETS	GROSS BLOCK			
--	--	-----------------------------------	--	--
PARTICULARS	Cost/valuation as at the begin- ning of the year (01.04.2011)	Additions during the year 2011-12	Deductions during the year 2011-12	
A. FIXED ASSETS:				
1. LAND:				
a) Freehold	16894605.51	0.00	0.00	
b) Leasehold				
2.BUILDINGS:				
a) On Freehold Land *	43438708.88	169388.00	0.00	
b) On Leasehold Land				
c) Ownership Flats/Premises				
d) Superstructures on Land not belonging to the entity	124216260.88	0.00		
3. PLANT MACHINERY & EQUIPMENT	1564324968.18	172716611.00	1049653.00	
4. VEHICLES	7474233.74	0.00	0.00	
5. FURNITURE, FIXTURES	42286050.61	1240419.00		
6. OFFICE EQUIPMENT	976203.54	0.00		
7. COMPUTER/PERIPHERALS				
8. ELECTRIC INSTALLATIONS	37939698.67	7037936.00		
9. LIBRARY BOOKS	127980921.57	11021960.00		
10. TUBEWELLS & W.SUPPLY	174615.00	0.00		
11. OTHER FIXED ASSETS				
a)OXYGEN CYLINDERS	234319.42	0.00		
b)AIR CONDITIONERS	24559897.91	1408096.00		
c)TELEPHONE INSTALLATIONS	2151441.94	0.00		
d) COLD ROOM INSTALLATION	341700.00			
e) WATER COOLERS	62866.50			
f) LIFT INSTALLATION	11250942.10	0.00		
g) KITCHEN EQUIPMENTS	1405978.22			
h)CANTEEN EQUIPMENTS	151482.59	49376.00		
I) PAINTINGS	382715.63	67500.00		
k) LIVESTOCK	31848.00			
I) GAS PLANT INSTALLATIONS				
m) AMC AIR CONDITIONERS				
Total for the year (Total -A)	2006279458.89	193711286.00	1049653.00	
Total for the previous year	1723751268.89	283106508.00	578318.00	
Captial Work in Progress (B)	560426019.00	26352003.00		
Total for the year (A+B)	2566705477.89	220063289.00	1049653.00	
* Depreciation for item2(a) has been provided along with depre- ciation on 2(d)				

		Depreciation		NET BL	.OCK
Cost/valuation at the year end (31.03.2012)	Depreciation as at the beginning of the year (01.04.2011)	During the year 2011-12	Total up to the year end (31.03.2012)	As at the end of current year end (31.03.2012)	As at the previous year end (31.03.2011)
 16894605.51	0.00	0.00	0.00	16894605.51	16894605.51
43608096.88	0.00	0.00	0.00	0.00	0.00
 124216260.88	91777516.03	3802342.09	95579858.12	72244499.64	75877453.73
 1735991926.18	908167738.51	124173628.15	1032341366.66	703650559.52	656157229.67
7474233.74	4523496.00	590147.55	5113643.55	2360590.19	2950737.74
43526469.61	28295532.14	2284640.62	30580172.76	12946296.85	13990518.47
976203.54	893455.01	12412.28	905867.29	70336.25	82748.53
44977634.67	18772853.60	3930717.16	22703570.76	22274063.91	19166845.07
139002881.57	90531241.08	7270746.07	97801987.15	41200894.42	37449680.49
174615.00	159361.64	2288.00	161649.64	12965.36	15253.36
234319.42	219984.92	2150.18	222135.10	12184.32	14334.50
25967993.91	19269796.34	1004729.64	20274525.98	5693467.93	5290101.57
2151441.94	1899022.57	37862.91	1936885.48	214556.46	252419.37
341700.00	339404.08	344.39	339748.47	1951.53	2295.92
62866.50	62651.93	32.19	62684.12	182.38	214.57
11250942.10	6299368.05	742736.11	7042104.16	4208837.94	4951574.05
1405978.22	854038.51	82790.96	936829.47	469148.75	551939.71
200858.59	122642.88	11732.36	134375.24	66483.35	28839.71
450215.63	345967.97	15637.15	361605.12	88610.51	36747.66
31848.00	28361.32	523.00	28884.32	2963.68	3486.68
2198941091.89	1172562432.58	143965460.78	1316527893.36	882413198.53	833717026.31
2006279458.89	1037596922.19	134965510.39	1172562432.58	833717026.31	686154346.68
586778022.00	0.00	0.00	0.00	586778022.00	560426019.00
2785719113.89	1172562432.58	143965460.78	1316527893.36	1469191220.53	1394143045.31

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
SCHEDULE 9 - INVESTMENTS FROM EARMARKED/ENDOWMENT FUNDS		
1. In Government Securities	50414956.00	76690331.00
2. Other approved Securities	5685391.00	5685391.00
3. Shares	0.00	0.00
4. Debentures and Bonds	0.00	0.00
5. Subsidiaries and Joint Ventures	0.00	0.00
6. Others (to be specified) Sinking Fund Investments	350059901.00	303995127.00
Technology Fund	60682967.45	51192866.70
Pension & staff funds	50921140.00	50658474.00
TOTAL	517764355.45	488222189.70
SCHEDULE 10-INVESTMENTS-OTHERS		
1. In Government Securities		
2. Other approved Securities		
3. Shares		
4. Debentures and Bonds		
5. Subsidiaries and Joint Ventures		
6. Others (to be specified)		
TOTAL		
SCHEDULE 11-CURRENT ASSETS, LOANS, ADVANCES ETC		
A. CURRENT ASSETS		
1. Inventories:		
a) Stores and Spares	226753215.13	224274225.51
b) Loose Tools	6731530.00	5399533.00
c) Stock-in trade		
Finished Goods		
Work-in-progress		
Medicine	8782277.00	8354623.00
2. Sundry Debtors:		
a) Debts Outstanding for a period exceeding six months		
b) Others	77268199.00	39629987.00
3. Cash balances in hand(including cheques/drafts and imprest)	868645.18	801568.18
4. Bank Balances:		
a) With Scheduled Banks:		

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
-On Current Account	1.15	1.15
-On Deposit Accounts(L.C. margin & Commitment deposit)	788406645.00	861111471.00
-On Savings Accounts	201042234.83	231896817.31
b) With non-Scheduled Banks:		
-On Current Account	0.00	0.00
-On Deposit Accounts	0.00	0.00
-On Savings Accounts	0.00	0.00
5. Post-Office-Savings Accounts	0.00	0.00
TOTAL(A)	1309852747.29	1371468226.15
B.LOANS, ADVANCES AND OTHER ASSETS		
1. Loans:		
a) Staff	13378624.00	11736597.00
b) Other Entities engaged in activities/objectives similar to that of the Entity	0.00	0.00
c) Other(specify)		
2. Advances and other amounts recoverable in cash or in kind or for value to be received:		
a) On Capital Account	217851647.10	199074305.10
b) Prepayments	18068291.53	85965676.53
c) Others		
3. Income Accured:		
a) On Investments from Earmarked/endowment Funds	0.00	0.00
b) On Investments-Others	0.00	0.00
c) On Loans and Advances	0.00	0.00
d) Others	0.00	0.00
(includes income due unrealised Rs)		
4. Claims Receivable		
From Govt of India on Plan Funds	0.00	0.00
TOTAL(B)	249298562.63	296776578.63
TOTAL(A+B)	1559151309.92	1668244804.78
Savings bank account includes Rs.15/- (GL code No.2410-Synd Bank vikas certificate)		
SCHEDULE 12- INCOME FROM SALES/SERVICES		
1. Income from Sales		
a) Sale of Finished Goods	0.00	0.00
b) Sale of Raw Material	0.00	0.00

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
c) Sale of Scraps	0.00	0.00
2. Income from Services		
a) Labour and processing charges	0.00	0.00
b) Professional/Consultancy Services	0.00	0.00
c) Agency Commission and Brokerage	0.00	0.00
d) Maintenance Services	0.00	0.00
e) Others (Specify)	0.00	0.00
From Hospital Services-Gross Income Rs.57,73,65,295.00	0.00	0.00
Less concession to poor Patients Rs.19,08,95,165.00	386470130.00	311949503.40
From Projects	3972145.00	4814785.00
Testing & Facility charges received	4332863.50	4837884.00
TOTAL	394775138.50	321602172.40
SCHEDULE 13- GRANTS/SUBSIDIES		
(Irrevocable Grants & Subsidies Received)		
1. Central Government	239495165.00	258676264.00
2. State Government(s)	0.00	0.00
3. Government Agencies	0.00	0.00
4. Institution/Welfare Bodies	0.00	0.00
5. International Organisations	0.00	0.00
6. Others(Specify)	0.00	0.00
TOTAL	239495165.00	258676264.00
SCHEDULE 14-FEES/SUBSCRIPTIONS		
1. Entrance Fees	1210330.00	1483500.00
2. Annual Fees/ Subscriptions	2707370.00	5016910.00
3. Seminar/Program Fees	0.00	0.00
4. Consultancy Fees	0.00	0.00
5. Others(Specify) Examination Fees	1136167.00	523812.00
TOTAL	5053867.00	7024222.00
SCHEDULE 15- INCOME FROM INVESTMENTS		
(Income on Invest.from Earmarked/Endowment Funds transferred to Funds)		
1) Interest		
a) On Govt. Securities	0.00	0.00

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
b) Other Bonds/Debentures	0.00	0.00
2) Dividends:		
a) On Shares	0.00	0.00
b) On Mutual Fund Securities	0.00	0.00
3) Rents	0.00	0.00
4) Others(Specify) On Sinking Fund	22648562.00	26776447.00
On Technology Fund	4645969.45	2952876.00
TOTAL	27294531.45	29729323.00
TRANSFERRED TO EARMARKED/ENDOWMENT FUNDS		
SCHEDULE 16- INCOME FROM ROYALITY, PUBLICATION ETC		
1) Income from Royalty	2302598.00	877864.00
2) Income from Publications	0.00	0.00
3)Others(Specify)		
TOTAL	2302598.00	877864.00
SCHEDULE 17- INTEREST EARNED		
1) On Term Deposit		
a) With Scheduled Banks	72531466.00	68936301.00
b) With non-scheduled banks	0.00	0.00
c) With Institutions	0.00	0.00
d) Others	0.00	0.00
2) On Savings Account	0.00	0.00
a) With Scheduled Banks	4564117.91	3006204.57
b) With non-scheduled banks	0.00	0.00
c) Post Office Savings Account	0.00	0.00
d) Others	0.00	0.00
3) On Loans		
a) Employees/Staff	1313987.00	2100817.00
b) Others	0.00	0.00
4) Interest on Debtors and other Receivables		
TOTAL	78409570.91	74043322.57

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
SCHEDULE 18- OTHER INCOME		
1. Profit on Sale/disposal of Assets:		
a) Owned assets	0.00	0.00
b) Assets acquired out of grants, or received free of cost	0.00	0.00
2. Rent	1491644.50	1324049.00
3. Fees for Miscellaneous Services	0.00	0.00
4. Miscellaneous Income (income from Projects)	170000.00	130000.00
Other Income	2635043.20	3325782.30
TOTAL	4296687.70	4779831.30
SCHEDULE 20-ESTABLISHMENT EXPENSES		
a) Salaries and Wages	540690563.90	524813718.00
b) Allowances and Bonus	6264537.00	2874948.00
c) Contribution to Provident Fund	0.00	0.00
d) Contribution to other fund(specify)	0.00	0.00
e) Staff Welfare Expenses	11630183.35	12761048.60
f) Expenses on Employee's Retirement and Terminal Benefits	214525802.00	40004589.00
g) Others(Specify) PG Training & Accademic payments	100379317.00	86532279.00
TOTAL	873490403.25	666986582.60
SCHEDULES 21- ADMINISTRATIVE EXPENSES		
a) Purchases	359413265.00	305173543.82
b) Labour and processing expenses	0.00	0.00
c) Cartage and Carriage Inwards	148927.00	97184.00
d) Electricity and power	29029302.00	29202681.00
e) Water charges	3753342.00	3645050.00
f) Insurance	379832.00	238405.00
g) Repairs and maintenance	30040706.00	42759598.00
h) Excise duty	0.00	0.00
i) Rent,Rates and Taxes	378726.00	515853.00
j) Vehicles Running and Maintenance	866496.00	643382.11
k) Postage, Telephone and Communication Charges	3112683.00	2922051.00
I) Printing and Stationary	2587599.00	2924400.00

SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY, TRIVANDRUM

	2011-12	2010-11
PARTICULARS	[Rs.]	[Rs.]
m) Travelling and Conveyence Expenses	2456262.00	2064721.00
n) Expenses on Seminar/Workshop	2423045.00	1464035.00
o) Subscription Expenses	71060.00	87060.00
p) Expenses on Fees	0.00	0.00
q) Auditors Renumeration	0.00	0.00
r) Hospitality Expenses	0.00	0.00
s) Professional Charges	0.00	0.00
t) Provision for Bad and Doubtful Debts/Advances	0.00	0.00
u) Irrecoverable Balances Written-off	0.00	0.00
v) Packing Charges	0.00	0.00
w) Freight and Forwarding Expenses	0.00	0.00
x) Distribution Expenses	0.00	0.00
y) Advertisement and Publicity	5659801.00	5486929.00
z) Others(specify)	18458782.98	16693543.51
TOTAL	458779828.98	413918436.44
SCHEDULE 23-INTEREST		
a) On Fixed Loans		
b) Bank Charges)	118974.00	114518.25
c) Others(specify)	0.00	0.00
TOTAL	118974.00	114518.25

S/d-FINANCIAL ADVISOR S/d-DIRECTOR

ANNUAL REPORT 2011-12-

RECEIPTS & PAYMENTS ACCOUNTS FOR THE

	RECEIPTS	2011-12	2010-11	
		Rs.	Rs.	
I	Opening Balances			
a)	Cash In Hand	801568.18	602186.38	
b)	Bank Balances			
	I) In Current Account	1.15	1.15	
	ii)In deposit Account			
	iii)Savings Account *	231896817.31	196850834.31	
П	Grant Received			
	From Government of India			
	Under Plan scheme	861400000.00	838500000.00	
	Unde Plan scheme -NCMMR/Nurses Training	250000.00	661200.00	
	Non-Plan scheme	48600000.00	61500000.00	
III	Receipts against Earmarked Funds			
	a) Earmarked funds	65755355.00	106453161.00	
	b)Own funds			
IV	Interest Received			
	a) On Bank deposits	57176127.50	59495788.78	
	b) Loans Advances etc	417789.00	282785.00	
V	Receipts from services			
	Receipts from Patient services	445075179.00	387114139.40	
	Other receipts including Royalty	19057254.40	21546782.30	
VI	Other receipts			
	Grant received for Projects	86834139.66	90388446.96	
	Refund of Deposits(LC Margin)			
	Other receipts	268749286.75	265359733.41	
	Total	2088263517.95	2028755058.69	
	*Closing balance of Bank include grant amount received from DST for setting up of NCMMR, Thiruvananthapuram			

Sd/-FINANCIAL ADVISOR

PERIOD FROM 01-04-2011 TO 31-03-2012

	Payments	2011-12	2010-11
		Rs.	Rs.
1	Expenses		
	a) Establishment expenses	512148996.60	510470294.70
	b) Administrative Expenses		
	For Purchases	329055435.00	302784635.50
	Other expenses	49146667.00	46374588.75
Ш	Payments made against funds for various		
	Projects		
	As Per schedule	77680338.00	84850937.40
III	Investments & Deposits made		
	a) Out of Earmarked funds	246830140.00	177178908.00
	b) Out of own funds		
IV	Expenditure on Fixed Assets & Capital work		
	-in- progress		
	a) Purchase of Fixed Assets	113533276.00	85347072.00
	b)Capital work-in-progress		
V	Refund of Loans		
VI	Finance Charges(Bank charges)	98743.00	122711.00
VII	Other Payments		
	To Funds/Deposit- refunds	555359041.19	588927539.70
VIII	Closing Balance		
	a) Cash in hand	868645.18	801568.18
	b) Bank Balances		
	I) In current Account	1.15	1.15
	ii) In Deposit Account		
	iii) Savings Account *	203542234.83	231896802.31
	Total	2088263517.95	2028755058.69

SCHEDULES FORMING PART OF ACCOUNTS AS AT 31-03-2012 SCHEDULE 24- SIGNIFICANT ACCOUNTING POLICIES

1. ACCOUNTING CONVENTION

Financial Statements are prepared on the basis of historical cost convention unless otherwise stated and on the accrual method of accounting.

2. INVENTORY VALUATION

Stores and spares including machinery spares are valued at cost.

3. INVESTMENTS

Investment including long term investments are carried at cost.

4. FIXED ASSETS

Fixed assets are stated at cost of acquisition inclusive of inward freight, duties and taxes incidental and direct expenses related to acquisition.

5. DEPRECIATION

Depreciation is provided on reducing balance method at the rates specified by the Income Tax Act 1961 (Pre Amended ie. Upto AY 2002-03). In respect of additions to/deductions from fixed assets, during the year depreciation is provided for full year.

6. GOVERNMENT GRANTS/SUBSIDIES

Government Grant from Plan fund are treated as additions to Capital fund of Institute. Grants in respect of specific fixed assets acquired are shown as deduction from the cost of the related asset. Government Grants/subsidies are accounted on Grant release order basis.

7. FOREIGN CURRENCY TRANSACTIONS

Transactions denominated in foreign currency are accounted at exchange rate prevailing at the date of transactions.

8. RETIREMENT BENEFITS

Gratuity : From the year 2006, (with the implementation 6th Pay Commission report), the gratuity payments are treated as Institute expenses and accounted on actual payment basis.

Leave Salary : Leave encashment eligible at the time of retirement/reliving is treated as Institute expenses and accounted on actual payment basis.

Pension : From the year 2004, (with the implementation 6th Pay Commission report) 12% of the salary is transferred to the Pension Fund.

New Pension Scheme : In the case of employees who joined on or after 01.01.2004 10% of the salary is deducted as employees subscription and equal contribution is being made by the Institute. The funds are remitted to NPS Trust Account maintained by GOI and subscription details forwarded to NSDL/CRA every month.

9. PROVIDENT FUND

Assets and Liabilities of General Provident Fund account were separated from Balance sheet of Institute and shown as separate statement. Interest is provided on the accumulations as per the rates prescribed by Central Government from time to time.

10. EMERGENCY RESERVE FUND

An amount equal to 7.50 percent of receipts from patient are transferred to a Fund for meeting unexpected requirements for Fixed assets.

11. TECHNOLOGY DEVELOPMENT FUND

Receipts against technology developed by the Institute are transferred to the above fund for meeting additional expenses on Improvement of technologies already developed.

SCHEDULE 25- CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS 1. CONTINGENT LIABILITIES

	Rs. In lakhs	
	2011-12	2010-11
Claims against the Institute not acknowledged		
as debts	NIL	NIL
Bank Guarantee given by Institute	22.12	22.24
Letters of credit opened on behalf of Institute	46.00	81.87
Disputed demands on Income tax etc	NIL	NIL
In respect of claims from parties for non- execution	NIL	NIL
of orders		
2. UNEXPIRED CAPITAL COMMITMENTS		
	Rs. In l	akhs
	2011-12	2010-11
Estimated value of orders remaining to be executed on Capital Account including	2365.37	2323.53
Construction under vision 2020		
Lease obligation for rentals for Plant & Machinery	NIL	NIL

3. CURRENT ASSETS, LOANS & ADVANCES

The aggregate amount shown in the Balance sheet for the Current assets, Loans and Advances, have the value which is realisable in the ordinary course of business.

4. PROVISIONS

Provision for Income tax not made since there is no taxable income for Institute under Income tax Act 1961, during the year.

5. FOREIGN CURRENCY TRANSACTIONS:

	Rs. In lakhs	
	2011-12	2010-11
5.1 Value of Imports		
Capital Goods	133.40	275.19
Stores Spare & Consumables	57.71	54.94
5.2 Expenditure in foreign currency		
Travel Expenses	NIL	USD 2000
	Earnings:	
5.3. Earnings:		
Value of Exports	NIL	NIL

6. Other items :

6.1 Transfer to Emergency Reserve Fund & Technology Development Fund

During the year an amount of Rs.516.34 lakhs (previous year Rs. 501.72 lakhs) and Rs.81.11 lakhs (previous year Rs. 34.07 lakhs) was transferred to Emergency Reserve Fund & Technology Development Fund. During the year Rs.28.81 lakhs has been spent from Technology Development Fund.

6.2 Gratuity and Pension Contribution

Subsequent to the change in the accounting policy on account of the implementation of the 6th Pay Commission and approved by

ß

Governing Body with regard to Gratuity and Pension payments, an amount of Rs.731.42 lakhs has been charged to Institute Account. Similarly an amount of Rs.1161.42 lakhs has been transferred from Institute Account to the Pension Fund.

6.3 Setting up of NCMMR, Thiruvananthapuram

Institute received an amount of Rs.25.00 lakhs as grant from DST for the setting up of National Centre For Molecular Materials Research (NCMMR), Thiruvananthapuram, and the same has been accounted separately and annexed to the Balance Sheet.

7. Corresponding figures for previous years have been regrouped, where ever necessary.

Schedules 1 to 25 are annexed to and form integral part of the Balance Sheet as at 31-03-2012, and Income & Expenditure Account for the year ended on that date.

Sd/-Financial Advisor Sd/-Director

Particulars	2011-12	2010-11
	[Rupees]	[Rupees]
LIABILITIES		
MEMBERS BALANCE	244354602.00	231250745.00
MEMBERS CREDITS [for march]	3854740.00	3812417.00
BALANCE DUE TO MEMBERS NOT IN SERVICE		
Under EPF scheme	8371886.00	7751746.00
,, GPF ,,	532055.00	532055.00
PENSION FUND DUES	51168169.00	47377934.00
RESERVES&SURPLUS-INTEREST	10079095.39	7173407.39
TOTAL	318360547.39	297898304.39
ASSETS		
INVESTMENT AT COST	287659515.00	273726256.00
DUES TO PF ACCOUNT		
FROM INSTITUTE	3854740.00	3812417.00
FROM PF COMMISSIONER	8403467.00	12969487.00
INTEREST ACCRUED NOT DUE	1000280.00	1000280.00
BALANCE WITH BANKS		
SBT -GPF A/C	17442545.39	6389864.39
TOTAL	318360547.39	297898304.39

PROVIDENT FUND ACCOUNT FOR THE YEAR ENDED 31-03-2012

Financial Advisor

Sd/-Director

NATIONAL CENTRE FOR MOLECULAR MATERIALS RESEARCH ACCOUNT FOR THE YEAR ENDED 31-03-2012

Particulars	2011-12	
	[Rupees]	
LIABILITIES		
GRANT RECEIVED	2500000.00	
(Grant received from DST for the setting up of the National Centre for Molecular Materials Research (NCMMR), Thiruvananthapuram, vide order No.Al/NCMM/003/2011/2 & 4 dt.19.01.2012)		
TOTAL	2500000.00	
ASSETS		
BANK BALANCE	2500000.00	
(Union Bank of India Account No.541502010002675)		
TOTAL	2500000.00	

Financial Advisor

Sd/-Director

Separate Audit Report on the Comptroller and Auditor General of India on the Accounts of Sree Chitra Tirunal Institute of Medical Sciences and Technology (SCTIMST), Thiruvananthapuram for the year ended 31 March 2012

1. We have audited the Balance Sheet of Sree Chitra Tirunal Institute of Medical Sciences and Technology (SCTIMST) Thiruvananthapuram as at 31 March 2012, the Income & Expenditure Account and the Receipts & Payments Accounts for the year ended on that date under Section 19(2) of the Comptroller & Auditor General's (Duties, Powers & Conditions of Service) Act, 1971 read with section 18(2) of the SCTIMST Act, 1980. These financial statements include the accounts of Bio-Medical Technology (BMT) wing of the SCTIMST. These financial statements are the responsibility of the SCTIMST's management. Our responsibility is to express an opinion on these financial statements based on our audit.

2. This Audit Report contains the comments on the accounting treatment with regard to classification, conformity with the best accounting practices, accounting standards and disclosure norms, etc. Audit observations on financial transactions with regard to compliance with the Law, Rules & Regulations (Propriety and Regularity) and efficiency-cum-performance aspects etc., if any are reported through Inspection Reports/CAG's Audit Reports separately.

3. We have conducted our audit in accordance with auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements. An audit includes examining, on a test basis, evidences supporting the amounts and disclosure in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of financial statements. We believe that our audit provides a reasonable basis for our opinion.

4. Based on our audit, we report that:

i. We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit;

ii. The Balance Sheet, Income & Expenditure Account and Receipt & Payment Account dealt with by this report have been drawn up in the format approved by the Government of India, Ministry of Finance. Accounts furnished by SCTIMST were audited and based on the observations made by Audit, following revisions were made by SCTIMST in their Accounts: An amount of ₹2.19 crore paid as advance to the suppliers contractors which were booked under 'Repairs and Maintenance' under Schedule 21 of Income & Expenditure account this expenditure was rechecked and classified correctly under advances paid to the supplier's contractors for capital works under Schedule II-current assets, loans and advances as per the common format of accounts. Similarly, the year '2006' was corrected as '2004' in the 'Schedule 24 - Significant Accounting Policies (Item no.8), in the Revised Accounts.

iii. In our opinion, proper books of accounts and other relevant records have been maintained by the SC-TIMST as required under Section 18 (1) of SCTIMST Act, 1980 in so far as it appears from our examination of such books subject to observations made hereunder.

iv. Based on our audit, we further report that:

5 Comments on Accounts

5.1 Asset Registers: In terms of Rule 190 (2) of the General Financial Rules, 2005 (GFR) fixed assets such as plant, machinery, equipment, furniture, fixtures etc. should be maintained in the Form GFR-40. On scrutiny it was observed that the Institute is not maintaining Asset Register for fixed assets. The value of Fixed Assets shown in the annual accounts (Schedule- 8) could not be verified in the absence of an Asset register and audit

could not vouch the correctness of value of fixed assets shown in the annual accounts (Schedule-8) as regards their existence/ownership as well as valuation in the absence of proper records.

Income & Expenditure Account

6.1 Understatement of Depreciation account: As per Paragraph 5 of Schedule 24-Significant Accounting Policies, depreciation is provided on reducing balance method at the rates specified by the Income Tax Act 1961 (Pre amended i.e. up to AY 2002-03). In respect of additions to/ deductions from fixed assets, during the year depreciation is provided for full year. The scrutiny of the balance sheet and schedule 8-Fixed Assets for the year ending 31 March 2012 revealed that the depreciation was not charged as per the accounting policies declared by the institute. The fixed assets account was thus overstated by ₹ 65.34 crore and depreciation account in the expenditure side of the Income & Expenditure account was understated by the same amount.

7. General

7.1 Revenue recognition. According to common format of accounts prescribed by Ministry of Finance for autonomous bodies, Annual Accounts were to be prepared on the basis of accrual basis of accounting. As per the significant policies (Schedule 24) of SCTIMST, financial statements are prepared on the accrual method of accounting. However, it was observed that the institute recognized its income such as income from projects, testing charges, facility utilization charges, fees, subscriptions, royalty, interest on fixed deposits etc. on cash basis. The income receivable, claims receivable, income accrued etc. were not accounted and not shown under current assets, loans and advances (Schedule-II). Since the institute did not compute the amount receivable, monetary impact of such items could not be quantified in Audit.

8. Grants in aid

Out of Grant-in-aid of ₹ 91.00 crore received during the year, the organisation utilised the entire sum.

9. Management letter

Deficiencies which have not been included in the Audit Report have been brought to the notice of the SC-TIMST through a Management letter issued separately for remedial/corrective action.

- i) Subject to our observations in the preceding paragraphs, we report that the Balance Sheet and Income & Expenditure Account Receipt & Payment Account dealt with by this report are in agreement with the books of accounts.
- ii) In our opinion and to the best of our information and according to the explanations given to us, said financial statements read together with the Accounting Policies and Notes on Accounts, subject to the significant matters stated above and other matters mentioned in Annexure I to this Audit Report give a true and fair view in conformity with accounting principles generally accepted in India.

a. In so far as it relates to the Balance Sheet of the state of affairs of the Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram as at 31st March 2012; and

b. In so far as it relates to Income & Expenditure Account of the deficit for the year ended on that date.

Other Matters

Annexure-1 to Draft Separate Audit Report

1. Internal Control

1.1. Internal control in purchases

A grant of ₹ 23.55 crore was received under Plan head for creation of capital assets during 2011-12. Expenditure incurred on the same was 27.33 per cent of overall release of the Plan Funds. Purchases/ procurement are made by institute from foreign and indigenous suppliers for equipments and other fixed assets.

In terms of General Instructions relating to purchase of imported items as per Institute's Store Purchase Procedure of April 1996, when a letter of credit (L/c) is opened with the bank, the institute is committed to make the payment to supplier on submission of shipping documents by the supplier to the bank. The banks make payment to the supplier after verification of documents and send the debit advice to the institute. Such Llc applications have to be routed through accounts division. Similar procedures have to be followed for sight draft payments also. The L/c margin and commitment deposit with the bank was to the extent of ₹ 78.84 crore and almost equivalent Annual Grant received by the institute.

The internal control mechanism existing in the Institute was test checked in Audit. Audit observed that the internal control, which the Accounts Division had to exercise over commitment of funds, was not being exercised. Even receipt vouchers of final payments and clearance of supplies received were missing. Further, the details of list of purchase orders, the funds committed there against aggregating to ₹ 78.84 crore, the pendency of purchase orders, L/cs and revised delivery schedule of the supplies were also not available with the Accounts Division. Audit could not vouch for the amount of ₹ 78.84 crore held in L/c margin and Commitment Deposits against the Foreign, Import purchase orders placed. Institute stated that a proper register showing L/c margin and commitment deposit would be maintained jointly by the purchase division, accounts division and other divisions from next year onwards.

1.2. Bank Guarantee Register/ Performance Bank Guarantee

As per Rule 159 (1) of GFR, 2005 regarding Advance payment to supplier: and Rule 158 of GFR, 2005 on Performance Security, the GFR provisions stipulate that as and when a Bank Guarantee is received the Accounts Officer concerned has to confirm the genuineness of the instrument from the issuing Bank and keep under his safe custody until the Bank Guarantee is valid. Due to non-maintenance of Bank Guarantee/ Performance Bank Guarantee Register, Audit could not verify and ascertain the validity of Bank Guarantees, Bank Guarantees expired and Bank Guarantee revoked for not fulfilling the contractual obligation. Institute admitted that BG/ PBG are maintained by concerned departments and assured that internal steps to confirm the genuineness of the instrument from the issuing bank would be taken up.

1.3. Lack of Internal control in CHIS Plus scheme

SCTIMST is having an MoU dated 12 November 2011 with Executive Director, CHIAK, Government of Kerala wherein a BPL family holding smart card under RSBY scheme will be eligible for reimbursement upto ₹ 70,000/- per year for medical treatment. The institute claimed a balance of ₹ 30 lakh due to the institute from CHIAK in April 2011. The Executive Director intimated the institute in May 2012 that there was a mismatch between the claims raised through online and billed amount which had resulted in ₹ 13.91 lakh payable by the institute to CHIAK authorities. The differences between the claims raised by the institute and reimbursable by CHIAK authorities clearly point towards lack of internal control. Institute replied on 24 July 2012 that CHIAK Authority assured that as a onetime measure they would settle dues of ₹ 5.40 lakh. It was however, observed that SCTIMST had claimed a balance of ₹ 30 lakh.

1.4. Internal Audit

The Internal Audit Division (IAD) is functioning under an Internal Audit Officer assisted by one UDC of the Institute for regular periodical Audit of Hospital wing and BMT wing; the observations are not converted in Report format. Though the same was highlighted in the earlier Reports, no action has been initiated for strengthening the said Division. Institute replied on 24 July 2012 that action would be taken to settle the observations of IAD.

2. Physical verification of assets and inventories

In terms of Rule 192(nand 192(2) of GFRs, Fixed Assets, consumables goods and materials should be verified at least once in a year, the outcome of the verification need to be recorded in the register and the discrepancies should be promptly investigated. The records made available to Audit, however revealed that the latest annual Physical Stock Verification of 42 divisions/sections of Hospital wing for the year 2009-10 was conducted. Physical verification of assets and inventories for the year 2010-11 & 2011-12 is yet to be carried out. Further, latest annual Physical Stock Verification of BMT wing also having 42 divisions/sections for the year 2009-10 was conducted. On verification of the report, some discrepancies were found. The store & purchase division requested the divisions concerned to look into the matter and offer their remarks latest by 10.08.2011. Institute replied on 24 July 2012 that the stock verification report would be submitted during next year.

3. Non maintenance of Broadsheets/ Registers

In respect of accounts which did not close at the financial year end, a broadsheet containing details of previous year transactions were to be maintained and a certificate of reconciliation of the balances of broadsheets with that of ledger balances was to be recorded on the broadsheet/ registers. The broadsheets/ Registers were not maintained for (i) Sinking Fund Reserve (ii) Project Registers/ Broadsheets of Hospital wing and BMT wing (iv) Registers of. new pension scheme (GL Code 1014) (v) Patient Welfare fund (GL Code 1075) (vi) Institute Ethics Committee Fund (GL Code 1077) (vii) Staff Benevolent Funds (GL Code 1080) (viii) Employee Pension Fund (GL Code 1301) (ix) Sundry creditors (x) Advances received (xi) Statutory liabilities (xii) other current liabilities (xiii) Sundry Debtors (xiv) Loans to staff (xv) Recoverable advances to examine outstanding transactions of the previous years (xvi) Land (xvii) Building (xviii) Plant & Machinery (xix) Vehicles' (xx) Furniture and Fixtures (xxi) Office equipment (xxii) Computer Peripherals (xxiii) Electric installations (xxiv) Library books (xxv) Tube wells & water supply (xxvi) Other fixed assets.

Though institute is having computerised broadsheets for SD (GL 1335), EMD (GL 1330) of Hospital wing and amount receivable from PMF (GL 1317) for the period 2011-12, details pertaining to previous years are not available. Institute replied on 24 July 2012 that GL accounts schedules would be prepared and submitted to Audit next year.

4. Accounting of inventories

The accounting policy of the Institute stipulated accrual method of accounting. Further, as per the common

format of accounting prescribed for autonomous bodies also stipulate accrual method of accounting. Audit however observed that inventories issued from general store/pharmacy to departments and divisions were treated as consumed in inventory account when the inventories were lying in departments/divisions. Thus inventories under Schedule: 11 Current Assets was understated. Since divisional stock register of inventories are not maintained audit is not able to quantify the amount understated.

Institute stated that now it has developed a computerised management system and the issues from the stores/ pharmacy to department/ division have also been computerised. Institute assured that from next year onwards the stock available in the department/ division would also be included in the stock in hand.

5. Self sustenance and diversion of plan funds for non plan activities

According to Rule 208(iii) of GFR 2005, all Autonomous Organizations, should be encouraged to maximize generation of internal resources and eventually attain self sufficiency. According to Rule 208(iv) of GFR 2005, instead of giving recurring grants, wherever possible, the Ministry or Department may consider creating a Corpus Fund, the return on investment of which should enable the Autonomous Organization to meet its revenue expenditure. The scrutiny of final accounts of SCTIMST for the year ending March 2012, however revealed that institute has not only spent its entire non-plan grant of ₹ 23.95 crore but also utilized ₹ 60.26 crore¹ of plan funds for non plan expenditure. Institute replied that the patient care charge was revised on an ad-hoc basis during the year 2010-11. Institute added that it is thriving to maximize internal generation of income with a view to attain self sufficiency

6. Plan and non-plan categorisation

According to Rule 209 6(xiii) of GFR, 2005, Central Autonomous Organisations which receive Plan as well as Non-Plan Grants, should account for expenditure (Capital and Revenue) separately under Plan and Non-Plan Heads. The central autonomous bodies are required to ₹ 60.26 crore¹ being the debit balance of Income & Expenditure account for the year ending March 2012 of ₹ 74.66 crore reduced by depreciation amount of Rs.14.40 crore during the year. compile their accounts in the Common Format of accounts prescribed by the Govt. of India, Ministry of Finance. It was however observed that the accounts of 5CTIM5T, did not ref ect grants and expenditure separately for Plan and Non-Plan category. Institute replied that this would be taken up with D5T.

Place : New Delhi Dated : 15-11-2012

S/d-Principal Director of Audit Scientific Departments

¹ ₹60.26 crore being the debit balance of Income & Expenditure account for the year ending March 2012 of ₹74.66 crore reduced by depreciation amount of ₹14.40 crore during the year.

REPLY OF THE INSTITUTE

Para No.	Reply of SCTIMST
5.1. Assets Register	Institute is developing a new coding system to identify the various equipments (Electrical/Electronics), vehicles etc. Based on this coding system a fixed asset format has also been designed. After completing the above process a fixed assets register to show the value, depreciation, WDV. etc. will be prepared. The Register will be submitted to audit during the year 2012-13.
6.1 Understatement of Depreciation Account	Proper disclosure were made in the Significant accounting policies that the rates of depreciation applied on the fixed assets are the rates as per the Income Tax Act 1961 (Pre-amended ie upto AY 2002-03). Kindly note that Institute adopted the rates for charging depreciation on fixed assets. From the year 2012-13 Institute will adopt new depreciation rates and charged to fixed assets based on the recommendations of the committee which is formed by the Governing Body of the Institute.
7.1 Revenue Recognition	Income like Royalty, Interest on Investments etc will be accounted accrual basis from the Year 2012-13 onwards.
8.	The facts stated that grant of $₹91$ crores received to be utilized during the year has been noted.



